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Table of abbreviations 
sec second(s) 
min minute(s) 
hr hour(s) 
µl microliter 
mL millilitre 
µm micrometer 
rpm Revolutions per minute 
°C centigrade degree 
UV light ultraviolet light  
A° angstrom 
v/v volume per volume 
RT room temperature 
µg mL-1 microgram per milliliter 
w/v weight per volume 
mmol milimoles 
L liter 
mg kg-1  milligram per kilogram 
nM nano molar 
mm millimeter 
u mL-1 Unit per milliliter 
ng mL-1 nanogram per milliliter  
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1 Introduction 
1.1 Circulating Tumor Cells (CTCs) 
1.1.1 Clinical implications 
Tumor-derived circulating tumor cells (CTCs) represent a heterogeneous 
population of malignant cells that disseminate from tumors into the bloodstream, as 
single cells or tumor cell clusters, enabling their transportation to distant sites and the 
seeding of metastatic tumors.1-3  
One avenue that holds promise in developing accurate predictive tools and 
pharmacodynamic biomarkers to guide patient care is the analysis of viable CTCs.1, 4-17 
Monitoring CTCs in cancer patients has been described as a “liquid biopsy” or “live 
biopsy”,18 which could be a potential alternative to invasive biopsies for detection of 
metastasis and monitoring therapies19 if one can capture the entire heterogeneity of the 
disease. Detection, quantification, and molecular characterization of CTCs in peripheral 
blood have been recognized as a highly valuable emerging technique in the diagnosis 
of cancer and detection of metastasis.1, 7, 20, 21  
In early stage disease, CTCs might be used to predict the risk of metastasis, 
while over the course of therapy they may be useful for evaluating response to therapy 
and choosing the most suitable therapeutic regime. Furthermore, molecular analysis of 
CTCs may provide insight into the process of metastasis, revealing new biological 
therapeutic pathways.19 If CTCs are demonstrated to be useful as biomarkers, 
eventually they could represent a new way to diagnose cancer.1   
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1.1.2 Biology of CTCs 
Thomas Ashworth, an Australian physician, observed CTCs for the first time in 
the blood of a man with metastatic cancer in 1869. He postulated, “Cells identical with 
those of the cancer itself being seen in the blood may tend to throw some light upon the 
mode of origin of multiple tumors existing in the same person.”22 After comparing the 
morphology of the CTCs with tumor cells, he concluded that “one thing is certain, that is 
they (CTC) came from an existing cancer structure, they must have passed through the 
greater part of the circulatory system to have arrived at the internal saphena vein of the 
sound leg”.22 Researchers have been studying metastasis for about 149 years and 
research has indeed demonstrated the critical role of CTCs in these phenomena 
recently.  
1.1.2.1     Seed and soil hypothesis 
Stephen Paget in 1889 proposed the seminal ”seed and soil” hypothesis based 
on the idea that metastasis depends on cross-talk between selected cancer cells (the 
seeds) and specific organ microenvironments (the soil), and that metastasis only 
happens when the soil and seed are compatible.23 
1.1.2.2     The relation between CTCs and EMT 
CTCs are cells that extravasate from the primary tumor and enter the blood 
stream, enabling their transportation to distant sites and potential formation of 
metastatic tumors.1-3 CTCs may enter the blood circulation in two ways: by passive 
shedding of tumor cells from the primary tumor, which may occur in large numbers and 
in early stages of tumor formation, or by an active mechanism involving the epithelial-to-
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mesenchymal transition (EMT).2 EMT is a complex molecular and cellular program by 
which cells of epithelial origin lose their apical-basal polarity and adhesiveness to 
neighboring cells and gain mesenchymal features, including aggressiveness, motility, 
invasiveness, and resistance to apoptosis.2, 5, 12, 20, 24-26 Thus, EMT can be molecularly 
defined by tumor cells losing intracellular adhesions, with down-regulation of epithelial 
markers (e.g. epithelial cell adhesion molecule (EpCAM) and cytokeratins) and up-
regulation of mesenchymal markers (e.g. CD133, Vimentin).27 Furthermore, EMT is 
known as “Cadherin switching”; down regulation of E-cadherin and up regulation of N-
cadherin.27-33 EMTs are encountered in three general subgroups: type I EMT is 
correlated with implantation, embryogenesis, and organ development and can generate 
mesenchymal cells; type II EMT is associated with wound healing, tissue regeneration, 
and organ fibrosis; and type III EMT occurs in cancer progression and metastasis 
(Table  1-1).34 
Table ‎1-1: Classification of EMT according to the biological context 
34, 35 36
 
Characteristics 
                       Types of EMT 
Type 1 Type 2 Type 3 
Moment of appearance 
during human life 
Embryo formation:✓
Organ development 
Adult life:✓Trauma✓
Inflammation 
Adult life:✓Epithelial 
cancer 
Physiological processes 
in which EMT is involved 
Generates the first set of 
mesenchymal cells = 
primary mesenchyme 
Wound healingTissue 
regenerationOrgan fibrosis  
Pathological processes in 
which EMT is involved 
Without 
Ongoing fibrosis with organ 
destruction 
Systemic progression = 
metastases 
It has been shown that Vimentin contributes to EMT via i) gene expression 
(regulates gene expression of proteins required for execution of EMT like Axl), ii) 
protein-protein interaction, and iii) phosphorylation.32 Vimentin is a type III intermediate 
filament protein which is the major cytoskeletal component of mesenchymal cells.27, 33 
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This 57-kDa protein is responsible for maintaining cell shape, integrity of the cytoplasm, 
and stabilizing cytoskeletal interactions.33 Evaluating the expression of this protein in 
normal and cancerous tissues can be of great value in tumor diagnosis as well as in the 
development and progression of cancers.27 Therefore, because of dramatic 
compositional changes in intermediate filaments during EMT, Vimentin has been 
recognized as a selective expression marker of EMT.27, 31  
Recent studies have shown that a small number of cells have stem cell-like 
characteristics in various cancers and are called cancer stem cells (CSCs).37, 38 CSCs 
and cells undergoing EMT play important roles in tumorigenesis, metastasis, and 
chemo and radio-resistance.39, 40 Therefore, detecting and analyzing these cells among 
CTCs in circulation could lead to better understanding of EMT and tumor metastasis.  
1.2 BioMEMS in life science 
BioMEMS stand for biomedical microelectromechanical systems which have 
become an important subset of MEMS (microelectromechanical system) or MST 
(microsystem technology) devices that have biological and/or biomedical functions or 
applications for the improvement of human health.41, 42 BioMEMS brings together the 
skills of electrical, mechanical, optical and chemical engineers, material specialists, 
clinical laboratory scientists, and physicians.43 BioMEMS are increasingly being used for 
miniaturization of implantable medical devices for diagnostic and therapeutic 
applications44.  
BioMEMS research and applications include diagnostics, therapeutic and organ 
development, bio-microelectrodes, tissue engineering, and bio-inspired materials for 
self-healing.41, 45-47 For diagnostic applications they are normally used to detect cells, 
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proteins, microorganisms, viruses, and molecules of interest.41 Microfluidics as powerful 
network of BioMEMS platforms is commonly used for rapid detection and cell 
characterization in diagnosis.41 The applications of the microfluidic technologies in the 
cancer disease are explained in details in section 1.3.2.1.2. 
1.2.1 Fabrication and structure 
BioMEMS refer to systems which use micro- and nanoscale (200 µm-100 nm) 
fabrication techniques for the analysis and delivery of biological and chemical 
particles.41 They may be platforms for nanotechnologies, or they may be key 
constituents of much larger devices such as a medical imaging machines.43 They may 
also operate in vivo or in vitro. Generally, devices and integrated systems using 
bioMEMS are also known as lab-on-a-chip (LOC) and micro-total-analysis systems 
(µTAS).41 µTAS may be hybrids of multiple chips, integrated electronic and external 
supports, while LOC refers to a microfluidic chip.48 Both techniques result in increased 
efficiency through smaller scales and therefore are capable of performing analyses that 
cannot be done conveniently by other methods.  
Traditional microfabrication approaches require expensive equipment, access to 
cleanroom facilities, multistep processes, and are often limited to rigid and non-
transparent substrates.49 However, microfabricated on-chip microfluidics do have the 
advantage of achieving high sensitivity, quantitative detection, low costs, and shorter 
turnaround times compare to traditional microfabrication approaches.49  
1.2.2 Bioapplications of Microfluidic Devices 
Microfluidics can be used to study fluid transport processes, in channels with 
dimension of tens to hundreds of microns.47, 50 The use of microfluidic channels has 
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scaled down fluidic processes, shortened reaction times, and lowered costs.47, 50 Many 
new techniques are being used for molding, replication, casting, and bonding which are 
essential for mass production, reproducibility, and functional reliability at low cost in the 
bioMEMS field.  
Microfluidic technologies are widely used in different areas of research from 
bioengineering and biomedical science, to chemistry and nanotechnology.51 For 
instance in immunoassays, DNA sequencing, polymerase chain reaction (PCR), 
electrophoresis, DNA separation, enzymatic assays, cell counting, cell sorting and cell 
culture.51 The small volumes of reagents required, short reaction time, portability, low 
cost, low consumption of power, versatility in design and potential of parallel operation 
in microfluidic systems, make these technologies attractive and powerful platforms.51  
Innovation in modern healthcare diagnosis techniques continues to improve 
patient outcomes. There is a huge interest in lab-on-a-chip devices for point-of-care 
detection as low-cost and portable solutions to health screening, diagnosis, and 
personalized medicine.49  
1.3 CTC enrichment strategies  
1.3.1 Technology challenges 
Detection and isolation of CTCs is challenging due to the low number of CTCs in 
the blood of cancer patients (on the order of 1 CTC per 106–109 normal blood cells) and 
the biological heterogeneity of CTCs.52 Therefore, both high efficiency and high purity 
isolation of CTCs from patient blood is urgently needed. Over the past decades, 
researchers have focused on the enrichment and identification of CTCs in blood. The 
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main approach for enrichment has been to capture cells of interest using specific 
epithelial markers on the cell surface to distinguish them from leukocytes.1 
Multiple approaches have been considered to overcome the limitation of 
low numbers of CTCs in peripheral blood. CTC enrichment technologies are 
based on the exploitation of either biological (label-dependent or immunoaffinity-
based) or physical (label-independent or size-based) properties of cells.1, 53-60 
CTC isolation technologies are summarized in Table  1-2.61  
1.3.2 Immunoaffinity-based enrichment methods 
These methods use specific cell surface biomarkers to capture cells either 
by positive or negative selection. During positive selection, tumor-associated cell 
surface antigens such as epithelial cell adhesion molecule (EpCAM) are targeted. 
Negative selection methods deplete hematopoietic cells by targeting the common 
white blood cell antigen CD45.62  
1.3.2.1     Positive enrichment 
With positive enrichments methods, antibodies targeting tumor-associated 
antigens are tethered to either magnetic particles or device surfaces to capture CTCs.61 
Positive enrichment techniques include immunomagnetic, microfluidic-based, and in 
vivo enrichment methods.  
1.3.2.1.1      Immunomagnetic 
Immunomagnetic methods capture CTCs by attaching micron sized 
magnetic beads to the CTCs via formation of an antigen-antibody complex, and 
then isolating CTCs by passing them through a magnetic field.1 CellSearch is the 
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only FDA-cleared immunomagnetic semi-automated CTC enrichment device for 
prognostication of breast, prostate, and colorectal cancers.63 Some drawbacks to 
this method are the fact that only EpCAM positive CTCs are detected, and the 
possibility of false positive and false negative.63  
Another approach is the magnetic activated cell sorting (MACS) method.64 
Some advantages of this method are flexibility and preserved cell integrity, and 
some difficulties of these methods are the possibility of false positives due to the 
expression of the same antigens on non-tumor cells and false negatives due to 
the loss of antigens on CTCs.65, 66  
The AdnaTest is another established method for CTCs enrichment, which 
is based on the use of specific antibodies against epithelial and tumor markers. 
Some advantages of this test are recognition of fixed markers, the ability of 
downstream analysis (e.g. RT-qPCR), and the possibility of characterization for 
stemness and EMT. The disadvantages of using this method are the possibility of 
both false positives and false negatives as with other immunomagnetic based 
methods.63 The MagSweeper technology is another immunomagnetic CTC 
enrichment method isolates CTCs by sweeping through wells containing pre-
mixed samples with antibody-coated magnetic bead.60 
1.3.2.1.2      Microfluidic-based 
1.3.2.1.2.1      Micropost arrays and surface-based 
Microfabrication methods create structures at the nano/mico scale, providing a 
unique advantage for CTC separation. The first implementation of a microfluidic device 
for this purpose, the CTC-Chip, consisted of an array of 78,000 microposts chemically 
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functionalized with anti-EpCAM antibody.4 60% capture efficiency with 50% purity was 
obtained using a flow rate of 1 mL hr-1.4 Since then, different microfluidic-based 
technologies have been investigated by various research groups focused on the 
development of CTC enrichment methods (e.g. GEDI,67 OncoCEE,68 and OncoBean69).  
 Due to limitations with imaging of captured CTCs on microposts arrays, surface-
based microfluidic devices have been developed by different groups (e.g. herringbone 
(HB) chip,70 geometrically enhanced mixing (GEM) chip, 71 graphene oxide (GO) chip,72 
and Modular Sinusoidal Microsystem73).  
One of the drawbacks of using these types of enrichment is the inability of 
retrieving the captured CTCs which are immobilized on the post/surface of the device, 
therefore the downstream analysis is challenging.  
1.3.2.1.2.2      Immunomagnetic 
Immunomagnetic microfluidic techniques utilize antibody-conjugated 
magnetic beads to facilitate CTC separation (e.g. Ephesia,74 Magnetic Sifter,75 
LiquidBiopsy,76 Isoflux,77 and CTC-iChip78). The CTC-iChip technology uses 
either negative or positive selection of cells. Using positive selection ≥0.5 CTCs 
mL-1 was detected in 90% of patient samples in one study and ≤30 CTC 7.5 mL-1 
from patient samples in another study.61 The technology has some drawbacks 
including, low purity yield and biased pre-processing of blood samples with 
magnetic beads. In positive selection cells are sorted based on their EpCAM 
expression. Negative selection depletes leukocytes immunomagnetically. 
Although, the negative selection module of CTC-iChip allows isolation of 
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heterogeneous populations of CTCs, the isolated CTCs are a mixed population of 
CTCs. 
1.3.2.1.3      In vivo enrichment 
The GILUPI Cell Collector captures CTCs using a structured medical Seldinger 
guidewire functionalized with anti-EpCAM.79 The guidewire is inserted into a patient’s 
peripheral vein to allow continuous sampling of a relatively large volume of blood 
compared to other CTC enrichment methods. One drawback is that the method can be 
considered invasive to the patient.  
1.3.2.2     Negative enrichment 
As mentioned above, negative enrichment methods deplete unwanted 
background cells by utilizing antibodies targeting leukocyte-associated antigens 
conjugated to magnetic particles or the device surface. EasySep Human CD45 
Depletion Kit,80 QMS,81 MACS,82 Negative selection disk,83 and CTC-iChip 78 are some 
examples of the available negative selection methods. These methods provide 
unbiased CTC isolation, however at the cost of lower purity compared with positive 
enrichment.61 
1.3.3 Biophysical properties enrichment methods 
In order to overcome the limitation of biased cell selection using biological 
properties, researches have proposed CTC enrichment based on biophysical 
properties. These are mainly referred to as “label-free” technologies, relying on physical 
characteristics such as density, size, deformability, and electric charge.61 Size-based 
CTC enrichment technologies rely on the size of CTCs, which has a larger morphology 
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(12-25um) than leukocytes (8-14 um).84, 85 One of the drawbacks of the size-based 
technology is the loss of smaller CTCs during enrichment.61  
1.3.3.1     Density Gradient Centrifugation 
Centrifugation is one of the first methods recorded for CTC isolation.86 Blood 
samples were centrifuged to separate different cells populations based on their relative 
densities. Density gradient methods separate CTCs and mononuclear cells using 
different methods including Ficoll-Paque,87 OncoQuick,88 RosetteSep CTC Enrichment 
Cocktail,89 and Accucyte Enrichment and CyteSealer.90 OncoQuick has the advantage 
of preventing cross contamination by using an additional barrier, however the specificity 
is still low.1, 88, 91 RosetteSep CTC Enrichment Cocktail is based on negative selection, 
though there is still the possibility of cross contamination with this method.92, 93  
1.3.3.2     Microfiltration 
Microfiltration technology uses pore sizes around 7-8 µm or 3D geometries for 
CTC enrichment.61 Microfiltration methods include 2D microfiltration systems (isolation 
by size of epithelial tumor cells (ISET),94 ScreenCell,95 CellSieve,96 and Flexible Micro 
Spring Array (FMSA)97) and 3D microfiltration systems (FaCTChecker,98 Resettable Cell 
Trap,99 and Cluster Chip100). 
ISET technology uses a filter with 8 μm pores to separate smaller leukocytes 
from the larger epithelial cells. Advantages of this method are that it is simple to use and 
inexpensive, as well as capable of capturing both EpCAM positive and negative tumor 
cells. The fundamental disadvantages of ISET are its low specificity in capturing CTCs, 
the possibility of loss of smaller CTCs which can pass through the pores, and the 
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enrichment of large leukocytes.1, 94 Although microfiltration systems in general allow 
rapid processing of blood, they are prone to clogging, parallel processing with multiple 
filters, achieving very low purities (<10%), large variability in CTC recovery, and 
concentrated stresses that affect the viability of enriched CTCs.61, 101 These 
complications leave an opportunity for improvement of these types of technologies.102 
1.3.3.3     Inertial focusing 
Inertial focusing passively separates CTCs from other blood cells based on cell 
size. The relative positioning of cells passing through microfluidic flow channels is 
affected based on the equilibrium between lift forces and dean flow.61, 103 In general, 
inertial focusing methods exert minimal stress on isolated cells and allow viable cell 
recovery.61 Some methods that apply inertial focusing include Vortex,85 Dean Flow 
Fractionation,104 and Labyrinth.113 Labyrinth technology is explained in detail in section 
1.4.6.1.2       
1.3.3.4     Dielectrophoresis (DEP) 
Dielectrophoresis (DEP) separates cells based on their electrical signature using 
an applied electric field.61, 105 The electrical signature of different cells depends on the 
composition, morphology, and phenotype of the cells.105, 106 ApoStream,107 
DEPArray,108 and MOFF and DEP chip109 are some examples of technologies that 
apply DEP for the CTC enrichment. DEPArray is a commercially available technology 
that is likely to be limited to samples with high CTC numbers due to the ~40% CTC lost 
during sample loading.110  
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1.3.3.5     Acoustophoresis 
Acoustophoresis Chip separates CTCs based on the acoustophoretic mobility, by 
exposing them to acoustic waves.111 Separation depends on physical characteristics of 
the cells including, size, density, and compressibility.111 87% cell recovery and 99.3% 
purity at a flow rate of 4.2 mL hr-1 using cell lines was reported.111 However, due to the 
low sample volume (100 µL) using this technique, it is not feasible to generate data for 
samples with any clinically relevant low concentrations of CTCs.111 Increasing sample 
volumes results in long processing times which may affect long-term stability.111 
1.3.4 Direct imaging modalities 
All of the mentioned technologies require subsequent verification to identify the 
captured cells. Hence, researchers have developed technologies to improve efficiency 
of imaging following CTC enrichment. Some of these technologies listed as Microfluidic 
Cell Concentrator (MCC),112 ImageStream,113 EPIC Science,114 FASTCell,115 
CytoTrack,116 and Photoacoustic flow cytometry (PAFC).117  
MCC technology uses passive pumping between small transport channels and a 
large collection ring to concentrate samples, therefore reducing imaging time.112 
ImageStream combines flow cytometry with fluorescence imaging.113 However, the 
capture efficiency is variable, and highest with elevated CTC numbers.118 The 
enrichment-free CTC detection technology, EPIC Science, uses HD-CTC imaging 
system to screen a monolayer of three million nucleated cells spread on custom glass 
slides.114 CTCs were detected in 68% of NSCLC patient sample using this technology.61 
In another study ≥5 CTC mL-1 was detected in 50% of patients with pancreatic 
cancer.119 
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FASTcell and CytoTrack technologies both rely on imaging only. The first 
technology uses an array of optical fibers to form a wide collection aperture that 
provides a much larger field of view than traditional optical systems.115 CTCs were 
detected in a rate of ≥2 CTC mL-1 in 42% of patients with NSCLC.120 The latter 
technology prescreens the samples at high rates and records potential CTC targets for 
additional image analysis and verifications.116 PAFC platform is a laser-based 
technology for real-time CTC detection within patient veins by interrogating the blood 
flow through the skin.117    
1.3.5 Functional Assays 
Functional assays exploit viable CTC enrichment based on bioactivity of cells, 
such as protein secretion (e.g., EPISPOT121) or cell adhesion (Vita-Assay122). Various 
groups have utilized the Epithelial ImmunoSPOT Assay (EPISPOT) to capture CTCs 
based on specific secreted/released/ shed tumor-associated proteins. 121, 123-125 
1.3.6 Perspectives 
It is important to develop optimal CTC isolation techniques that enable us to 
achieve high recovery and high purity of CTCs by depleting off-target cells, while 
employing a high throughput system to ensure handling of large sample volumes. As 
mentioned earlier, each technology has advantages and disadvantages. Below is the 
summary of pros and cons of the immunoaffinity and size-base separation methods. 
1.3.6.1     Advantages and disadvantages of Immunoaffinity CTC isolation 
Immunoaffinity methods offer very high specificity for CTC capture. Using these 
technologies, CTC isolation needs to be tailor-made to answer relevant biological 
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questions. By utilizing the right antibodies, an assorted pool of CTCs can be recovered 
from cancer patients regardless of the cell morphology. This isolation method can 
capture CTCs in various size ranges (>4-30 µm).126 Although there is no need to pre-
process the samples, the purity of recovered CTCs is high, therefore more options for 
downstream analysis are feasible.67 The immunoaffinity method also offers the ability to 
capture CTC clusters.70, 127 However, they suffer from a few limitations including, low 
throughput,78 and difficulties releasing the cells form the chip for single cell analysis and 
CTC derived xenografts models.128  
1.3.6.2     Advantages and disadvantages of size-based separation CTC isolation 
The main advantage of using biophysical properties for CTC enrichment is that 
cell selection is not biased according to expression of a particular biomarker. Hence, 
these methods can recover heterogeneous CTC populations that are viable and not 
immobilized on a surface. Therefore, off-chip standard cell culture techniques for 
expanding patient derived CTCs and further downstream analyses are feasible. Another 
advantage is the ability to process a large sample volume (high throughput), however, 
clogging difficulties may still remain.129 The main disadvantage of size-based separation 
methods is the loss of smaller CTCs, which may result in losing valuable information 
from the patient.126, 130  
In light of the limitations of current CTC enrichment technologies, we applied two 
different microfluidic technologies (the immunoaffinity CTC Carpet Chip, and the size-
base separation device, Labyrinth) to study CTCs in pancreatic and non-small cell lung 
cancers patient samples. 
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Table ‎1-2: CTC isolation technologies
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Principle Technology 
Selection 
criteria 
Flow rate 
Capture 
efficiency 
Purit
y 
Application Ref 
Im
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e
 E
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Immunomagnetic 
CellSearch EpCAM 
   
FDA-Approved 
131
 
AdnaTest 
Antibody 
Cocktail    
CTCs captured then multiple cancer markers measured by RT-PCR 
132
 
MACS EpCAM 
   
Pos/Neg enrichment, high surface area to volume 
64
 
MagSweeper EpCAM 9 mL hr
-1
 62% 51% 17 metastatic breast cancer patients, whole blood 
60
 
Microfluidic 
Micropost Arrays 
CTC-Chip EpCAM 1 mL hr
-1
 60-65% 50% 
Micropost array optimized for cell-antibody contacts, 116 patients 
with metastatic lung, prostate, pancreatic, breast and colon cancer 
4
 
GEDI 
PSMA/ 
HER2, Size 
1mL hr
-1
 85% 68% 20 patients with prostate cancer 
67
 
CTC Carpet Chip 
EpCAM/ 
CD133 
1mL hr
-1
 97.5% 76% 
Heterogeneous CTCs separation from whole blood of 36 pancreatic 
cancer patients   
133
 
OncoCEE 
Antibody 
Cocktail    
Staining procedure labels capture antibodies 
68
 
OncoBean 
Antibody 
Cocktail 
10 mL hr
-1
 >80% 
 
6 patients with lung, breast, and pancreatic cancer 
69
 
Microfluidic 
Surface Capture 
Herringbone Chip EpCAM 
1.5-2.5  
mL hr
-1
 
90% 
 
Microvortices mix sample,15 patients with metastatic prostate 
cancer, clusters observed 
70
 
GEM EpCAM 3.6 mL hr
-1
 
  
Microvortices mix sample 
71
 
Graphene Oxide Chip EpCAM 1 mL hr
-1
 82.30% 
 
20 patients with breast, pancreatic, and lung cancer 
72
 
Modular Sinusoidal 
Microsystem  
EpCAM 
>7.5 
mL hr
-1
  
>86% 
Three modules; selection, impedance, and imaging, clusters 
observed 
73
 
Microfluidic 
Immunomagnetic 
Ephesia EpCAM >3 mL hr
-1
 
  
Self-assembly of magnetic μm-beads into columns 
74
 
Magnetic Sifter EpCAM 10 mL hr
-1
 
  
Vertical flow configuration 
75
 
LiquidBiopsy 
Antibody 
Cocktail 
5 mL hr
-1
 
  
Automated, sheath flow minimizes non-specific binding, continuous 
flow 
76
 
Isoflux™ EpCAM 
   
Automated, continuous flow 
77
 
CTC-iChip 
EpCAM, 
Size 
8 mL hr
-1
 
  
Pos/neg enrichment, size-based separation, whole blood, inertial 
focusing aids in magnetic deflection 
78
 
Immunomagnetic
, in vivo 
GILUPI CellCollector™ EpCAM 
   
Can process large volumes of blood 
79
 
N
e
g
a
ti
v
e
 E
n
ri
c
h
m
e
n
t  
Immunomagnetic 
EasySep 
CD45 
   
Simple, easy-to-use batch separation 
80
 
QMS 
   
Continuous flow, high throughput 
81
 
MACS 
   
  
82
 
Negative selection disk  
  
60% 
 
Isolation of breast cancer cells from mononuclear cells mixture  
83
 
Microfluidic 
Immunomagnetic 
CTC-iChip 
CD45, 
CD66b, 
Size 
   
  
78
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  Ficoll-Paque Density 
 
84% 
 
Inexpensive, easy-to-use 
87
 
OncoQuick 
Density, 
Size  
70.60% 
 
Porous membrane above separation media for additional separation 
by filtration 
88
 
RosetteSep CTC 
Enrichment Cocktail 
Density, 
Antibody 
Cocktail 
   
Antibody-labeling alters cell density 
89
 
Accucyte Enrichment 
and CyteSealer 
Density 
   
Sequential density fractionation enriches target cells. Additional 
CyteFinder™ and CytePicker™ modules for high throughput 
imaging and single-cell recovery 
90
 
M
ic
ro
fi
lt
ra
ti
o
n
  
 
  
ISET 
Size, 
Deforma-
bility 
 NA 
Filters fixed samples through 8 μm pores, 10–12 wells can process 
1 mL each, clusters observed 
94
 
ScreenCell 
   
Hydrophilic surface, fixed/live samples, 7.5-6.5 μm pores 
95
 
CellSieve 
   
Constructed from a transparent, flexible, non-fluorescent 
photoresist, 7 μm pores 
96
 
Flexible Micro Spring 
Array (FMSA)    
Constructed from parylene-C, can process whole blood, captures 
viable cells, clusters observed 
97
 
FaCTChecker 
   
Constructed from parylene-C, captures viable cells between 
membrane layers 
98
 
Resettable Cell Trap 
   
Pneumatically-controlled microvalves 
99
  
Cluster Chip 
   
Triangular pillars designed for CTC clusters 
100
 
 I
n
e
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l 
F
o
c
u
s
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Vortex 
Size 
7.5 mL   
20 min
-1 
~18% with 
cell lines 
57-
94% 
No RBC lysis required, captures viable cells, clusters observed, 
tested with 12 patient samples (breast and lung cancer) 
85
 
Dean Flow 
Fractionation 
7.5 mL    
8 min
-1 
>80% with 
cell lines 
~4 log 
dep 
Tested with 10 patient samples (breast and lung cancer) 
104
 
Labyrinth 
2.5 mL  
min
-1
 
>95% 
600 
WBC
s mL
-1
 
RBC removal required, capture viable cells, easy to manufacture, 
clusters observed 
103
 
E
le
c
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o
p
h
o
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e
s
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  ApoStream 
Electrical 
Signature 
>10 mL hr
-1
 
  
DEP-FFF, continuous flow, captures viable cells 
107
 
DEPArray 
   
Requires pre-enrichment, allows recovery and manipulation of 
viable, single cells through DEP cages 
108
 
MOFF and DEP chip 
 
126 µl min
-1
 99% 
 
Isolation of breast cancer cells from blood 
109
 
A
c
o
u
s
to
p
h
o
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s
is
 
 
  
Acoustophoresis Chip Size 
   
Acoustic pre-alignment and separation 
111
 
  
D
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e
c
t 
Im
a
g
in
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M
o
d
a
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Pre-Enrichment 
Required 
Microfluidic Cell 
Concentrator (MCC) 
None 
   
Passive pumping concentrates samples ∼5x 112 
ImageStream 
CK, CD45, 
DRAQ5    
Hybrid of flow cytometry and fluorescence microscopy, 
5000 cells/sec 
113
 
Enrichment-Free EPIC CK, CD45, 
   
Automated digital microscopy, clusters observed 
114
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FASTCell 
DAPI 
   
Fiber-optic array allows larger field-of-view, 25 M cells min
-1
, low 
resolution 
115
 
CytoTrack 
   
Special glass disc scanned as it spins, clusters observed, 100 M 
cells/min 
116
 
In vivo 
Photoacoustic flow 
cytometry (PAFC) 
Absorption 
spectra    
Non-invasive label-free interrogation of large blood volumes 
117
 
  
F
u
n
c
ti
o
n
a
l 
A
s
s
a
y
s
 
 
  
EPISPOT 
Protein 
secretion    
Discriminates between viable and apoptotic CTCs using protein 
secretion 
121
 
Vita-Assay 
Cell 
adhesion 
matrix 
   
Enriches for viable CTCs based on preferential CAM adhesion, 
clusters observed. 
122
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1.4 CTC detection in pancreatic cancer  
1.4.1 Pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-
related death in the United States.134 The median survival time is less than 6 months, 
with a bleak 5-year survival rate of 8%, making it one of the most lethal malignancies in 
humans.134 The inability to detect pancreatic cancer in early stages means that tumor 
invasion to other organs has often already occurred by the time of diagnosis. This may 
be due to the aggressive nature of pancreatic cancer. Hence, there is an urgent need 
for methods that enable early detection.  
There are two main types of pancreatic cancers: exocrine tumors, which are 
called adenocarcinomas, and endocrine tumors (islet cell tumors or pancreatic 
neuroendocrine tumors (PNETs)), which are most often benign and affect the hormone- 
producing cells, making up about 1% of pancreatic cancers.135  
Approximately 95% of pancreatic tumors originate from the ducts of the pancreas 
and are known as PDAC.135 They may evolve from premalignant lesions to fully invasive 
cancer.136 This type of cancer can penetrate into neighboring tissues such as 
lymphatics, spleen, peritoneal cavity, and, in advanced stages of metastasis, the liver 
and lungs.135 Three known human PDAC precursor lesions have been identified in 
clinical and histopathologic studies, including pancreatic intraepithelial neoplasm 
(PanIN), mucinous cystic neoplasm (MCN), and intraductal papillary mucinous 
neoplasm (IPMN).135, 137 PanIN is the most common of these lesions and is graded into 
different stages from I to III, representing the earliest through advanced stages, and 
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ultimately transforms into invasive PDAC137 (Figure  1-1). Genetic alterations are the 
drivers of these defects, and will be explained in detail in section  1.4.2.  
 
Figure ‎1-1: Pancreatic precursor lesions in pancreatic adenocarcinoma progression. A) Normal duct, B) 
pancreatic intraepithelial neoplasm (PanIN), and C) PDAC.
135, 137
  
1.4.2 The biology of pancreatic cancer 
Almost all patients with pancreatic cancer carry one or more of four genetic 
defects: activation of KRAS2 oncogene (90% of tumors), inactivation of the tumor-
suppressor gene CDKN2A (95%), inactivation of the tumor-suppressor genes TP53 
(50%-75%), and deleted in pancreatic cancer4 (DPC4 or SMAD4) (50%).136 These 
sequences of events are extremely complex and heterogeneous. Furthermore, these 
arrangements were also observed in mouse models.136, 138-141 
Pancreatic cancers are composed of several elements (Figure  1-2), including 
pancreatic cancer cells (carries an average of 63 genetic alterations per cancer, which 
can be grouped into 12 main signaling pathways),142 pancreatic cancer stem cells (≤5% 
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of cells population), and the tumor stroma (mainly pancreatic stellate cells which are 
responsible for the poor vascularization).136  
The 12 cancer-relevant pathways that are involved in pancreatic cancer cells 
include: apoptosis, DNA damage repair, cell-cycle control, RAS, TGF-β, cell adhesion, 
Hedgehog, Integrin, JNK, wingless in drosophila (Wnt)- β-catenin, invasion, and small 
GTPases.136 Pancreatic cancer stem cell populations are capable of asymmetric 
division; therefore, they are able to generate mature cells as well as cancer stem cells. 
Pancreatic cancer stem cells, which can be identified with some specific markers 
such as CD24, CD44, CD133, and ALDH are resistant to chemotherapy and 
radiography but they have alterations in developmental pathways such as, Notch, 
Hedgehog, and Wnt- β-catenin which may result in a new therapeutic targets.136  
Tumor stroma is a dense formation of both cellular (e.g., fibroblasts, pancreatic 
stellate cells, endothelial cells, immune and inflammatory cells and adiopocytes) and 
extracellular matrix components (e.g., collagen I and III, laminin, fibronectin, MMP, 
TIMP, SPARC, and CTGF).136 The stroma is critically involved in tumor formation, 
progression, and metastasis.137, 143  
1.4.3 Detection and diagnosis 
Lack of early symptoms and reliable screening tests for early detection are major 
reasons why over 85% of PDAC patients are inoperable at the time of diagnosis.144 The 
inability to detect pancreatic cancer in early stages means that tumor invasion to other 
organs has often already occurred by the time of diagnosis. This may be due to the 
aggressive nature of pancreatic cancer.  
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Figure ‎1-2: Cell components of pancreatic cancer. Pancreatic cancers are composed of several distinct elements, 
including pancreatic cancer cells, pancreatic cancer stem cells, and the tumor stroma.
136
 
For the initial evaluation for detection and staging in suspected pancreatic 
patients helical computed tomography (CT) is the most widely used technique.145 Other 
than CT, contrast-enhanced Doppler ultrasound (US), enhanced magnetic resonance 
imaging (MRI), and endoscopic US (EUS) techniques are used in the diagnosis of 
pancreatic cancers of different stages and zones.145   
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Presently, measuring the carbohydrate antigen 19-9 (CA19-9), and the 
carcinoembryonic antigen (CEA) are the only blood-based markers for diagnosis, 
monitoring of treatment, and prediction of survival in pancreatic cancer patients.10 
CA19-9 is a sialylated Lewis antigen of the mucin 1 (MUC1) protein with an overall 
sensitivity of 80% and specificity of 82%.14 However, this biomarker is not applicable to 
all patients, since, not all patients are in a Lewis blood group. Patients with blood type of 
Lewis A- and B- genotype are incapable of synthesizing the CA- 19-9 epitope.10  
1.4.4 Staging of pancreatic cancer 
Pancreatic cancer is staged based on the American Joint Committee on Cancer 
(AJCC) tumor-node-metastasis (TNM) classification which is based on assessment of 
resectability by means of CT.136 Each cancer is assigned a letter (T, N, and M stands for 
tumor, node, and metastases) and number. TX means the tumor cannot be measured, 
T0 shows there is no evidence of primary tumor, and Tis indicates that the cancer cells 
are only growing in the most superficial layer of tissue without growing into deeper 
tissues, which may be called in situ cancer or pre-cancer. Finally, T1, T2, T3, and T4 
describe the tumor size and/or the spread into nearby tissues. The same explanations 
apply for N and M. Additional information about pancreatic cancer staging is provided in 
appendix section (Table  9-1). 
1.4.5 Treatment 
The inaccessibility of the pancreas limits the possibility of surgical removal, and 
the aggressive nature of the tumor leads to a rapid progression, which is strongly 
resistant to chemotherapy.15 In select patients with localized PDAC (only less than 20% 
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of patients),136 surgical resection is the only treatment offering long time survival.146 
Adjuvant and neoadjuvant treatments for pancreatic cancer include chemo-radiotherapy 
and chemotherapy which have been evaluated in several trials with the goal of 
improving patient prognosis.146 In advanced stages, chemo-radiotherapy and 
chemotherapy in locally advanced disease, fluoroprimidines, cisplatin, and gemcitabine 
or more recently FOLFIRINOX is applied.146 Although administering these treatments 
has been successful at reducing tumor burden and prolonging survival, effects of these 
treatments are limited and they cannot eliminate all PDAC cells.147 Furthermore, 
molecularly targeted therapies have failed to show an additional advantage over 
chemotherapy.10 Obtaining tissue from pre- and post- treatment pancreatic cancer 
patients to monitor pharmacodynamic responses during clinical trials is challenging.10 A 
critical factor in the frequently poor outcome is the silent nature of pancreatic cancer 
until late in the disease process.148  
Therefore, early detection is an essential strategy to improve outcomes, such as 
screening of high-risk individuals.149-151 Therefore, there is an urgent need to establish 
new sensitive prognostic methods capable of identifying patients. Meanwhile, better 
understanding of the biology of pancreatic cancer could open new avenues for 
treatment.  
1.4.6 CTCs in pancreatic cancer 
Since access to tumor biopsies in pancreatic cancer is quite challenging due to 
its anatomical position, biomarkers are required to provide better diagnosis and explore 
alternative therapies. Isolation of CTCs from pancreatic cancer is possible, however, 
due to poor sensitivity of many CTC assays for patients with PDAC2, 3 the investigation 
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of their clinical utility has proven less successful than in other cancer types. Some 
examples of CTC enrichment techniques using immunoaffinity, size-based separation, 
negative enrichment, and some other methods in pancreatic cancer field are 
summarized in details in appendix Table  9-2. 
1.4.6.1     CTC detection methods in pancreatic cancer  
Among various developed technologies for the CTC enrichment, some have 
been used to detect CTCs in pancreatic cancer (e.g., CellSearch,63 ISET,10 CTC-Chip,4 
CTC iChip,78 GEM,71 and GEDI67). CellSearch is the only FDA-cleared CTC isolation 
technology, which is able to detect only 2±6 CTC per 7.5 mL of blood in pancreatic 
cancer patients.63 Using the same technology, other groups reported 11-45% CTC 
detection among PDAC patients.6, 152, 153 Utilizing CTC-iChip 66.7% of PDAC patients 
had detectable CTCs.78  
Although Rhim et al. developed a sensitive method to tag and track pancreatic 
epithelial cells in a mouse model of pancreatic cancer,154 there is no specific method 
available for human studies of pancreatic cancer in the clinic. Recently, another 
microfluidic technique, which is an optimized version of HB-chip, was applied to study 
pancreatic cancer.71 A geometrically enhanced mixing (GEM) chip was designed to be 
able to get higher performance of captured cells (90%) compared to HB-chip.71  
1.4.6.1.1     CTC Carpet Chip 
CTC Carpet Chip is designed to capture heterogeneous populations of rare 
pancreatic CTCs (epithelial CTCs (EpCs) and EMT-like CTCs (EMTCs)) using antibody-
coated microposts (Figure  1-3).133 Successful capture of heterogeneous CTC 
populations with high specificity and sensitivity was dependent on the flow velocities 
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and shear forces within the device. Flow velocity is optimized to allow maximal contact 
between cells and microposts, while shear forces are sufficient to prevent non-specific 
cell attachment to posts.  
In order to increase the sensitivity of capture of phenotypically distinct CTCs, the 
previous CTC-Chip developed by Nagrath et al.4 was modified by implementing an 18o 
rotation of hexagonal arrays of 100 μm x 100 μm microposts with an average distance 
of 50 μm between them. We have incorporated novel rearrangements of the posts 
which greatly enhances the capture of different CTCs subpopulations on different chips. 
This employs a dual immunoaffinity and physical discrimination approach enabled by 
the lateral flow distribution and cell post interactions within the CTC Carpet Chip.  
For a more thorough representation of biologically diverse CTCs in patients with 
pancreatic cancer sequential microfluidic devices were set up using antibodies against 
EpCAM, to capture EpCAM+ CTCs, and antibodies against CD133 to capture more 
stem cell like cells, or putative EpCAM- CTCs.155 
CD133 (Prominin-1 or alias PROML1 or AC133) expressed on the cell surface is 
now recognized as a prospective marker for the isolation and characterization of 
pancreatic stem and progenitor cells.156-158 CD133+ pancreatic CSCs showed more 
aggressive behavior such as increased cell proliferation, migration, and invasion 
compared with the CD133- cells because they underwent EMT more readily.159-161 
Therefore, this finding suggests that CD133 might be a meaningful cell surface 
marker for pancreatic cancer cells. In the progression of pancreatic cancer, CSCs are 
linked with the aggressiveness of pancreatic cancer with association of EMT,40 by 
changing the expression of cell surface marker of stem-cell like phenotype and 
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increasing formation of tumor.160 Other than CD133, CD44, CD24, CXCR4, ATP-binding 
cassette subfamily G member2 (ABCG2), and Nestin are also known as pancreatic 
CSCs specific membrane markers.147  
 
Figure ‎1-3: Schematic representative images of the immunoaffinity CTC Carpet Chip. The device uses 
sequential immunoaffinity-based microfluidics to study the biological relevance of heterogeneous circulating tumor 
cell (CTCs). Rare CTCs including both circulating epithelial cells (EpCs, dark pink) and EMT-like cells (EMTCs, 
orange) can be captured simultaneously from the peripheral blood of pancreatic cancer patients by using two markers 
of interest, anti-EpCAM and anti-CD133, in two different chips. The white/red blood cells are shown in green/red 
respectively. The posts are displayed in different colors only for visualization of the device pattern.  
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Obtaining pure CTC populations is crucial for robust downstream gene analysis. 
Therefore, applying the novel sequential microfluidic Carpet CTC Chip we can 
demonstrate enumeration, detection, and downstream molecular analysis of distinct 
CTC populations from pancreatic cancer patients.133 
1.4.6.1.2     Labyrinth device 
The high throughput, label-independent, size-based inertial microfluidic 
separation device, Labyrinth, which was developed in the Nagrath lab, has been used to 
detect CTCs in breast, pancreatic, and lung cancer patients.103  
The design of the Labyrinth device is inspired by the Labyrinth in Greek 
mythology.103 Both inertial focusing and dean flow were incorporated for sized-based 
separation, enabling continuous focusing of all cells while separating CTCs from smaller 
blood cells at the outlet.103 The equilibrium between inertial lift forces and dean flow 
result in migration of particles during laminar flow through the microfluidic device within 
curved channels.103 The Labyrinth device employs a combination of long curvature 
structure with loops and sharp corners to enhance differential focusing, allowing ease of 
separation of CTCs and white blood cells (WBCs) from patient blood samples.103 The 
CTCs can be recovered from other blood components in curved microfluidic devices by 
focusing different sized cells into different stream lines and collecting them into 
individual outlet channels (Figure  1-4).103 Particles are focused by inertial forces which 
can be considered as the driving forces, while particle migrates away from the center of 
the channel by drag forces from dean flow, leading to size-based separation.103 
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Figure ‎1-4: Size-based separation Labyrinth device. The device contains loops and corners to separate CTCs 
from other blood components individually into different streams (outlet channels).   
1.5 CTC detection in lung cancer  
1.5.1 Lung cancer 
Lung cancer is among the most prevalent forms of cancer and has one of 
the highest mortality rates (>234,000 new cases and >154,000 death cases in the 
United State in 2018), with a 5-year survival rate of only 18%.134, 162, 163  
There are two major types of lung cancers based on the appearance of 
lung cancer cells under the microscope, small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). About 10-15% of lung cancers are SCLC, while 
80-85% of lung cancers are classified as NSCLC which mainly comprises 
adenocarcinoma (~40%), squamous cell (epidermoid) carcinoma (25-30%), and 
large cell (undifferentiated) carcinoma (10-15%).164  
1.5.2 The biology of lung cancer 
A recent study revealed that less than two thirds of lung cancers have an underlying 
driver mutation responsible for tumor proliferation (e.g. KRAS, EGFR, ALK, MET, 
HER2, FGFR1, ROS1, RET, BRAF, PI3KCA, MEK1, AKT1, MAP2K1, and NRAS) 
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(Figure  1-5).165 Of the known driver mutations, about 30% have FDA-cleared targeted 
therapies.163      
                           
Figure ‎1-5: Pie chart of NSCLC mutations
165
 
1.5.3 Detection and diagnosis 
Imaging tests including chest x-ray, CT scan, MRI scan, positron emission 
tomography (PET) scan, and bone scan are some examples of the commonly used 
screening tests for NSCLC.166 Upon the non-small lung cancer detection, further 
diagnostics are performed, including, sputum cytology, thoracentesis, needle biopsy, 
and bronchoscopy.166 The commonly used low-dose CT scan technique is not an ideal 
screening test for patients with lung cancer primarily due to poor specificity (high false 
positive rates).167 In addition, CT scans are expensive and require tissue biopsies for 
confirmation of cancer. Alternative methods to detect cancers that can either supplant or 
complement the existing screening tests are an unmet need.168 
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1.5.4 Staging of lung cancer 
Lung cancer is staged based on the American Joint Committee on Cancer 
(AJCC) tumor-node-metastasis (TNM) system. Additional information about lung cancer 
staging is provided in appendix section (   Table  9-3). 
1.5.5 Treatments 
The most effective treatment option for NSCLC patients is surgical intervention, 
however, patients are usually not diagnosed until advanced stages.169 The practice of 
non-invasive liquid biopsy as a diagnostic, prognostic, and theranostic tool may be an 
attractive approach in NSCLC patients.170 This approach may provide complementary 
data for prognostication and treatment responsiveness, and allow identification of newer 
genomic alterations that inform treatment resistance and alternative therapies.170 
1.5.6 CTCs in lung cancer 
As mentioned above, CTCs have been detected in blood of patients with 
various solid tumors, including lung cancer, where their presence is associated 
with poor clinical outcomes.171-178 Lung cancer CTCs have shown similar 
morphology and greater than 70% common histology with the primary tumor.179 
Therefore, CTCs may eventually serve as important blood-based biomarkers that 
could aid in early detection of lung cancer and the identification of early 
recurrence following therapy. However, there are currently no FDA-cleared CTC 
platforms for analyzing CTCs in lung cancer. The following section describes the 
merits and demerits of current CTC platforms for lung cancer. 
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1.5.6.1     CTC detection methods 
Several studies have demonstrated the presence of CTCs using different 
detection technologies in patients with lung cancer.4, 174-178, 180, 181 It has been 
reported that in metastatic NSCLC patients only 21-39% of patients had 
detectable CTCs at baseline using CellSearch.174, 181-184 In contrast, the presence 
of CTCs (>5 CTC mL-1) has been demonstrated in 100% of patients with 
metastatic lung cancer using the immunoaffinity microfluidic CTC-Chip.4 In 
another study using NanoVelcro technology, 4-17 CTCs mL-1 were detected in 
NSCLC patients.185 One drawback of these label-dependent technologies is that 
they miss EpCAM- CTCs in NSCLCs that have undergone EMT. Among label-
independent isolation approaches, ISET technology has detected 1-5 CTCs 4 
mL-1 in 36%-56.7% of NSCLC patients.186, 187 Recently, using Dean Flow 
Fractionation (DFF), CTCs were isolated (39.1±24.8 CTCs mL-1) at a flow rate of 
3 mL hr-1 in metastatic NSCLC patients.188 Additional information about CTC 
detection methods in lung cancer is provided in appendix section (Table  9-4). 
There is a need for a simple, reliable, inexpensive, efficient, and high 
throughput system to enrich and characterize all relevant CTC subsets from lung 
cancer patient samples. Taking the advantage of the Labyrinth device, we can 
isolate heterogeneous populations of CTCs in NSCLC patients. 
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2 Materials and Methods 
2.1 Microfabrication  
Microfabrication is the method of fabrication of miniature structures of micro-
nanometer scales. The microfabrication device pattern is first designed by employing 
AutoCAD software (version 2011), and then it was converted to a photomask (FineLine 
Imaging) for fabrication. The photomask was fabricated using traditional soft 
lithography,189 bonded to a substrate, and then finally surface functionalized 
(Figure  2-1A). All microfabrication processes were done at the clean room facility 
available at Lurie Nanofabrication Facility at College of Engineering University of 
Michigan (Figure  2-1B). 
 
Figure ‎2-1: Microfabrication process. A) The flow chart of the microfabrication processes. B) The clean room 
facility available at Lurie Nanofabrication Facility at College of Engineering University of Michigan. 
2.1.1 Computational analysis of the microposts 
Finite element simulations were performed in COMSOL Multiphysics 4.2 (Comsol 
Inc.) with an inlet flow rate of 1 mL hr-1 on a portion of diamond shape of the CTC 
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Carpet Chip. A symmetry boundary condition was applied on the two similar boundaries 
flanking the posts. A wall (no slip) boundary condition was applied on the post outlines. 
The particle tracing plot was simulated with rigid particles 15 μm in size, with a condition 
of sticking to any encountered wall being applied. 
2.1.2 Photolithography 
Photolithography is a process by which an image is optically transferred from one 
surface to another, most commonly by the projection of light through a mask onto a 
photosensitive material such as photoresist. Photoresists are radiation sensitive 
materials that typically consist of a polymer resin, a radiation sensitizer, and a carrier 
solvent. Photoresist can be classified as either positive or negative based on their 
solubility following UV exposure. The solubility of exposed areas in positive resists 
increases, whereas in the negative photoresist the solubility is decreased.190 Generally, 
a negative photoresist is strengthened by radiation exposure so the remaining pattern 
after being subject to a developer solution appears as the inverse of the opaque regions 
of the mask. 
In our study, SU-8 100 (MicroChem Corp) was selected as a negative 
photoresist, and was used to prepare a mold with a final thickness of range 100 µm. 
The SU-8 was spin coated onto a silicon wafer at 500 rpm for 10 sec and then 2350 rpm 
for 60 sec. This was followed by two steps of soft baking, first at 65°C for 10 min and 
then 95°C for 1 hr, after which the coated wafer was exposed to UV light for 15 sec 
using a Karl Suss MA6 aligner. Post exposure baking was done first at 65°C for 3 min 
followed by 95°C for 10 min and the pattern was developed in SU-8 developer for 2 min, 
followed by rinsing with isopropyl alcohol for 2 min and hard baking at 150°C for 3 min. 
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The resulting thickness was confirmed to be within the range of 98-100 A° as 
determined using Dektak 6M Surface Profilometer. The steps involved in 
photolithography techniques for our study were shown in Figure  2-2. 
 
Figure ‎2-2: Photolithography process. A negative photoresist (SU-8) spin coated onto a silicon wafer followed by 
baking and exposure through a photomask, and developing to achieve the desire patter.  
2.1.3 Rapid prototyping 
Rapid prototyping the microfabrication of the chambers can be done using 
transparent polymers such as, poly-dimethyl siloxane (PDMS) and poly-metheyl 
methacrylate (PMMA).189, 191 PDMS is popular because it is not only optically 
transparent, but also allows for additional histochemical stains and markers to be 
applied post-enumeration, and is conducive to bright field imaging (currently a limitation 
in the silicon CTC Chip).189, 191 PDMS is a flexible elastomeric polymer that is an 
excellent material for microfluidic device fabrication. In order to produce an inexpensive, 
disposable, and high throughput point-of-care multiplex microfluidic chip, the current 
design is reproduced in PDMS elastomer, Sylgard® 184 (Dow Corning). Sylgard is a 
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two part resin system containing vinyl groups and hydrosiloxane groups. Mixing the two 
resin components together leads to a cross-linked network of dimethyl siloxane groups. 
Because this material is flexible, it can be unmolded (peeled) from the SU-8 master, 
leaving the master intact and ready to produce another device.  
PDMS (mixed in a 10:1 ratio of PDMS base with curing agent, Sylgard® 184) 
was degassed in a desiccator for about 30 min, after which it was cast over the SU-8 
mold, and degassed again for about 2 hr. Degassed PDMS was placed in an oven at 
65°C overnight. The cured PDMS casting was released by peeling it away from the 
mold and fluidic ports were punched at the designated ends of the chamber to create 
inlet and outlet holes. These holes were later used for incorporating tubing inputs. The 
punched hole was slightly smaller than the outer diameter of the tubing being used, 
providing adequate sealing for typical fluidic pressures. The schematic of the rapid 
prototyping of PDMS devices and its bonding to glass slides is shown in Figure  2-3. 
 
Figure ‎2-3: Rapid prototyping of PDMS devices. The silicon master mold is used to create PDMS molds, which 
are bonded to the substrate (glass) by plasma bonding. 
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2.1.4 Bonding, surface chemical modification and functionalization 
One of the most useful properties of PDMS is that its surface can be chemically 
modified in order to obtain the interfacial properties of interest. The most reliable 
method to covalently functionalize PDMS is to expose it to oxygen plasma, whereby 
surface Si-CH3 groups along the PDMS backbone are transformed into Si-OH groups 
by the reactive oxygen species in the plasma. These silane surfaces are easily 
transformed with alkoxysilanes to yield much different chemistry as shown in Figure  2-4. 
 
Figure ‎2-4: Silanization of plasma-exposed PDMS 
PDMS replicas and glass slides were cleaned with oxygen plasma and then 
immediately placed in contact to bond the surfaces irreversibly. The PDMS slab was 
bonded with a glass substrate, post oxygen plasma treatment for oxidization the 
surfaces, and therefore for having a hydrophilic area, along with a 10 min baking at 
80°C hot plate for having a stronger bonding (Figure  2-3).  
The chemical modification and functionalization of the surface of the device was 
done immediately after the bonding as depicted. Initially, the surface of the device was 
modified with 4% (v/v) 3-mercaptopropyl trimethoxy silane (Gelest) in ethanol (1:25 
ratio) for making the surfaces more hydrophilic, at room temperature (RT) for 1 hr. Then 
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it was treated with the coupling agent N-gamma-Maleimidobutyryloxy-Succinimide 
(GMBS) (Pierce) in ethanol (1:357 ratio) for 30 min, resulting in GMBS attachment to 
the microposts as a linker. Next, the device was treated with 100 µg mL-1 Neutravidin 
(Invitrogen) in phosphate buffered saline (PBS) 1:10 ratio) at RT, leading to 
immobilization onto GMBS, and then flushed with PBS to remove excess of avadin. The 
functionalization process was checked with Biotin fluorescence labeled at a 
concentration of 10 µg mL-1 in PBS with 1% (w/v) bovine serum albumin (BSA) with a 
positive control device, the negative one does not coated with Avadin, hence it doesn’t 
show the fluorescence (Figure  2-5). 
 
Figure ‎2-5:  Biotinylated functionalized PDMS micropost chamber. Representative photomicrograph showing 
FITC conjugated biotinylated functionalized PDMS micropost chamber with (A) and without (B) inclusion of Avidin 
coating. 
Finally, biotin-conjugated anti-Epithelial cell adhesion molecule (EpCAM) (RnD 
Systems) antibodies or anti-CD133 (Miltenyi Biotec) antibodies at a concentration of 
20 µg  mL-1 in PBS with 1% (w/v) Bovine Serum Albumin (BSA) (Sigma) was allowed to 
react for 30 min for each inlet and outlet before washing with PBS. The device was 
immediately used for capturing CTCs or cancer cells (Figure  2-6).   
 48 
 
Figure ‎2-6: PDMS surface modification and functionalization. Antibodies can be immobilized on PDMS by 
silanization.  
2.2 Cell culture  
Six different human cancer cell lines, colon adenocarcinoma cell line (HT-29), 
pancreatic cell line (Panc-1), prostate cancer cell line (PC-3), and breast cancer cell 
lines (MCF-7, SUM-159, and Hs-578T) were obtained from ATCC. Capan-1 cancer cell 
line was obtained from Dr. Howard Crawford’s lab at University of Michigan. Human 
non-small lung cancer cell lines H1650, PC-9, A549, HCC827, and H1975 were 
obtained from the Beer and Hassan laboratories at the University of Michigan. 
The HT-29 cells were cultured in McCoy’s 5A Medium (ATCC), PC-3, SUM-159,  
and Hs-578T cells in low-glucose Dulbecco’s modified Eagle’s-F12 medium (DMEM-
F12) (Invitrogen), MCF-7 and Panc-1 cells in DMEM+++ medium (Invitrogen), Capan-1 
cells in IMDM medium (HyClone), H1650, PC-9, HCC827, H1975, and A549 cells in 
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RPMI 1640 medium (Invitrogen). All supplemented with 10% Fetal Bovine Serum (FBS) 
(Invitrogen) and 1% penicillin-streptomycin (Pen-Strep) (Sigma) and maintained in an 
incubator at 37°C in 5% CO2 and 95% relative humidity. The cells were cultured in 
sterile 25 or 75 cm2 flasks (Corning) and media replaced every 48 hr. Upon reaching 
>75-80% confluence, the cells were harvested with 0.05% Trypsin-EDTA (Invitrogen). 
Prior to characterization experiments, cells were labeled with green CellTracker 
fluorescent dye (Invitrogen). 
2.2.1 CellTracker dye protocol  
Sub-confluent monolayers of cells were detached using 0.05% Trypsin-EDTA 
solution and washed in standard media, followed by centrifugation at 1000 rpm for 5 
min. Cell pellet was washed two times with phosphate buffered saline (PBS) and 
resuspended with 5 mL of serum free media plus 5 µL dye (green CellTracker) followed 
by incubation for 30 min at 37°C. The cells were washed with PBS and incubated in 
complete media at 37°C for 30 min. After washing the pellet with PBS, 1000 cells mL-1 
were prepared by serial dilution. The density of cell suspensions were counted using a 
hemocytometer and spiked into PBS or healthy control (HC) blood for analysis of CTCs 
using CTC Carpet Chip or Labyrinth. 
2.2.2 Primary human pancreatic cancer and cancer-associated fibroblast (CAF) cell 
lines 
Primary human pancreatic cancer cell lines (UM18 and cancer associated 
fibroblast (CAF)) were generated from primary PDAC patient in Dr. Diane Simeone’s 
laboratory at the University of Michigan hospital under Institutional Review Board (IRB) 
guidelines.192 Both cell lines were cultured in RPMI 1640 supplemented with 10% heat-
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inactivated FBS, 2 mmol L-1 L-glutamin, 100 units mL-1 penicillin, 100 µg mL-1 
streptomycin (Invitrogen) in 95% air and 5% CO2 at 37˚C.  
2.2.3 Patient-derived CTC expansion 
Prior seeding the recovered CTCs from NSCLC patient samples using Labyrinth, 
the 48-well plates were coated with 100 µl of Matrigel (Corning), 51.6 µl of Collagen I 
(Invitrogen), and 48.4 µl of HEPES (Invitrogen) to make a 3D culture models. For 
making a 2D culture models, the well plates were coated with 5 µg of Fribronectin 
(Corning) diluted in distilled water (Invitrogen). The well plates were incubated for 1 hr at 
RT and then washed with distilled water prior the culture. 
After CTC enrichment, small portion of the samples were stained for CTC counts. 
The rest of the samples were seeded on a 3D coated 48-well plate using media #1 for 
3-4 weeks under normoxic conditions (5% CO2) and 95% relative humidity at 37°C. 
Media #1 contains 200 µl of conditioned media (from pancreatic cancer-associated-
fibroblast 19 (CAF-19)) supplemented with 10% FBS, 1% Pen-Strep, 8 µl of human 
platelet lysates (hPL-MAX) (Mill Creek), and 0.06 µl of insulin (Sigma). 
To be able to passage the cells from the 3D culture, 10 µl of collagenase type I 
(Invitrogen) diluted into 400 µl of HBSS (Invitrogen) and were added to the well plates to 
dissolve the Matrigel. The well plates were incubated 3-4 hr in the incubator, following 
centrifugation at 1000 rpm for 10 min. The cell pellet was resuspended with media #2 
and then were seeded into a 2D culture condition for another 3-4 weeks. Media #2 
contains 200 µl of conditioned media from CAF-19, 10% FBS, 1% Pen-Strep, and 8 µl 
of hPL-GOLD (Mill Creek)). Upon the cell confluency on 2D culture, the cells were 
passaged using 0.25% Trypsin-EDTA (Invitrogen). The cell pellet was resuspended with 
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media #2 and seeded into a 2D culture model. A small portion of this sample was used 
for the CTC counts. 
2.3 Western blot 
Whole cell lysates were prepared from PC-3 and HT-29 cell lines. For the 
Western blotting analysis, equal amount of proteins were separated using SDS-PAGE 
(RnD Systems) and transferred to a PVDF membrane (RnD Systems) and then 
incubated with anti-EpCAM and anti-CD133 antibodies. Proteins were visualized using 
horseradish peroxide-conjugated secondary antibodies followed by exposure of 
immunoreactive bands to photographic film. Glyceraldehyde 3-Phosphate 
Dehydrogenase (GAPDH) (Santa Cruz) was used as an internal loading control.   
2.4 Flow cytometry analysis (FACS) 
After harvesting the cell lines by trypsinization, cells were washed with PBS and 
the pellet resuspended with 4% paraformaldehyde (PFA) (Pierce), and 0.2% Triton X-
100 (Sigma), followed by 30 min incubation time for each step. Next, the cells were 
washed with PBS and blocked with 3% BSA plus 2% goat serum (Invitrogen), followed 
by 30 min incubation time. Then cells were divided into unstained, isotype, and stained 
groups. The specific antibodies, anti-EpCAM and anti-CD133 were added followed by 1 
hr incubation time. After PBS washing, the pellet was resuspended with secondary 
antibodies followed by 1 hr incubation in dark, and then PBS wash. All steps were 
followed by centrifuge at 2500 rpm for 4 min. 
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2.5 Capture efficiency in single CTC Carpet Chip 
Four different cancer cell lines with different EpCAM expression levels, HT-29, 
Panc-1, PC-3, and Hs-578T, and a CD133 positive cell line, Capan-1, were 
fluorescently-labeled with green CellTracker (section  2.2.1). To determine the 
percentage of cells captured on a functionalized CTC Carpet Chip, coated with either 
anti-EpCAM (for EpCAM expression cell lines) or anti-CD133 (for CD133 expression 
cell line), 1000 cells from each of the fluorescently-labeled cancer cell lines were spiked 
into whole blood collected from HCs and flowed through the microfluidic device at a 
constant flow rate (1 mL hr-1). Then cells were fixed and permeabilized on the chip by 
using Cytofix/Cytoperm (BD Bioscience) followed by staining with DAPI (4’,6-diamidino-
2-phenylindole) (Invitrogen) to identify DNA content. Capture efficiency was calculated 
as the percentage of captured cells on the device divided by the total number of cells 
flowed through the chip. Captured cancer cells were identified and enumerated by 
scanning the entire micropost chamber of the device using a Nikon Eclipse Ti 
fluorescence microscope.     
2.6 Capture efficiency in dual CTC Carpet Chip  
In order to facilitate separating circulating epithelial (EpCAM-expressing) and 
EMT-like (CD133-expressing) cells in different devices in sequential order from the 
same sample, two separate CTC Carpet Chips were connected to each other using a 2-
inch piece of connective tubing (Fisherbrand™ Tygon S3™ E-3603 Flexible Tubings). 
The first chip was coated with anti-EpCAM and the second one with anti-CD133. Blood 
sample was then processed through each chip in succession. After this step, the chips 
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were disconnected from one another, and washed with PBS (10 mL hr-1) for the 
immunofluorescence staining process.  
2.7 Characterization experiments for Labyrinth (Cell lines)  
The Labyrinth device was primed with 1% Pluronic acid solution (Sigma) at a flow 
rate of 100 μL min-1 for 10 min followed by 10 min incubation time to prevent cell 
adhesion to channel walls. To demonstrate cell specificity in the Labyrinth, same 
number of pre-labeled cancer cells (from cell lines) and DAPI-labeled WBCs (1000 cells 
mL-1) were mixed and spiked into PBS and flowed through the device at different flow 
rates ranging from, 1500-3000 µL min-1. Products from outlet #2 were collected after 1.5 
min flow stabilization for cell counting to calculate the recovery and percent of depleted 
WBCs. Images were taken using a fluorescence microscope under FITC and DAPI 
filters to categorize and document cancer cells in isolation from other blood 
components. 
2.8 Pancreatic cancer patient CTC capture using CTC Carpet Chip and 
Immunofluorescence staining (IF) 
This study was approved by the institutional review board (IRB) of the University 
of Michigan. 1 mL of whole blood from each pancreatic cancer patient was processed 
through two CTC Carpet Chips connected in series at the designated flow rate (1 mL hr-
1), followed by fixation and permeabilization with 4% PFA and 0.2% Triton X-100 
respectively, followed by blocking with 3% BSA plus 2% goat serum.  
In order to identify and characterize sub-populations of pancreatic CTCs and 
distinguish them from other blood cells, we used the following criteria: cells that were 
captured on the anti-EpCAM coated chip and stained positive for pan-cytokeratin 
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(PanCK) (Biorad), negative for CD45 (Biorad), and positive for cell nucleus staining 
(DAPI) were characterized as epithelial CTCs (EpCs); and cells that were captured on 
the anti-CD133 coated chip and stained positive for Vimentin (BD Bioscience), negative 
for CD45, and positive for DAPI were characterized as EMT-like CTCs (EMTCs.)1 Alexa 
Fluor 488-, 546-, 647-conjugated secondary antibodies (Invitrogen) were applied in 
order to detect CD45, PanCK, and Vimentin respectively.  
2.9 Pancreatic and NSCLC cancer patient CTC isolation using Labyrinth 
and Immunofluorescence staining (IF) 
The experimental protocol was approved by the Ethics (Institutional Review 
Board) and Scientific Review Committees of the University of Michigan and all patients 
and healthy blood donors gave their informed consent to participate in the study. Briefly, 
blood samples (~7-10 mL) from metastatic pancreatic cancer and (~20 mL) from 
NSCLC patients were collected in EDTA tubes and processed through the Labyrinth 
within 2 hr of collection. RBCs in the blood samples were removed using density 
separation with 6% dextran (Spectrum) prior to Labyrinth processing. The blood sample 
mixed with dextran solution was kept at RT for 1-1.5 hr to settle the RBCs driven by 
density difference. The supernatant, which included all whole blood components except 
RBCs, was carefully removed and diluted with PBS (1:3). The diluted dextran 
supernatant was then processed through the Labyrinth at a flow rate of 2000 μL min-1 
for pancreatic cancer patient samples and 2500 μL min-1 for NSCLC patient samples. 
The product from outlet #2 was collected after stabilization.  
The product from outlet #2 was processed using a Thermo ScientificTM Cytospin 
Cytocentrifuge. A poly-lysine coated slide was placed into the cytospin funnel and 250 
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μL of sample was added to each cytospin funnel and cytrocentrifuged at a speed of 800 
rpm for 10 min. Samples were fixed on the cytoslides using 4% PFA and 
cytrocentrifuged at the same conditions as described above. Slide samples were 
permeabilized by applying 0.2% Triton X-100 for 3 min. Slides were then washed with 
PBS (times 3) for 5 min and blocked using 10% donkey serum for 30 min at RT.  
For the pancreatic cancer CTC enumeration, slides were incubated with the 
panel of primary antibodies including rabbit anti-human Zeb1 (Santa Cruz), mouse anti-
human anti-PanCK (IgG1) (Biolegend), mouse anti-human anti-CK19 (IgG2a) (Santa 
Cruz), and rat anti-human CD45 (IgG2b) (Santa cruz) overnight at 4˚C. The next day, 
slides were washed with PBS (times 3) for 5 min and then incubated with the secondary 
antibodies (Alexa Fluor 488, 549, and 647) in dark for 1.5 hr at RT.  
For CTC enumeration of NSCLC patient samples, slides were incubated with the 
panel of primary antibodies including (mouse anti-human CD45 (IgG2a) (Biorad), 
mouse anti-human anti-PanCK (IgG1) (Biorad), anti-human anti-EpCAM, biotinlated 
(goat IgG) (R&D System), and rabbit anti-human anti-Vimentin (Abcam) overnight at 
4˚C, followed by PBS wash (times 3) for 5 min the following day. Slides were incubated 
in dark with secondary antibodies (Alexa Fluor 488, 549, 750, and 647) for 1.5 hr at RT. 
Finally, slides were washed with PBS (times 3) for 5 min and mounted using Prolong 
Gold Antifade Mountant with DAPI (Invitrogen). The immunofluorescently stained slides 
were imaged using a fluorescence microscope for the CTC enumeration. 
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2.10 RNA extraction and quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) analysis 
Isolated CTCs within the device were incubated at 42°C for 30 min with 
extraction buffer of Arcturus PicoPure kit (Invitrogen) to lyse the cells. Then RNase free 
water (Invitrogen) was passed through the chip to collect the cell lysate. Total RNA was 
then prepared from the CTC lysate using the Arcturus PicoPure kit and was subjected 
to a reverse transcription reaction followed by 18 cycles of pre-amplification of cDNAs of 
96 cancer-related genes (Error! Reference source not found.) using the pooled 
TaqMan Gene Expression Assays and Cell-to-CT Ambion Kit (Invitrogen). Finally, the 
gene expression pattern of pre-amplified cDNAs was determined using TaqMan Gene 
Expression Assays for 96 genes and the BioMark HD qPCR platform (Fluidigm) (35 
cycles) (Figure  2-7). 
Table ‎2-1: Table of 96 genes analyzed by TaqMan Gene Expression Assays 
96 genes analyzed by TaqMan Gene Expression Assays 
AKT1 BRAF CDH2 ERCC1 KLF4 MCL1 PDX1 SPON2 
ALDH1A1 BRCA1 cMYC ESR1 K-Ras MET PGR TGFB1 
ALDH1a2 CCDC80 COL1a2 GAPDH KRT18 MGP PIK3CA TIMP1 
ALDH1a3 CCND1 COL3a1 GEMIN2 KRT19 MKI67 PON1 TIMP2 
ALK CD133 CTNNB1 GLi1 KRT20 MMP2 POU5F1 TIMP3 
ANXA2 CD14 CXCR1 HPRT1 KRT5 MMP9 PTEN TP53 
AR CD24 CXCR4 IGFBP5 KRT7 MS4A1 RAB7A TTF-1 
ATDC CD3D DCN IL6 KRT8 NANOG RB1 TWIST1 
ATL1 CD44 EGFR IL6R LGALS3 NES Shh Vimentin 
BAX CD45 EMP2 IL6ST LGALS3BP NKX2-1 SNAI1 WNT2 
BCL2 CD90 EPCAM IL8 MAPK p63 SNAI2 ZEB1 
BMi1 CDH1 ERBB2 ITGAM MCAM PCNA SPARC ZEB2 
 57 
 
Figure ‎2-7: BioMark HD Real-Time PCR system. 
2.11 Immunohistochemistry (IHC) 
A gastrointestinal pathologist reviewed each patient’s hematoxylin & eosin (H&E) 
stained resection specimen and identified a representative section of formalin-fixed, 
paraffin-embedded tumor and normal tissue. The unstained 5 µm-thick tissue section 
was reacted with anti-BMi1 (Cell Signaling), anti-MKi67 (Cell Marque), anti-PIK3CA 
(Abcam), anti-TP53 (Cell Marque), MCAM (Abcam), and CD133 (Miltenyi Biotec) 
antibodies using immunohistochemistry (IHC) technique to determine levels of tumoral 
protein expression of BMi1, MKi67, PIK3CA, TP53, MCAM, and CD133. The staining 
intensity and percentage of positive cells out of total tumor cells were graded by a 
pancreatic pathologist who was blinded to patients’ outcomes. The intensity of IHC 
staining is graded on a scale of 0 to 3, where 0 is no staining, 1 is weak, 2 is moderate, 
and 3 is strong staining. 
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2.12 Fluorescence in situ hybridization (FISH) analysis 
Interphase FISH was carried out as previously described by other groups.193, 194 
Briefly, bacterial artificial chromosomes (BACs) were obtained from the BACPAC 
Resource Center (Oakland) for the preparation of probes.195 For detection of gene 
rearrangements, deletion or amplification, the following probes were used:  for ROS1, 
RP11-1110L9 (5’ to ROS1) and RP11-605K7 (3’ to ROS1), for RET, RP11-124O11 (5’ 
to RET) and RP11-718J13 (3’ to RET), for EGFR, RP11-23F4 (5’ to EGFR) and RP11-
56P1 (3’ to EGFR), and for ALK, RP11-993C21 (5’ to ALK) and RP11-984I21 (3’ to 
ALK). The integrity and accurate localization of all probes were verified by hybridization 
to metaphase spreads prepared from normal peripheral lymphocytes. Slides were 
examined using a Zeiss Axioplan 2 microscope equipped with image processing 
software ISIS (Metasystems). FISH signals were scored manually under 100X oil 
immersion in morphologically intact and non-overlapping nuclei and greater than 100 
cells from each slide were recorded. 
2.13 In Vivo tumorigenicity assays  
Six-week old NOD/SCID mice were housed under pathogen-free condition at the 
University of Michigan Animal Care center. Mice were anesthetized with intraperitoneal 
injection of xylazine (9 mg kg-1) and ketamine (100 mg kg-1). A median laparotomy was 
performed, and 105 primary human pancreatic cells (UM18) infected with a lentivirus 
encoding GFP-luciferase (University of Michigan Vector Core) alone or with and equal 
number of DsRed-labeled CAF cells were injected into the pancreatic tail using a 30-
gauge needle (n=5 per group). Six to 8 weeks following cell injections, mice were 
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euthanized with CO2 inhalation. Blood was collected for enumeration analysis of 
circulating GFP-labeled tumor cells and DsRed-labeled CAF.   
2.14 RBC lysis buffer 
RBC lysis buffer (Qiagen) was utilized for RBCs removal from the products of 
either single or double Labyrinth. Recovered CTCs from outlet #2 of Labyrinth were 
incubated with this buffer (1:3) for 2 min on ice following the centrifugation step. A small 
portion of this solution was used for CTC enumeration, and the rest was used for the 
culture. 
2.15 Drug testing 
Different NSCLC cell lines were plated at a seeding density of 200, 400, and 
2000 cells well-1 on either 96-well or 384-well plates. Each drug concentration (0,100, 
500, 1000, 5000, and 10000 nM) had wells in triplicates. Cells were incubated with 
various drugs for 72 hr. After treatment, different cell viability assay kits including; 
CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega), CellTiter-Glo 
luminescent cell viability assay (2D kit) (Promega), and CellTiter-Glo 3D cell viability 
assay (3D kit) (Promega) were used for 30 min, 1hr, 1.5 hr, and 2 hr to assess half 
maximal inhibitory concentration (IC50) values of tyrosine kinase inhibitors (TKIs) along 
with relevant sensitive or resistant NSCLC cell lines. Luminescent signals were 
measured with a Biotek-Synergy Neo-Plate Reader (BioTek Instruments, Winooski, VT) 
and the optimal duration of incubation was determined. IC50 values were calculated 
with nonlinear regression model using Prism Graphpad.  
 60 
Various drugs including, Erlotinib and Crizotinib (Sigma), Ceritinib, Afatinib, and 
Osimertinib (Selleckchem) were reconstituted in DMSO, and Cetuximab (BioVision) was 
reconstituted in PBS (1 μg μL-1) for in vitro drug testing. 
2.16 Statistical analysis 
For studying CTCs in pancreatic cancer using CTC Carpet Chip, all results 
present as mean±standard deviation. Unpaired t-tests (two-tailed) were used to 
compare the differences between total CTCs of patient samples (n=35) vs. healthy 
controls (n=9). Paired t-tests (two-tailed) were used to compare the differences between 
EpCs and EMTCs from patient samples (n=35). Unpaired t-tests (two-tailed) were used 
to evaluate the effect of stage, resection, tumor size, lymph node involvement, and 
metastasis on EpCs and EMTCs levels (n=35). Statistical significance was defined as a 
two-sided p<0.05.  
For the RNA expression analysis, non-detect values were replaced by a pseudo 
cycle number of 40 and in the analyzed samples typically out of 96 genes, around 50% 
of them showed positive data. Also a cut off n>2 (greater than 2 patients displaying 
gene expression in each group for each gene) was applied when genes in different 
groups were compared to each other, and 75 of 96 genes met this criterion. GAPDH 
was used as an internal reference to normalize cycle threshold (Ct) values for the genes 
of interest by subtracting each gene expression value by GAPDH to generate a -ΔCt. 
Median fold changes were generated by dividing the median gene expression (2–ΔCt) of 
group A by that of group B. Wilcoxon signed-rank test was used in RNA expression for 
paired samples (n=17). Mann-Whitney test was used to quantify differences in RNA 
expression for non-paired samples using the average -ΔCt value across both sample 
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chips (n=17). Analyses were conducted using GraphPad Prism, Python, R software 
environment, and iPathwayGuide (Advaita). P-values were not adjusted for multiple 
testing due to the small number of patient samples. The median expressions of genes 
(2-ΔCt) across all patients were used as cut-off points for Kaplan Meier graphs. Log-rank 
(Mantel-Cox) tests were used to analyze Kaplan-Meier overall survival (OS) and 
progression free survival (PFS) graphs in all patient CTCs samples (n=17). P-values 
threshold of 0.05 were used in the iPathwayGuide analysis.  
For studying the CTCs in pancreatic cancer using Labyrinth, paired t-test was 
used to analyze the recovered CTCs from patient samples (n=141) in treatment naïve 
and treatment groups.   
For studying CTCs in NSCLC cancer using Labyrinth, Mann-Whitney test (two-
tailed) was used to compare the differences between total numbers of CTCs in patient 
samples (n=21) vs. healthy controls (n=3). Unpaired t-tests (two-tailed) were used to 
compare EpCAM+ and EpCAM- CTCs, Vimentin+ and Vimentin- CTCs, as well as 
single CTC versus CTC-clusters. The IC50 values were calculated with nonlinear 
regression model using Prism Graphpad. Results are shown as mean value with 95% 
confidence intervals calculated based on results triplicate wells. All drug testing 
experiments were repeated at least three times.   
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3 Results 
3.1 Different design configurations of immunoaffinity microfluidic 
devices  
As mentioned earlier, there are no unique technologies to enumerate CTCs from 
human pancreatic cancer in clinic. Therefore, to determine the highest CTC capture 
efficiency different micropost geometries and arrangements of the arrays and other 
parameters were explored in the process of optimization of the CTC Carpet Chip 
including, CTC Original, Split, Modified, Rotated, and Carpet Chip.  
The Split and Modified Chips were different versions of the Original CTC Chip 
with some changes on the outliers to make them more specific and sensitive for 
capturing purpose. All had pattern of repetition of 10 × 10 arrays of 100 μm posts. The 
modifications were shown in red arrows (Figure  3-1).  
                           
Figure ‎3-1: AutoCAD design of different version of the Original CTC Chip. A) Original, B) Split, C) Modified. The 
modification in the Split and the Modified CTC Chip were shown with red arrows. 
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In the Rotated device, the post arrays were rotated 10° relative to the previous 
array until reaching a total rotation of 180° and then decreasing rotation from 180° to 0° 
for the subsequent row (Figure  3-2B). CTC Carpet Chip is based on an 18° rotation of 
hexagonal arrays of 100 μm posts (Figure  3-2C). 
 
Figure ‎3-2: AutoCAD design of different configurations of the CTC Chip. A) Original, Split, Modified, B) Rotated, 
and C) Carpet. 
Among all other CTC Chips, CTC Carpet Chip showed the highest % capture 
efficiency of spiked pre-labeled PC-3 cell line into buffer/blood at 1 mL hr-1 as well as 
the purity among the other tested CTC Chips (Figure  3-3). The summary of the 
comparison between different devices is mentioned in Table  3-1. Different design 
configurations are explained in details in appendix section ( 9.1). 
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Figure ‎3-3: % Capture efficiencies among different configuration of the CTC Chip. % Capture efficiencies of 
EpCAM with pre-labeled cancer cells (PC-3) spiked into buffer and blood in 4 different CTC Chip, including Original, 
Modified, Rotated, and CTC Carpet Chip. Carpet CTC Chip showed the highest capture efficiency with PC-3 spiked 
into blood (87.73%) compared to the other CTC-Chips.   
 Table ‎3-1: Comparison between different microfluidic devices, including, Original, Modified, Rotated, and 
Carpet. 
3.1.1 General optimization of the microfluidic CTC chip 
3.1.1.1     Different confluency of cell lines 
The effects of % cell confluency (40-50%, 70-80%, and 90-95%) on the EpCAM 
capture efficiencies were analyzed with HT-29 cell line with Original, Modified, and 
Rotated CTC Chips. The results showed the highest % capture efficiencies in the 70-
80% cell’s confluency group in buffer and blood samples among different devices 
(Figure  3-4).  
Microfluidic Devices Array Rotation 
Capture efficiency in 
Buffer (%) 
Capture efficiency in  
Blood (%) 
Original 10 × 10 - 25.2 75.2 
Modified 10 × 10 - 25.3 71.9 
Rotated 10 × 10 10° 35.1 82 
Carpet 8 × 8 18° 31.6 87.7 
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Figure ‎3-4: The effect of different cell %confluency of HT-29 cell line on the capture efficiencies of EpCAM. 
The 70-80% cell’s confluency group showed the highest % capture efficiencies among the other groups. 
3.1.1.2     Different blocking agent 
In terms of increasing sensitivity as well as specificity using CTC Carpet Chip, 
different blocking reagents with different flow rates using MCF-7 cell lines were 
conducted. Different percentages of BSA alone or with the combination of different 
percentages of goat serum were used as a blocking reagent. The results in Figure  3-5 
indicated that 3% BSA with 10 mL hr-1 flow rates had the highest % purity (48.5%) 
among the other parameters with 71.7% of capture efficiency.  
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Figure ‎3-5: The effect of different blocking reagents on the capture efficiencies of EpCAM. BSA alone or with 
the combination of different percentages of goat serum with MCF7 cell line at different flow rates. 3% BSA at 10 mL 
hr
-1
 flow rate had the highest sensitivity and specificity among the other parameters. 
3.1.1.3     Forward vs. backward PBS washing 
To be able to increase % purity, the effect of forward (from inlet to outlet) and 
backward (from outlet to inlet) PBS wash were checked within different CTC Chips 
(Original, Rotated, and Carpet) using HT-29 cell line. Backward wash had higher % 
purity in CTC Carpet Chip (76.4%) among the other parameters (Figure  3-6). 
 
Figure ‎3-6: The effect of backward and forward PBS wash on the % purity. 
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3.2 CTC Carpet microfluidic Chip technology  
CTC Carpet Chip has around 80,000 microposts and the overall size of the 
microfluidic device is 44.6 mm × 16.9 mm. The design of CTC Carpet Chip and 
representative SEM images of the microposts are shown (Figure  3-7A). The master 
mold of the Carpet Chip is shown in Figure  3-7B. 
 
Figure ‎3-7: Schematic representation of CTC Carpet Chip. A) CTC Carpet Chip designed by AutoCAD software 
based on an 18° rotation of hexagonal arrays of 100 μm posts. It has around 80,000 post patterns with dimension of 
100 μm × 100 μm, the distance between each post is 50 μm in which the posts are distributed in a way to have lateral 
flow. The overall size of the microfluidic device is 44.6 mm × 16.9 mm. The red box is showing the SEM image of 
some posts in the CTC Carpet Chip. B) The CTC Carpet Chip master mold. 
Velocity magnitude profile and the particle tracing plot on a portion of the 
diamond shape of the CTC Carpet Chip are shown in Figure  3-8. Cell trajectories (blue 
lines) are based on particle tracing and the end position of the cells (15 μm rigid 
particles) is shown by red dots (Figure  3-8B). The simulations clearly had shown the 
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lateral distribution of fluid around the Carpet design as well as effective cell post 
interactions. 
 
Figure ‎3-8: Finite element simulations of the CTC Carpet Chip. Simulation studies were done on ¼ of a diamond 
shape of the CTC Carpet Chip to ensure the sensitivity and specificity of the designed chip. A) Velocity magnitude of 
flow on a portion of diamond shape of the CTC Carpet Chip. B) Particle tracing plot around microposts near the inlet 
demonstrating typical streamlines (blue) and capture of 15 μm rigid particles (red) upon encountering a wall (post). 
3.2.1 CTC Carpet Chip optimization 
3.2.1.1     Different distance sizes and flow rates 
The effects of different distance sizes (50 µm and 25 µm) between the CTC 
Carpet Chips and different flow rates (1, 3, 5, and 10 mL hr-1) on the capture efficiencies 
were analyzed. The 50 µm distance showed higher % capture efficiency (94.9%) with 
Panc-1 cell line compared to the 25 µm (Figure  3-9A). By increasing flow rate from 1 mL 
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hr-1 to 10 mL hr-1, capture efficiencies significantly decreased (Figure  3-9B). Therefore, 
1 mL hr-1 flow rate was selected as a constant flow rate. 
 
Figure ‎3-9: The effect of different distances between posts of CTC Carpet Chip and different flow rates on the 
capture efficiencies of EpCAM. A) Capture efficiencies were higher when there is a 50 µm distance between posts 
(94.9%). B) Capture efficiencies were higher when 1 mL hr
-1
 flow rate was used (87.7%) compared to the other flow 
rates (3, 5, and 10 mL hr
-1
). 
3.2.1.2     Different cell line 
Four cancer cell lines with different levels of EpCAM expression and one cell line 
with high CD133 expression were used for testing and optimization of the CTC Carpet 
Chip; HT-29 and Panc-1 (high EpCAM expression), PC-3 (low EpCAM expression), Hs-
578T (no EpCAM expression/negative control) and Capan-1 (high CD133 
expression).196 These cell lines were labeled with green CellTracker dye and spiked into 
blood at a concentration of 1000 cells mL-1 to test the capture efficiencies of the single 
CTC Carpet Chip functionalized with either anti-EpCAM or  anti-CD133 antibodies. The 
CTC Carpet Chip yielded the following efficiencies across the different cell lines; 
97.5%±2.2 (HT-29) and 94.9%±2.4 (Panc-1), 87.7%±13.9 (PC-3), 13.6% (Hs-578T), 
and 73% ±16.6 (Capan-1) (Figure  3-10).  
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Figure ‎3-10: The effect of different cell line on the capture efficiencies of EpCAM. Different cell lines with 
various levels of EpCAM expression including; HT-29 and Panc-1 (high EpCAM expression), PC-3 (low EpCAM 
expression), and Hs-578T (none), and one cell line with high CD133 expression (Capan-1) were used. 1000 green 
CellTracker cells were spiked into blood and processed through single CTC Carpet Chip coated with anti-EpCAM or 
anti-CD133.  
A representative image of entire chip with captured pre-labeled PC-3 cells is 
shown in Figure  3-11A. A pseudo-colored SEM image of captured cancer cells spiked 
into blood on the CTC Carpet Chip is shown in Figure  3-11B. In the Carpet design, the 
posts are arranged in a way to enhance lateral flow in addition to longitudinal flow. In 
order to further examine this phenomenon, the number of PC-3 cells captured along the 
length of the device was calculated. It was found that the density of the captured PC-3 
cells in the Carpet device was high near the inlet (Figure  3-11C) similar density 
observations were made for the contaminating blood cells (Figure  3-11D).   
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Figure ‎3-11: Profile capturing across the CTC Carpet Chip. A) Scanned image of the CTC Carpet Chip, shows 
increased cell capture near inlet area. B) Pseudo-colored SEM image of the captured cancer cells spiked into blood 
on the CTC Carpet Chip. Cancer cells and WBCs are shown in red and green respectively. C) Number of spiked PC-
3 cells into blood captured along the X-axis of Carpet device indicates peak capture area near inlet, along with the 
number of WBCs captured along the X-axis of Carpet device (D).  
3.3 Dual capture 
In order to facilitate separating circulating epithelial EpCAM-expressing and 
EMT-like CD133-expressing cells in different devices in sequential order from the same 
sample, we connected two devices functionalized with different antibodies (anti-EpCAM 
in one device and anti-CD133 in the other device) in series as shown in Figure  3-12. 
Blood was passed through the connected chips at a flow rate of 1mL hr-1 through the 
inlet of the first device.  
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Figure ‎3-12: Representative image of a dual CTC Carpe Chip. 1 mL blood was sent through the anti-EpCAM 
coated CTC Carpet Chip which was connected to the anti-CD133 coated CTC Carpet Chip in sequence. 
3.3.1 Optimization and re-evaluation of the dual CTC Carpet Chip 
3.3.1.1     Western blot and FACS on the capture antibodies; EpCAM and CD133  
In order to check the expression of EpCAM and CD133 on PC-3 and HT-29 cell 
lines, western blot analyses were conducted. The results indicated over/less-expression 
of EpCAM and high/none expression of CD133 on HT-29/PC-3 cell line respectively 
(Figure  3-13). 
 
Figure ‎3-13: Western blot analysis of EpCAM and CD133 on HT-29 and PC-3 cell lines. 
FACS analyses were conducted on HT-29 and Panc-1 cell line to check the 
expression of EpCAM and CD133. Results showing higher expression of EpCAM 
(99.7%) and CD133 (19.6%) in HT-29 cell line, compared to the Panc-1 cell line (70.9% 
and 0.7% of EpCAM and CD133 respectively) (Figure  3-14A-B). 
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Figure ‎3-14: The FACS analysis to check the expression of capture antibodies (EpCAM and CD133) on 
different cell lines. The FACS results of HT-29 (A), Panc-1 (B) indicated over-expression of EpCAM (99.7% / 
70.88%) and less expression of CD133 (19.6% / 0.68%) for HT-29 and Panc-1 respectively. 
3.3.1.2     FACS analysis on the detection antibodies; Cytokeratin and Vimentin  
The expression of the detection antibodies, CK and Vimentin, were checked with 
FACS analysis on three different cancer cell lines, PC-3, MCF-7, and SUM-159 
(Figure  3-15 and Figure  3-16). The expression of CK7&8 and three different Vimentin 
antibodies from different resources (#1-Santa Cruz, #2-Cell Signaling, and #3-BD 
biosciences) and different hosts (rabbit and mouse) were checked.   
The FACS analysis showed 99.3% of CK7&8 expression on PC-3 cell line 
(Figure  3-15A), 84.6% on MCF-7 (Figure  3-15B), and 31.6% on SUM-159 
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(Figure  3-15C). All three cell lines did not show any expression of Vimentin from source 
#1 and #2 (Figure  3-16A1, A2, B1, B2, C1, and C2). However, Vimentin #3 were 
expressed 33.5% on PC-3 (Figure  3-16A3), 53.9% on MCF-7 (Figure  3-16B3), and 
88.8% on SUM-159 (Figure  3-16C3). Therefore, Vimentin #3 was selected for further 
analysis.  
 
Figure ‎3-15: FACS analysis to check the expression of detection antibodies (CK) on different cell lines. (A) 
PC-3, (B) MCF-7, and (C) SUM-159 cell lines expressed 99.3%, 84.6% and 31.6% of CK7&8 respectively.  
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Figure ‎3-16: FACS analysis to check the expression of detection antibodies (Vimentin) on different cell lines. 
A) PC-3), B) MCF-7, and C)SUM-159 cell lines did not express Vimentin from source #1 (Santa Cruz) (A-1, B-1, and 
C-1) and #2 (Cell Signaling) (A-2, B-2, and C-2). However, Vimentin #3 (BD bioscience) were expressed on PC-3 
(33.5%), MCF-7 (53.9%), and SUM-159 (88.8%) cell lines (A-3, B-3, and C-3). 
3.3.1.3     Sensitivity and specificity of the dual CTC Carpet Chip 
Four different set-ups were tested in order to evaluate the sensitivity and 
specificity of the capture rates of the chips, each coated with and without the antibodies 
of interest (anti-EpCAM and anti-CD133), using Panc-1 spiked into blood. Chips coated 
with no antibodies (EpCAM- and CD133-) showed <3% capture efficiency (false 
positive). However, in the presence of antibodies (EpCAM+ and CD133+), efficiency 
rates increased to 89.8%±9.5 EpCAM+ cells and 6.6%±3.3 CD133+ cells. EpCAM+ and 
CD133- dual chips showed 90.2% and 0.7% EpCAM+ and CD133+ cells capture 
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efficiencies. EpCAM- and CD133+ dual chips captured 2.4% and 7.2% EpCAM+ and 
CD133+ cells capture efficiencies (Figure  3-17), demonstrating high specificity and 
consistent yields for both of the captured antibodies in the dual isolation. In summary, 
applying dual CTC Carpet Chip technology in terms of isolating different type of cancer 
cells was quite sensitive and specific.  
 
Figure ‎3-17: Sensitivity and specificity of the capture efficiencies of the dual CTC Carpet chip. % Capture 
efficiencies of Panc-1 cell lines spiked into blood with or without antibodies (EpCAM and CD133) in the dual chips. 
The solid/hatched yellow and blue bars show the presence/absence of EpCAM and CD133 antibodies. 
3.3.1.4    Immunofluorescence staining  
After cell capture, cancer cells were detected by immunofluorescence staining 
protocol described in section  2.8. 
3.3.1.4.1     Optimization of the detection antibodies  
In order to optimize the immunofluorescence staining protocol different 
antibodies, alone or in a combination form, including (Pan) cytokeratins, CD45, and 
Vimentin with different isotypes from different resources were tested in 16 pancreatic 
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cancer patient samples. Additional information about this optimization is provided in 
appendix section (Table  9-5). 
Comparison between specificity of CK7&8 and PanCK antibodies on the number 
of EpCs per mL on EpCAM chip were checked on pancreatic cancer patient samples 
(n=3) (Table  9-5). Numbers of EpCs captured on the EpCAM chip were significantly 
higher when PanCK antibodies were used as detection antibodies compared to EpCs 
numbers when CK7&8 antibodies was used (p=0.009) (Figure  3-18).  
                      
Figure ‎3-18:‎Comparison between CK7&8 and PanCK in detecting the EpCs in pancreatic cancer patient 
samples (n=3). 
3.3.1.4.2     Triple staining of PanCK, Vimentin and CD45 
To determine the presence of EpCs+ in the CD133 chip and EMTCs+ in the 
EpCAM chip, 16 patient samples were tested through triple staining of each chip (CK 
and Vimentin along with CD45) (Figure  3-19). Two out of 16 samples were Vimentin+ 
cells in the EpCAM Chip (1 and 4 cells), and two out of 16 were CK+ cells in the CD133 
Chip (2 and 1 cells). As the results show in Figure  3-19, these markers were relatively 
specific for their origins, meaning there were few captured EMTCs (mean 0.3 cells mL-1 
) in EpCAM Chips and few circulating EpCs in CD133 Chips (median 0.2 cell mL-1). A 
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small number of double positive (PanCK+/CD45+) cells were found in some samples 
and were excluded from this study due to unknown origin and significance. 
 
Figure ‎3-19: Analysis of pancreatic cancer patient samples (n=16) with triple staining (CK, Vimentin, and 
CD45) for each CTC Carpet Chip. Two out of 16 samples were Vimentin+ cells in the EpCAM Chip (1 and 4 cells). 
Two out of 16 samples were CK+ cells in the CD133 Chip (2 and 1 cells). 
3.3.1.4.3     Finalized detection antibodies  
Each chip was stained with either PanCK (for the EpCAM chip) or Vimentin (for 
the CD133 chip) antibodies. The leukocytes were identified by CD45 and neoplastic 
cells were identified as expressing EpCAM or CD133 and lacking expression of CD45. 
Figure  3-20A-B shows representative images of captured cancer cells stained for 
PanCK (red) and CD45 (green) to distinguish EpCs and WBCs. The captured EMTCs in 
the CD133 chip are shown in Figure  3-20C, with Vimentin (orange) and CD45 (green) 
used as detection antibodies for the EMTCs and WBCs respectively. In summary, 
PanCK+/CD45-/DAPI+, and Vimentin+/CD45-/DAPI+ phenotypes were determined and 
enumerated as EpCs and EMTCs respectively. 
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Figure ‎3-20: CTC Carpet Chip cell line immunofluorescence staining. Anti-human CD45, anti-human PanCK, 
and anti-human Vimentin antibodies were tested with cancer cell lines. A) Confocal image of a typical CK+ cancer 
cell. The PanCK+ CTCs were detected with PanCK (red) along with a CD45+ (green) WBC (B) Captured CK+ cells in 
the EpCAM chip using PC-3 cells spiked into blood (C) and Vimentin+ cells in the CD133 chip using SUM-159 cells 
spiked into blood. 
3.3.1.5    CTC Carpet Chip sequence analysis 
The effect of the device order (EpCAM Chip connected to the CD133 device 
(EpCAM  CD133: Ep1/CD2) and vice versa (CD133  EpCAM: CD1/Ep2) on capture 
efficiencies of the spiked green CellTracker Panc-1 cell line into blood and pancreatic 
cancer patients samples (n=6) was tested (Figure  3-21). In the Panc-1 cell line, the % 
capture efficiency of the EpCAM Chip was 70.7% when the EpCAM Chip was run as the 
first Chip (Ep1) and 31.6% when the EpCAM Chip was conducted as the second Chip 
(Ep2), while, the % capture efficiency of the CD133 Chip was 15.7% and 7.1% when the 
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CD133 Chip being used as the first (CD1) compared to the second (CD2) Chip, 
respectively (Figure  3-21A).  
The effects of the reverse study on the number of captured CTCs mL-1 from 
different pancreatic cancer patient samples (n=6) are shown in Figure  3-21B. The 
numbers of captured EpCs/EMTCs mL-1 were higher in the Ep1/CD2 (22.5/85.3 CTC 
mL-1) group compare to the CD1/Ep2 (73.5/10 CTC mL-1). In summary, the cell line 
results indicated when the EpCAM/CD133 Chip was arranged as a first device (Ep1 and 
CD1), the capture efficiencies were higher, while the numbers of captured 
EpCAM+/CD133+ were higher in the Ep1/CD2 group compare to the CD1/Ep2 from 
pancreatic cancer patients.  
 
Figure ‎3-21:‎ ‎ The‎ effect‎ of‎ Chip’s‎ order‎ on‎ the‎ numbers‎ of‎ captured‎ cells‎ on‎ dual‎ study.‎ A) The effect of 
reverse study on the % capture efficiencies of Panc-1 cell line on different orders of EpCAM vs. CD133 CTC Chips 
(EpCAM  CD133 (Ep1/CD2) and CD133  EpCAM (CD1/Ep2)). B) The effect of reverse study on the number of 
CTCs mL
-1
 in pancreatic cancer patient samples (n=6). Yellow/blue bars show EpCAM/CD133 Chips. Solid bars 
show EpCAM  CD133 (Ep1/CD2), and hatched bars show CD133  EpCAM (CD1/Ep2).   
3.4 Application of the CTC Carpet Chip to evaluate heterogeneity in 
pancreatic cancer patient samples  
Thirty-five patients with histologically documented PDAC of varying stages were 
analyzed, with clinical data provided in details in appendix section (Table  9-6). Blood 
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samples from nine healthy controls were used for the CTC counts comparison 
(Table  9-6). 
3.4.1 Epithelial CTCs (EpCs) and EMT-like CTCs (EMTCs) recovered from pancreatic 
cancer patients 
The dual CTC Carpet Chips were connected in the sequential order of EpCAM 
first followed by CD133 in order to capture the EpCs and EMTCs (Figure  3-12) and then 
whole blood collected from the patients was flowed through the chips at 1mL hr-1.  
Figure  3-22A show representative images of EpCs cells on the EpCAM chip captured 
from pancreatic cancer patients. The EpCs and WBCs were stained with PanCK (red) 
and CD45 (green) respectively. EpCs demonstrating varied morphologies, ranging from 
round to oval in shape and in some cases occurring as cluster (Figure  3-22B).  
 
Figure ‎3-22: Characterization of circulating epithelial CTCs (EpCs) in the EpCAM Carpet Chip from pancreatic 
cancer patients. A) EpCs and WBCs were stained with PanCK and CD45 respectively, in addition to DAPI. Red 
arrow is showing a PanCK EpC. B) An EpC cluster captured around the posts. Post outlines are marked in white 
circle and bright field. The post outlines are marked with white circles.  
Figure  3-23A shows images of an EMTC and a leukocyte. As shown in 
Figure  3-23B, EMTCs captured on the chip had a wide range of cell sizes. Red, orange, 
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and green arrows indicate PanCK, Vimentin, and CD45 staining respectively. 
Figure  3-23C shows a representative confocal image of a EMTC (pink) and a WBC 
(green) captured from a Pancreatic cancer patient on the CD133 chip.  
 
Figure ‎3-23: Characterization of circulating EMT-like CTCs (EMTCs) in the CD133 Carpet Chip from 
pancreatic cancer patients. A) Vimentin (orange) and CD45 (green) staining for detection of EMTCs and WBCs 
respectively. Orange and green arrows are showing Vimentin and CD45 positive cells respectively. B) Different sizes 
of EMTCs captured on the device. C) Confocal image of EMTC (pink) and WBC (green).  
3.4.2 Pancreatic CTCs enrichment using the CTC Carpet Chip compared to healthy 
control samples 
We quantified the captured EpCs and EMTCs on EpCAM and CD133 chips and 
found that 97.5% of the patients had EpCs+ (≥5 PanCK+ CTCs mL-1) with a mean of 
22.4±17.7 mL-1, while all 35 patients had EMTCs (≥15 Vimentin+ CTCs mL-1) with a 
mean of 85.7±59.5 mL-1. In contrast, low numbers of EpCs (0.9±0.9 mL-1) and EMTCs 
(1.9±2 mL-1) were observed in the HCs samples (Figure  3-24). In summary, the results 
indicate significant differences between the overall number of CTCs in pancreatic 
cancer patients samples (108.1±63.5) vs. HCs (2.8±2.6) (p<0.0001), as well as the 
number of EpCs (20.8% of overall CTCs) vs. EMTCs (79.2% of overall CTCs). We 
 83 
found significantly higher numbers of EMT-like CTCs in circulation in pancreatic cancer 
patients compared to epithelial CTCs (p<0.0001). 
 
Figure ‎3-24: Analysis of EpCs and EMTCs from pancreatic cancer patient samples compared to the healthy 
controls. Enumeration of EpCs and EMTCs on the anti-EpCAM and anti-CD133 coated CTC Carpet Chips from 
pancreatic cancer patients (n=35) along with HCs (n=9). Significant difference between the overall number of CTCs in 
pancreatic cancer patients samples (108.1±63.5) vs. HCs (2.8±2.6) (p<0.0001) was observed using unpaired t-tests 
(two-tailed). Significantly higher numbers of EMTCs (85.7±59.5) compared to EpCs (22.4±17.7) were observed 
(p<0.0001) using paired t-tests (two-tailed) (n=35). 
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3.4.3 Pancreatic CTCs enrichment using the CTC Carpet Chip to explore associations 
with clinical outcomes 
To further explore the relationship of EpCs and EMTCs and clinical outcomes in 
the pancreatic cancer patient cohort (n=35), the CTC counts from these two cell 
populations were analyzed based on clinical disease stages (Figure  3-25). All stages 
except stage IIA showed significantly higher numbers of EMTCs compared to the 
number of EpCs (Figure  3-25A). Patients with stage IV disease showed higher numbers 
of EMTCs than EpCs (p=0.0008). 
Also, patients were categorized based on the tumor status as resectable (n=9), 
borderline resectable (n=2), locally advanced (n=13), and metastatic (n=11) groups. 
There were significantly higher numbers of EMTCs than EpCs between all these 
groups, except borderline resectable patients due to the small sample numbers 
(Figure  3-25B). The ratio of EpCs/EMTCs to total number of CTCs has a 
decreasing/increasing trend with later stages (Figure  3-25C). The percentage of EpCs 
decreased toward late stages, whereas the percentage of EMTCs increased.  
Figure  3-25D-F summarize the frequencies of EpCs and EMTCs characterized in 
different patient subgroups, including tumor size <2cm vs. >2cm, no lymph node 
involvement (N0) vs. lymph node involvement (N1), and non-metastatic (M0) vs. 
metastatic (M1) groups. Significantly higher numbers of EMTCs (p=0.04) were observed 
when the patients were grouped based on lymph node involvement (N1) compared with 
no lymph node involvement (N0) patients.  
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Figure ‎3-25: Analysis of EpCs and EMTCs from pancreatic cancer patient samples based on their clinical 
outcomes. A, B) Analysis of number of EpCs and EMTCs recovered in pancreatic cancer patient samples (n=35) 
based on their clinical disease stages from stage IIA (n=6), IIB&III (n=17), and IV (n=12), and based on tumor status 
(resectable (n=9), borderline resectable (n=2), locally advanced (n=13) and metastatic (n=11)). No significant 
differences were observed in the effect of stage and resection on the number of EpCs and EMTCs using unpaired t-
tests. C) Ratio of EpCs to total number of CTCs and ratio of EMTCs to total number of CTCs from early to advanced 
stage disease. D-F) Enumerated EpCs and EMTCs grouped according to tumor size (> or <2cm (D), lymph node 
involvement (N0 or N1) (E), and metastasis (M0 or M1) (F). Unpaired t-tests were used to analyze the effect of tumor 
size, lymph node involvement, and metastasis. N1 group (n=18) showed significantly higher number of EMTCs 
compared to N0 group (n=13) (p=0.04). No significant correlation between tumor size and metastatic burden were 
observed.
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3.5 Gene expression profiling of EpCs and EMTCs by quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) 
We profiled the mRNA expression of both of these populations using a panel of 
96 cancer-related genes (Table  2-1). RNA was extracted from captured CTCs and 
utilized for gene expression profiling by RT-qPCR. Gene expression profiles of CTCs 
isolated from blood samples of pancreatic cancer patients (n=17) which were run 
through the dual CTC Carpet Chip are present as heat map (Figure  3-26).  
3.5.1 Gene expression profiling on the captured CTCs on EpCAM Chip vs. CD133 Chip 
Figure  3-27A presents the median log fold change (logFC) of select genes with 
logFC>1.5 in EpCAM Chip (yellow) and in CD133 Chip (blue). Figure  3-27B-C present 
box plots showing expression of significant differential expression of genes in patient 
CTCs isolated by EpCAM and CD133 chips. CXCR1 (p=0.03) in the EpCAM chip 
(Figure  3-27B), and POU5F1 (or Oct-4) (p=0.008) and MYC (p=0.03) in CD133 chip 
(Figure  3-27C) were significantly differentially expressed.  
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Figure ‎3-26: Clustering heat map of gene expression profiling of CTCs in pancreatic cancer patients samples 
(n=17). Clustering heat map analysis of gene expression data based on CTCs captured by EpCAM vs. CD133 CTC 
Carpet Chips was performed using -ΔCt. The top section shows the heat map of CTCs captured on EpCAM chip and 
the bottom section of the panel presents the CTCs captured on the CD133 chip. The color scale shown at the top 
illustrates the relative expression level of genes across the samples: red represents an expression level above the 
mean, blue represents expression lower than the mean. 
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Figure ‎3-27: Gene expression profiling in pancreatic cancer patients CTC samples (n=17) based on the 
capture device. A) The median log fold change (logFC) of selected genes with logFC>1.5 is shown in yellow (for the 
EpCAM chip) and blue (for the CD133 chip). Each fold change is calculated from the 2
–ΔCt
. B-C) Box plot diagrams of 
significantly differently expressed individual genes in EpCAM chip (B), CXCR1 (p=0.03) and POU5F1 (or Oct-4) 
(p=0.008) and MYC (p=0.03) in CD133 chip (C). Yellow and blue bars represent the EpCAM and CD133 chips 
respectively. The Wilcoxon signed-rank test was used in RNA expression for paired samples (n=17). 
3.5.2 Hematoxylin & Eosin (H&E) staining and immunohistochemistry (IHC) analysis of 
primary tissues  
We obtained the PDAC tissues, and stained them for the markers of interest 
based on analysis of CTCs. We previously showed that genes including CXCR1 and 
BMi1 have ≥6 logFC in EpCAM Chip compared to CD133 Chip (Figure  3-27A). We 
found that, the primary tissues of early stage patients were highly positive (intensity of 3, 
100% positivity) for BMi1 protein expression shown by immunohistochemistry (IHC) 
analysis (Figure  3-28A). The Hematoxylin & Eosin (H&E) staining of the corresponding 
primary tumor tissue is shown in Figure  3-28A. 
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We also reported that genes including POU5F1 (or OCT-4), TP53 and MCAM (or 
CD146) showing ≥5 logFC in CD133 Chip compared to EpCAM Chip (Figure  3-27A). 
IHC analysis of TP53 protein expression in the primary PDAC tissue showed high 
positivity (intensity of 2, 90% positivity) of this marker (Figure  3-28B). The H&E staining 
of the corresponding primary tumor tissue is shown in Figure  3-28B. IHC analysis of 
MCAM protein expression in the primary PDAC tissue was moderate positive (intensity 
of 2, 30% positivity) (Figure  3-28C). The H&E staining of the corresponding primary 
tumor tissue is shown in Figure  3-28C.  
IHC analysis of CD133 protein expression in the primary PDAC tissue showed 
different range of positivity (intensity of 1 and 3, 5-60% positivity) of this marker 
(Figure  3-28D). The H&E staining of the corresponding primary tumor tissues are shown 
in this figure.  
To further explore the gene signatures in different stages of disease, the patients 
were grouped based on their disease stages (Figure  3-29, Figure  3-30, and 
Figure  3-31). The summary of selected genes (p<0.05) are shown in the box plots.  
3.5.3 Gene expression profiling on stage IIA pancreatic cancer patients (n=5) 
Stage IIA patients showed significant differential expression of genes including 
ATL1, BMi1, CD14, CDH2, ERCC1, MKi67, TTF1, and Vimentin compared to all other 
stages (Figure  3-29A). We also compared protein level expression of select differentially 
expressed markers by IHC of primary tissues. The H&E staining of the primary PDAC 
tissues of early stage patients is shown in Figure  3-29B. The corresponding primary 
tumor tissues were highly positive (intensity of 3, 100% positivity) for BMi1 protein 
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expression and moderate positive (intensity of 2, 10% positivity) for MKi67 protein 
expression shown by IHC analysis (Figure  3-29C). 
 
Figure ‎3-28: Immunohistochemistry of the primary tumor tissues of PDAC patients. A) BMi1 protein 
expressions (intensity of 3 in 100% tumor cells).  B) TP53 marker (intensity of 3 in 90% tumor cells). C) MCAM 
marker (intensity of 2 in 30% tumor cells). D) CD133 marker from different tissue samples (intensity between 1 and 3 
in 5-60% tumor cells). The H&E staining images of the corresponding primary tumor tissues of PDAC patients is 
shown. Original magnification: x100. 
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Figure ‎3-29: Gene expression profiling of CTCs based on stage IIA pancreatic cancer patients. Stage IIA 
samples (n=5) compared to the rest of stages (n=30) analysis. A) Box plot diagrams of significantly (p<0.05) highly 
expressed individual genes in stage IIA CTC samples compared to the rest of stages including ATL1, BMi1, CD14, 
CDH2, ERCC1, MKi67, TTF1, and Vimentin genes. B) The H&E staining image of the primary tumor tissues of early 
stage patient. C) IHC analysis of the corresponding primary tumor tissues of early stage patients for BMi1 and MKi67 
protein expressions revealed diffuse and strong positivity for BMi1 (intensity of 3 in 100% tumor cells), and patchy 
moderate positivity for Mki67 (intensity of 2 in 10%tumor cells) protein expression. The Mann-Whitney test was used 
to quantify differences in RNA expression for non-paired samples using the average -ΔCt value across both sample 
chips (n=17).  
3.5.4 Gene expression profiling on stage IIB&III pancreatic cancer patients (n=18) 
Pancreatic cancer patients in stages IIB&III showed significant differential 
expression of ALDH1A3, ESR1, KRT18 and KRT19 compared to stage IIA 
(Figure  3-30A). Comparing stages IIB&III with stage IV patients reveled significant 
differential expression of genes including AKT1 and CD3D (Figure  3-30B).  
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Figure ‎3-30: Gene expression profiling of CTCs based on stage IIB&III pancreatic cancer patients. A) Box plot 
diagrams of significantly highly expressed individual genes in stage IIB&III CTC samples (n=18) compared with the 
early stage (n=5) including ALDH1A3, ESR1, KRT18 and 19, and B) AKT1 and CD3D genes when stage IIB&III 
(n=18) compared with the late stage (n=12). The Mann-Whitney test was used to quantify differences in RNA 
expression for non-paired samples using the average -ΔCt value across both sample chips (n=17).  
3.5.5 Gene expression profiling on stage IV pancreatic cancer patients (n=12) 
Stage IV patients showed significantly elevated expression of CDH1, DCN, 
KRT19, PGR, and PIK3CA genes compared to the rest of the stages (Figure  3-31A). 
The H&E staining of the primary PDAC tissue of late stage pancreatic cancer patients is 
shown in Figure  3-31B. The protein expression of PIK3CA in the corresponding primary 
tumor tissues was moderate (intensity of 2, 20% positivity) (Figure  3-31C). 
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Figure ‎3-31: Gene expression profiling of CTCs based on stage IV pancreatic cancer patients. A) Stage IV 
samples (n=12) compared to the rest of the stages (n=23) showed significantly over expression of genes including, 
CDH1, DCN, KRT19, PGR, and PIK3CA. B) The H&E staining image the primary tumor tissues of late stage patient. 
C) PIK3CA protein expressions revealed patchy moderate positivity for this gene (intensity of 2 in 20% tumor cells) 
protein expression with IHC of primary tumor tissues. The Mann-Whitney test was used to quantify differences in 
RNA expression for non-paired samples using the average -ΔCt value across both sample chips (n=17).  
3.6 Molecular signature and prognosis 
In the cohort considered in this study, the median overall survival (OS) of all 
patients was 15±10.2 months (m) (2.5-33.7) and the median progression free survival 
(PFS) was 5.6±10.5 m (1.7-33.5). The survival estimated by Kaplan Meier (KM) were 
significantly better for patients with high expression of AKT1 (21.1 vs. 6 m p=0.08 for 
OS, and 11.6 vs. 4.6 m p=0.03 for PFS), BMi1 (20.4 vs. 13.6 m p=0.04 for OS, and 9.2 
vs. 4.6 m for PFS), CDH2 (30.2 vs. 14.8 m p=0.04 for OS, and 6.9 vs. 5.1 m for PFS), 
ERCC1 (22.3 vs. 10.6 m p=0.04 for OS, and 11.7 vs. 4.6 m p=0.02 for PFS), IL8 (21.1 
vs. 6 m p=0.08 for OS, and 11.6 vs. 4.6 m p=0.03 for PFS), TTF1 (20.4 vs. 12.8 m 
p=0.08 for OS, and 9.3 vs. 2.5 m p=0.04 for PFS), and TP53 (18 vs. 11.4 m for OS, and 
10 vs. 4.6 m p=0.03 for PFS) (Figure  3-32A-G). The H&E staining of the primary PDAC 
tissue of a pancreatic cancer patient is shown in Figure  3-32Hi. IHC analysis of TP53 
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protein expression in the corresponding primary tumor tissue showed high positivity 
(intensity of 2, 90% positivity) of this marker (Figure  3-32H-ii). Pancreatic cancer 
patients with higher expression of metastatic marker GEMIN2 (5 vs. 18 m p=0.01* for 
OS, and 4.6 vs. 7.7 m for PFS), and stem marker POU5F1 (13.4 vs. 20.4 m for OS, and 
4.6 vs. 10.1 m p=0.04* for PFS) showed worse OS or PFS respectively (Figure  3-32I-J).  
 
Figure ‎3-32: Relationship between CTCs gene expression and prognosis. Comparison of Kaplan-Meier overall 
survival (OS) and progression free survival (PFS) graphs in all patient CTCs samples (n=17) with low (blue) and high 
(red) expressions of selected genes are shown. The median expression of each gene (2
–ΔCt
) across all patients was 
used as cutoff points. Log-rank (Mantel-Cox) tests were used to analyze the Kaplan-Meier OS and PFS. A-G) Higher 
expression of genes including BMi1, CDH2, and ERCC1 in pancreatic cancer patients showed significantly greater 
OS (p=0.04). Higher expression of genes including AKT1 (p=0.03), ERCC1 (p=0.02), IL8 (p=0.03), TTF1 (p=0.04), 
and TP53 (p=0.03) were significantly correlated with prolonged PFS. H) The H&E staining image of (i) the primary 
tumor tissue, (ii) and TP53 marker showed diffuse positivity (intensity of 2 in 90% of tumor cells) of this marker in the 
corresponding primary tumor tissues. I-J) Patients with high expression of genes including, GEMIN2 (p=0.01) and 
POU5F1 (p=0.04) had a worse OS and PFS respectively compared with those with low expression of these genes.  
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3.7 Monitoring patients based on the treatment regime  
Analysis of heterogeneous population of pancreatic CTCs will provide greater 
insight into responses to therapeutic agents. In this study, we simultaneously isolated 
both EpCs and EMTCs at baseline (treatment naïve) and through treatment courses 
from limited number of pancreatic cancer patients.  
3.7.1 CTC burden monitoring 
In limited number of patients (n=8) we had multiple visits and subsequent 
molecular analysis (n=5) of these samples. Additional information is provided in 
appendix section (Table  9-7). All patients in visit 1 (treatment naïve) were naïve (n=8); 
however, 5 samples in visit 2 received chemo treatment in their second visit, and 3 
samples were on chemo plus radiation treatment. Patients in visit 3 were received either 
chemo alone (n=2) or chemo plus radiation treatment (n=2). Patients in visit 4 either 
received chemo (n=2) or off chemo treatment (n=1). The CTC numbers of pancreatic 
cancer patient samples (n=8) in different visits are shown in Figure  3-33. EpCs (yellow) 
and EMTCs (blue) mL-1 in different visits showed that the number of EMTCs were 
significantly higher in visit 1 and 2 compared to EpCs, also the number of EpCs 
significantly increased from visit 2 to visit 3 (Figure  3-33). 
3.7.2 Gene expression profiling  
Gene expression analysis were studied for some of these follow up patient 
samples (n=5) in their first (treatment naïve) and second (under chemo treatment) visits. 
The results showed that PIK3CA was significantly upregulated in visit 1 patients. Genes 
including, ERCC1, CD45, BAX, NANOG, and BCL2 in visit 1 patients, and ESR1, 
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MCAM, and KRas in visit 2 group showed >8.5 log FC compared to the other cohort 
(Figure  3-34A). 
 
Figure ‎3-33: CTC numbers of pancreatic cancer patient samples (n=8) over the treatment. A) Numbers of EpCs 
(yellow) and EMTCs (blue) mL
-1
 in different visits showed that the number of EMTCs in visit 1 and 2 are significantly 
higher compare to the EpCs. Numbers of EpCs significantly increased from visit 2 to visit 3. B-C) Numbers of EpC 
and EMTCs in individual patient samples. Patients were grouped based on increasing (P 20, 04, 30, and 33) and 
decreasing (P 21, 22, 29, and 31) group in EpCs numbers (B). Patients were grouped based on increasing (P 29, 20, 
30, and 33) and decreasing (P 21, 22, 31, and 04) group in EMTCs numbers (C). 
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The KM estimates were analyzed for these follow up patients (n=5). Patients with 
high expression of AKT1, CTNNB1, and ERCC1 showed better PFS (24.1 vs. 13.6 m 
for OS, and 11.7 vs. 3.2 m p=0.03* for PFS) (Figure  3-34B). The OS were significantly 
worse for patients with high expression of genes including MYC, PGR and, TP53 (13.4 
vs. 24.1 m p=0.03* for OS, and 5.1 vs. 11.7 m for PFS) (Figure  3-34C), and POU5F1 
(14.6 vs. 28.9 m p=0.06 for OS, and 4.6 vs. 22.6 m p=0.06 for PFS) (Figure  3-34D).   
 
Figure ‎3-34: Gene expression analysis of pancreatic cancer patient samples (n=5) over the treatment. The 
median log fold change (log FC) of selected genes with log FC>1.5 is shown for the visit 1 (treatment naïve) patients 
samples (light green) and for the Visit 2 patient (under chemotherapy) samples (dark green). Each fold change is 
calculated from the 2
^–ΔCt
. PIK3CA gene showed significantly higher in patients with naïve patients. B-D) The KM for 
OS and PFS of the selected genes which had log FC >1.5 in different visits of patients (n=5). B) Higher expression of 
genes including AKT1, CTNNB1, and ERCC1 led to longer OS and PFS (*). C-D) Higher expression of genes 
including MYC, PGR, TP53, and POU5F1 (or OCT-4) led to worse OS and PFS.   
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3.8 Application of the CTC Carpet chip in PDAC xenograft model 
PDAC is characterized by a dense stroma, which is heterogeneous and 
composed of both cellular and acellular components.197 The cellular component mostly 
consists of mesenchymal-appearing spindle-shaped cells (cancer associated fibroblast 
or CAFs), immune and vascular cells.197 It has been hypothesized that the stroma 
contributes to the aggressive nature of PDAC; however the precise role of the stroma in 
pancreatic tumoigenesis remains controversial. Earlier studies using in vitro assays, 
xenografts, and genetically engineered mouse models have suggested that activated 
cells promote tumor growth and metastasis.197  
The aim of this study was to isolate both CTCs and CFCs (circulating fibroblast 
cells) from a patient-derived PDAC xenograft model.197 The model system was 
established by injecting 105 GFP (green fluorescent protein)-luciferase-labeled tumor 
cells mixed with the same number of DSRed (red fluorescent protein)-labeled cancer 
associated fibroblast (CAF) and cancer associated mesenchymal stem cells (CA-MSC) 
subcutaneously into NOD-SCID mice (n=26). GFP-luciferase-labeled tumor cells (CAF 
and CA-MSC) injected alone served as the experimental controls. Upon tumor formation 
in mice, blood samples were collected for the CTC and CFC counts. Tumors were 
harvested from mice, digested into single cells and then cultured for secondary 
reimplantation in a new cohort of NOD-SCID mice after FACS flow sorting. After the 
formation of the secondary tumors, blood samples were again collected for the CTC and 
CFC counts. An overview of the experimental plan is shown in Figure  3-35. 
Injection of tumor cells alone resulted in the development of small tumors 
comparable in size to those generated by injection of tumor cells plus CAF cells over 
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the 1.4 week period of study, while larger tumors developed in the tumor cells plus CA-
MSC group197 (Figure  3-36).   
 
Figure ‎3-35: Strategies of the application of CTC Carpet Chip to isolate both CTCs and CFCs from pancreatic 
cancer mouse model.  
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Figure ‎3-36: Pancreatic cancer cells transduced with a luciferase-expressing lentivirus were subcutaneously 
injected alone or with CAF or CA-MSC into NOD/SCID mice. Bioluminescent-based tumor growth (measured by 
signal intensity p/s/cm2) of luciferase tumors alone or in combination with CAFs or CA-MSCs (MSCs). Larger tumor 
sizes were found the tumor plus CA-MSC group.  
For metastatic progression to occur, carcinoma cells must traverse through the 
basement membrane and disseminate into the bloodstream. Hence we examined the 
presence and extent of circulating GFP-labeled tumor cells and DSRed-labeled CAFs 
and CA-MSCs from the mouse blood samples using the CTC Carpet Chip. Figure  3-37 
presents some examples of the captured GFP-labeled tumor cells (CTCs) in the form of 
single CTCs (Figure  3-37A) and clusters (Figure  3-37B) in the CTC Carpet Chip. H&E 
staining of some captured cells are also shown in Figure  3-37C. 
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Figure ‎3-37: Representative images of captured circulating GFP+ tumor cells (CTCs) using CTC Carpet Chip 
from mice blood samples. A) A single captured CTC along with a WBC. B) Cluster form of CTCs. C) H&E staining 
of the capture CTCs around the posts.  
Circulating GFP+ tumor cells were detected in all three groups; tumor alone, 
tumor plus CAF and CA-MSC, however there was a significant increase in the number 
of circulating GFP+ tumor cells in the tumor cells plus CA-MSC group compared to the 
tumor cells alone and tumor cells plus CAF groups (Figure  3-38 and Table  3-2). Further 
DSRed positive circulating cells were detected in only the tumor cells plus CA-MSC 
mice group.  
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Figure ‎3-38: Quantification of circulating GFP+ tumor cells (CTCs) in tumor alone, tumor plus CAF, and CA-
MSC groups and DsRed+ fibroblasts cells (CFCs) in tumor+CAF and CA-MSC groups. The presence of CA-
MSC increased the number of CTCs compare to the tumor alone group significantly. 
Table ‎3-2: Numbers of GFP+ tumor cells (CTCs) in tumor alone, tumor plus CAF, and CA-MSC groups and 
DsRed+ fibroblasts cells (CFCs) in tumor+CAF and CA-MSC groups. 
Tumor Tumor+CAF 
(CTCs) 
Tumor+CAF 
(CFCs) 
Tumor-CA-MSC 
(CTCs) 
Tumor-CA-MSC 
(CFCs) 
316 160 0 382 2 
352 32 0 1180 12 
82 104 0 1096 8 
352 496 0 280 0 
52 - - 136 2 
Furthermore, the primary tumors from the mice were harvested, digested, and 
both tumor and CAF/CA-MSC cells were grown in culture. This mixed population was 
then FACS sorted, and only tumor cells were re-injected subcutaneously into NOD-
SCID mice (n=13). After the tumor formation, we examined the presence of circulating 
GFP-labeled tumor cells by using the CTC Carpet Chip. The number of the GFP 
positive cells (CTCs) in all tumor alone and tumor plus CAF/CA-MSC groups in the 
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second injection was significantly higher compared to the first injection group 
(Figure  3-39 and Table  3-3).  
 
Figure ‎3-39: The effect of the reinjection on the number of GFP positive cells on the tumor, tumor plus CAF 
CA-MSC groups. The CTC numbers in all groups were significantly higher in the 2
nd
 injection.  
Table ‎3-3: Numbers of GFP positive tumor cells (CTCs) in tumor, tumor plus CAF and CA-MSC groups in the 
first and second injection. 
Tumor (1st) Tumor (2nd) Tumor+CAF 
(1st) 
Tumor+CAF 
(2nd) 
Tumor-CA-MSC 
(1st) 
Tumor-CA-MSC 
(2nd) 
316 524 160 2750 382 2740 
352 1245 32 6840 1180 1445 
82 1530 104 1330 1096 1013 
352 2055 496 3130 280 2945 
52 - - - 136 3085 
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3.9 Application of the Labyrinth technology in pancreatic cancer patients 
The overall strategy of this clinical study was to validate the utility of CTCs as a 
tool for assessing tumor response to the only three therapy options available for 
pancreatic cancer: surgery, chemotherapy, and radiotherapy (Figure  3-40). 
 
Figure ‎3-40: Experimental outline for isolation of CTCs in pancreatic cancer patients using Labyrinth 
technology.  
3.9.1 Optimization of Labyrinth using pancreatic cancer cell line 
As demonstrated previously, the long loops and sharp corners in the Labyrinth 
device enhance the separation of CTCs from other blood components.103 The device 
consists of 11 loops and 56 corners. The loops have a small curvature ratio to provide 
enough channel length to achieve total focusing of CTCs from other blood cells. In 
contrast, the sharp corners have a high curvature ratio to enhance the focusing of blood 
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cells. Labyrinth has one inlet and 4 outlet channels (Figure  3-41A).  The device has 637 
mm channel length in total, with 500 µm in width and 100 µm in height (Figure  3-41B). 
The outlets were designed such that outlet #1 collects WBCs, outlet #2 collects CTCs, 
and outlets #3 and #4 collect red blood cells (RBCs) and other blood components. The 
device was loaded with red food dye to show the structure of Labyrinth (Figure  3-41C). 
The Labyrinth was first tested and optimized for CTC isolation using Panc-1 cell 
line. Different cell concentrations (10, 100, and 105) were spiked into whole blood and 
processed through the Labyrinth (section  2.9). In all cases the cell recovery was above 
88%, suggesting that the Labyrinth is a promising tool to isolate CTCs from pancreatic 
cancer patients (Figure  3-41D).198   
 
Figure ‎3-41: The illustration of Labyrinth device. A) Labyrinth device consisting of with one inlet and 4 outlets. B) 
SEM images of the channel in labyrinth and cross-sectional view of labyrinth taken with microscope. C) The Labyrinth 
was loaded with red dye to show the device’s structure as well as the inlet and outlets. D) Optimization of Labyrinth 
with Panc-1 cell line. 
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One hundred and forty one treatment naïve pancreatic cancer patients were 
enrolled in this study. Additional information is provided in appendix section (Table  9-8). 
Similar to the Carpet CTC Chip study in pancreatic cancer (section  3.4.1), the isolated 
CTCs were classified as epithelial CTCs and EMT-like CTCs. The epithelial CTCs were 
enumerated as PanCK+/CD45-/DAPI+ (Figure  3-42A), while the EMT-like CTCs were 
identified as PanCK+/Zeb1+/CD45-/DAPI+ (Figure  3-42B). Total CTC number was 
equal to the sum of these two populations.  
 
Figure ‎3-42: Characterization of heterogonous CTC populations in pancreatic cancer using Labyrinth. A) 
Circulating epithelial CTCs (PanCK+/CD45-/DAPI+), B) EMT-like CTCs (PanCK+/Zeb1+/CD45-/DAPI+). Scale bar is 
10µm.  
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3.9.2 CTC enumeration for treatment naïve cohort 
Utilizing Labyrinth device, CTCs were isolated from treatment naïve pancreatic 
cancer patient blood samples (n=141). These patients were classified according to their 
tumor staging: resectable (n=35), borderline resectable (n=32), locally advanced (n=25), 
and metastatic (n=49). Figure  3-43A shows the epithelial and EMT-like CTCs counts for 
treatment naïve pancreatic cancer patients. Overall, 18.7±21 total CTCs, 9.7±15.7 
epithelial CTCs, and 9±9.8 EMT-like CTCs were observed across all samples (n=141).  
The resectable group had 14.6±16.6 total CTCs, 6.3±10.1 epithelial CTCs, and 
8.3±8.8 EMT-like CTCs (n=35). The borderline resectable group had 29.5±28.9 total 
CTCs, 16.3±21.1 epithelial CTCs, and 13.2±12.8 EMT-like CTCs (n=32). The locally 
advanced cohort had 15.6±14.4 total CTCs, 8.3±11.8 epithelial CTCs, and 7.3±6.6 
EMT-like CTCs (n=25). The metastatic group had 16.3±18.5 total CTCs, 8.6±15.7 
epithelial CTCs, and 7.7±9.1 EMT-like CTCs (n=49) (Figure  3-43B). Statistical 
significance was observed when the borderline resectable cohort was compared to the 
resectable group (p=0.01), locally advanced group (p=0.03), and metastatic cohort 
(p=0.01) using the unpaired t-test.  
Figure  3-44 shows the overall survival probability for the treatment naïve cohort 
(Figure  3-44A). Classification based on the stages confirms the increased mortality rate 
in advanced stages (Figure  3-44B). 
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Figure ‎3-43: CTC enumeration of treatment naïve pancreatic cancer patients using Labyrinth. A) Enumeration 
of both epithelial CTCs and EMT-like CTCs across all the treatment naïve patient samples (n=141). B) Box plot graph 
of total CTCs counts stratified by cancer stage, resectable, borderline resectable, locally advanced, and metastasis. 
The CTC numbers were significantly higher in borderline resectable cohort compared to the other groups using 
unpaired t-test.  
 
Figure ‎3-44: KM curve for overall survival probability in treatment naïve (A), and in treatment naïve samples 
grouped by cancer stage (B). Advanced stages patient samples showed lower OS compared to the early stages 
samples.  
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3.9.3 CTC enumeration before and after the treatment regime 
Changes in CTC counts were evaluated for pancreatic cancer patients who were 
undergoing surgery, chemotherapy, and radiation. Additional information is provided in 
appendix section (Table  9-9) for the surgery cohort (n=29). The blood samples were 
collected 22 days (median) prior to surgery and 33 days (median) post-surgery. The 
total CTC numbers were decreased in the post-surgery cohort but not significantly 
(Figure  3-45A). However, when patients were categorized based on the stages, the 
CTC numbers were significantly decreased in the pre- and post-surgery samples 
(p=0.02) (Figure  3-45B).   
The effect of chemotherapy on CTC numbers was evaluated prior, during, and 
after the course of treatment. The blood samples (n=35) were collected 20 days 
(median) prior to the chemotherapy (pre-chemo), and 85 days (median) post treatment 
(on-chemo). Additional information is provided in appendix section (Table  9-10). The 
numbers of CTCs (total CTCs (p=0.04), epithelia CTCs (p=0.01), and EMT-like CTCs 
(p=0.03)) were significantly decreased from the pre-chemo group to on-chemo cohort 
(n=35) (Figure  3-46).  
For the pre- and post-chemotherapy group, the blood samples (n=22) were 
collected 13 days (median) prior to the chemotherapy (pre-chemo), and 51 days 
(median) post treatment (post-chemo). Additional information is provided in appendix 
section (Table  9-11). The numbers of total and epithelial CTCs were significantly 
decreased from the pre-chemo group to on-chemo cohort (p=0.002 and 0.005 
respectively) (Figure  3-47).  
We also evaluated the effect of radiotherapy on CTC counts for 12 patient 
samples. Sample collection was performed 135 days (median) prior to the treatment 
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and 72 days (median) post treatment. Additional information is provided in appendix 
section (Table  9-12). A statistically significant decrease was observed in total CTC 
counts after the treatment (p=0.04) (Figure  3-48).  
 
Figure ‎3-45: CTC enumeration for pre- and post-surgery cohort (n=29). A) No significant differences were 
observed across different CTC subpopulations (total CTCs, epithelial CTCs and EMT-like CTCs). B) Significantly 
lower numbers of CTCs were observed in the borderline group after surgery. Paired t-test was used to analyze the 
effect of surgery on the CTC numbers. 
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Figure ‎3-46: CTC enumeration for pre- and on-chemotherapy cohort (n=35). Significantly lower number of CTCs 
were observed across different CTC subpopulations (total CTCs p=0.04, epithelial CTCs p=0.01, and EMT-like CTCs 
p=0.03). Paired t-test was used to analyze the effect of chemotherapy on the CTC numbers.   
 
Figure ‎3-47: CTC enumeration for pre and post chemotherapy cohort (n=22). Significantly lower number of 
CTCs were observed across different CTC subpopulations (total CTCs p=0.02 and epithelial CTCs p=0.005). Paired 
t-test was used to analyze the effect of chemotherapy on the CTC numbers.   
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Figure ‎3-48: CTC enumeration for pre- and post-radiation cohort (n=12). Significantly lower number of CTCs 
were observed in total CTCs p=0.04. Paired t-test was used to analyze the effect of chemotherapy on the CTC 
numbers.   
3.9.4 CTC counts to predict the prognosis in pancreatic caner 
The correlation of overall survival with the decrease of CTC counts after 
treatment was evaluated for all of the mentioned treatments options. The KM curve for 
pre- and post-surgery (Figure  3-49A), pre- and on-chemotherapy (Figure  3-49B), pre- 
and post-chemotherapy (Figure  3-49C), and pre- and post-radiation (Figure  3-49D) 
cohort was graphed. In the surgery group, 17/29 patient samples had a decrease in 
CTC numbers. For chemotherapy treated patients sample groups, 24/35 and 18/22 
samples had significantly lower CTC numbers in pre-/on-chemotherapy and pre-/post-
chemotherapy groups respectively. The CTC numbers dropped in 9/12 radiotherapy-
treated patient samples. Therefore, a decrease in CTC counts was correlated with a 
higher probability of survival across all treatment options.  
 113 
  
Figure ‎3-49: CTC counts to predict the prognosis in pancreatic cancer. KM curve for overall survival in A) 
surgery, B-C) chemotherapy, and D) radiotherapy patient cohorts. In all groups decrease in CTC numbers in post 
treatment patient samples prolong their OS.    
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3.10 High throughput label-free isolation of heterogeneous CTCs from 
non-small cell lung cancer (NSCLC) patients for targeted therapy 
using Labyrinth 
The overall strategy of this clinical study was to utilizing the Labyrinth device to 
isolate CTCs from non-small cell lung cancer patients (NSCLC) (Figure  3-50). 
 
Figure ‎3-50:‎ High throughput and label-free Labyrinth device demonstrated the advantages of marker-
independent separation methods in identifying heterogonous CTC sub-population in non-small cell lung 
cancer patients. 
3.10.1 Optimization of Labyrinth for lung cell line recovery 
Labyrinth was optimized and tested for inertial separation of cancer cells 
using different human lung cancer cell lines. To demonstrate cell focusing in the 
device, the same concentration of pre-labeled cancer cells with green CellTracker 
and pre-labeled WBCs with DAPI (1000 cells mL-1) were spiked into PBS and 
separated using the Labyrinth. First, various flow rates ranging from 1500-3000 µl 
min-1 were tested to check the focusing and separation of labeled WBCs with 
DAPI (blue stream) and the pre-labeled lung cancer cell lines (green stream) into 
individual outlets (Figure  3-51A, Figure  3-52A, Figure  3-53A, and Figure  3-54A).  
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Products were collected after flow stabilization (1.5 min) for calculating the 
percentage of CTC recoveries and WBC depletion. Meanwhile, the intensity of 
separation of WBCs and cancer cells were measured (Figure  3-51B, 
Figure  3-52B, and Figure  3-53B). Afterward, the % cell recovery (Figure  3-51C, 
Figure  3-52C, Figure  3-53C, and Figure  3-54B) and % WBCs depletion were 
analyzed (Figure  3-51D, Figure  3-52D, Figure  3-53D, and Figure  3-54C).  
Using PC-9 cell line, 95% of cells were recovered from outlet #2 at a flow 
rate of 2400 µL min-1 (Figure  3-51C), with 93% WBCs depletion from outlet #1 
(Figure  3-51D). 
 
Figure ‎3-51: Labyrinth optimization using PC-9 cell line for cell recovery. A) The separation of labeled WBCs 
(blue) and PC-9 cell line (green) into individual outlets. B) The intensity of these separations was measured. C) % 
Recovery of PC-9 from all five tested flow rates (2100-2500 µl min
-1
). D) % WBCs depletion from the all five flow rates 
(2100-2500 µl min
-1
). 95% of the PC-9 cells were recovered from outlet #2 using 2400 µl min
-1
 with 93% WBCs 
depletion from outlet #1. 
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Using H1975 cell line, 46% of cells were recovered from outlet #2 at a flow rate 
of 2300 µL min-1 (Figure  3-52C), with 78% WBCs depletion from outlet #1 
(Figure  3-52D). 
 
Figure ‎3-52: Labyrinth optimization using H1975 cell line for cell recovery. A) The separation of labeled WBCs 
(blue) and H1975 cell line (green) into individual outlets. B) The intensity of these separations was measured. C) % 
Recovery of H1975 from all three tested flow rates (2100-2300 µl min
-1
). D) % WBCs depletion from the all five flow 
rates (2100-2300 µl min
-1
). 46% of the H1975 cells were recovered from outlet #2 using 2300 µl min
-1
 with 78% 
WBCs depletion from outlet #1. 
Using HCC827 cell line, 63% of cells were recovered from outlet #2 at a flow 
rate of 2400 µL min-1 (Figure  3-53C), with 67% WBCs depletion from outlet #1 
(Figure  3-53D). Finally using the H1650 cell line, 82% of cancer cells were 
recovered at a flow rate of 2500 µL min-1 (Figure  3-54B), while 78% of WBCs were 
removed (Figure  3-54C). This flow rate was used to process the patient samples.  
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Figure ‎3-53: Labyrinth optimization using HCC827 cell line for cell recovery. A) The separation of labeled WBCs 
(blue) and HCC827 cell line (green) into individual outlets. B) The intensity of these separations was measured. C) % 
Recovery of HCC827 from all three tested flow rates (2100-2500 µl min
-1
). D) % WBCs depletion from the all five flow 
rates (2100-2500 µl min
-1
). 63% of the HCC827 cells were recovered from outlet #2 using 2400 µl min
-1
 with 67% 
WBCs depletion from outlet #1. 
To identify CTCs in patient samples, immunofluorescence staining was 
optimized with a panel of antibodies (anti-CD45, anti-PanCK, anti-EpCAM, and 
anti-Vimentin) using NSCLC cell lines including H1975 and A549 (section  2.9) 
(Figure  3-55). Using the optimized immunofluorescence staining protocol, both 
H1975 and A549 were positive for PanCK and negative for CD45. Furthermore, 
these cells expressed EpCAM and Vimentin as expected.  
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Figure ‎3-54: Labyrinth optimization using H1650 cell line. A) Device’s optimization with H1650 cell line. 10
5
 cells 
of pre-labeled H1650 cell line were spiked into PBS and processed through the Labyrinth with different flow rates 
ranging from 1500-3000 μL min
-1
. B-C) Pre-labeled H1650 cell line and DAPI-labeled WBCs (1000 cells) were spiked 
into PBS and processed through the Labyrinth. Using flow rate at 2500 μL min
-1
, 82%±5% of H1650 cells were 
recovered from outlet #2 and 78%±18% of WBCs were removed through outlet #1. 
 
Figure ‎3-55: Immunofluorescence staining optimization using NSCLC cell lines. Anti-human CD45, anti-human 
PanCK, anti-human EpCAM, and anti-human Vimentin antibodies were tested with lung cancer cell lines, H1975 and 
A549.  
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3.10.2 Isolation of CTCs from NSCLC Patients 
CTCs were isolated from peripheral blood samples collected from 21 
patients with metastatic, stage IV NSCLC. Additional information is provided in 
appendix section (Table  9-13). These patient samples were processed through 
the Labyrinth (section  2.9). After isolation, the product from the outlet #2 was 
analyzed for CTCs. CTCs were detected by immunofluorescence staining 
(section  2.9). Cells with the PanCK+/CD45-/DAPI+ phenotype were identified and 
enumerated as CTCs. Figure  3-56A shows immunofluorescence staining of an 
isolated single CTC stained for PanCK (red) and CD45 (green) to distinguish 
CTCs from WBCs. Figure  3-56B and Figure  3-56C illustrate confocal images of 
isolated CTCs in clusters of 2 cells (Figure  3-56B) and 3 cells (Figure  3-56C).  
 
Figure ‎3-56: Immunofluorescence staining images of the representative images of some CTCs recovered 
from NSCLC patients samples. A) Fluorescent microscope image of a single CTC. Cells are stained with DAPI 
(blue), PanCK (red) and CD45 (green). B-C) Confocal microscopy images of some CTC clusters. 
We determined that all 21 patients (100%) had detectable CTCs with an 
average of 180 CTC mL-1 (10.2-631.4). In contrast, low numbers of CTC mL-1 (0-
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3) were observed in the HCs (Figure  3-57). Additional information is provided in 
appendix section (Table  9-14). 
 
Figure ‎3-57: Isolation of CTCs from NSCLC patients (n=21).  An individual bar plots of number of CTCs recovered 
from NSCLC patient samples, using Labyrinth, at baseline. Significant differences between the overall numbers of 
CTCs in NSCLC patients samples (180±167.9 mL
-1
) vs. HCs (1±1.7 mL
-1
) was observed (p=0.001). Mann-Whitney 
unpaired t-test analysis was used for comparing patient cohort vs. healthy controls.  
3.10.3 Identification of heterogeneous CTC subpopulations isolated using Labyrinth 
Isolated CTCs from a subset of NSCLC patients (n=19) were further examined to 
determine the percentage of cells that displayed epithelial and mesenchymal markers. 
We used EpCAM (for epithelial phenotype) and Vimentin (for mesenchymal phenotype), 
in addition to PanCK (tumor marker), CD45 (leukocyte marker), and DAPI (nuclear 
marker). CTCs were defined as cells positive for PanCK, and DAPI, but negative for 
CD45. We further categorized CTCs into subpopulations based on expression of 
EpCAM, Vimentin, or double expression of EpCAM and Vimentin (Figure  3-58).
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Figure ‎3-58: Immunofluorescence staining images of the representative images of heterogeneous CTC 
subpopulations recovered from NSCLC patients samples. Fluorescent microscope images of different 
subpopulations of CTCs (CTCs, EpCAM+ CTCs, Vimentin+ CTCs, and Double+ CTCs). Cells are stained with DAPI 
(blue), CD45 (green), PanCK (red), EpCAM (orange), and Vimentin (pink). 
Figure  3-59A-B demonstrates the percentage of CTCs expressing EpCAM 
(EpCAM+/- in dark/light orange, respectively) and CTCs expressing Vimentin 
(Vimentin+/- in dark/light pink, respectively) of each patient. Of 19 patient 
samples, 15 samples had more EpCAM- CTCs than EpCAM+ CTCs, whereas 
only 4/19 patients (P 02, P 07, P 10, and P 19) had a higher number of EpCAM+ 
CTCs than EpCAM- CTCs.  
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Figure ‎3-59: Identification of heterogeneous CTC subpopulations isolated from NSCLC patient samples 
(n=19). A-B) The percentage of CTCs expressing both EpCAM (A) and Vimentin (B) recovered from each NSCLC 
patient sample (n=19). The EpCAM+/- CTCs is shown in dark/light orange respectively and the Vimentin+/- CTCs is 
shown in dark/light pink respectively. An average of 28.7% of the captured CTCs was EpCAM+ and 71.3% were 
EpCAM- CTCs. An average of 39.6% of the captured CTCs were Vimentin+ and 60.4% were Vimentin- CTCs. Total 
number of CTCs/mL across all patient samples is shown on the bottom of the graph. 
An average of 71.3% (115.7 CTCs mL-1) of the captured CTCs were 
EpCAM- and 28.7% (39.1 CTCs mL-1) were EpCAM+ (p=0.01) (Figure  3-60). 
Checking the mesenchymal phenotype on the recovered CTCs demonstrated 
that 39.6% were Vimentin+ CTCs (64.4 CTCs mL-1), and 60.4% were Vimentin- 
CTCs (90.4 CTCs mL-1) (p=0.5) (Figure  3-60). 
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Figure ‎3-60: Analysis of total numbers of CTCs mL
-1
 in different subpopulation of CTCs. Significantly higher 
number of EpCAM- CTCs were observed (115.7 CTCs mL
-1
) compared to EpCAM+ CTCs (39.1 CTCs mL
-1
) 
(p=0.01). While 39.6% of the recovered CTCs were Vimentin+ CTCs (64.4 CTCs mL
-1
), and 60.4% were Vimentin- 
CTCs (90.4 CTCs mL
-1
). Unpaired t-test (two-tailed) analysis was used for comparing between these groups.  
3.10.4 Presence of clusters in CTCs isolated using Labyrinth 
In addition to single CTCs recovered from NSCLC patient samples, a large 
number of CTCs were observed in cluster forms (2 to 7 CTCs/cluster) 
(Figure  3-61). On an average, 28.9±27 CTCs mL-1 were in the form of single 
CTCs, whereas 125.9±138.9 CTCs mL-1 were in cluster forms (p=0.005). 
(Figure  3-62A-B). Among the analyzed NSCLC patients, 1/19 had only single 
CTCs and 18/19 (95%) had CTCs in cluster forms. Of the 19 samples, 17 had ≥2 
clusters. The majority (n=16) presented with at least 3 CTC clusters. There were 
others with 4 clusters (n=7), 5 clusters (n=4), 6 clusters (n=1) and 7 clusters 
(n=2) (Figure  3-62C). Significantly higher numbers of recovered clusters from 
Labyrinth were EpCAM- CTC-clusters (p=0.009) (Figure  3-63) and 36% of the 
recovered CTC in cluster form displayed mesenchymal markers (Figure  3-62D). 
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Analyzing recovered clusters from Labyrinth, we found that significantly higher 
numbers of clusters did not express EpCAM (EpCAM-) (p=0.009) and 35% of clusters 
expressed the EMT marker, Vimentin (p=0.3) (Figure  3-63).  
 
Figure ‎3-61: Immunofluorescence staining images of the representative recovered CTC clusters in NCSLC 
patients. CTCs are stained with DAPI (blue), CD45 (green), PanCK (red), EpCAM (orange), and Vimentin (pink). 
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Figure ‎3-62: Identification of CTC clusters recovered from NSCLC patient samples (n=19). A) The percentage 
of CTCs in single (light pink) vs. cluster (red) forms. Across all patients, only one patient did not have CTCs in cluster 
forms. B) The comparison between the total CTC numbers in single vs. cluster forms. Significantly higher numbers of 
clusters compared to the single CTCs were observed in the captured CTCs from NSCLC patients (n=19). C) Cell 
clusters of 2-7 CTCs were observed in 95% of patients. D) 36% of the recovered CTC clusters displayed a 
mesenchymal or EMT phenotype (53.4 CTCs mL
-1
). Unpaired t-test (two-tailed) analysis was used for comparing 
single vs. clusters CTCs.  
 
Figure ‎3-63: Analysis of CTCs clusters mL
-1
 in different subpopulation of CTCs. Analyzing recovered clusters 
from Labyrinth, we found that significantly higher numbers of clusters were not expressing EpCAM (EpCAM-) 
(p=0.009), and 35% of clusters expressing the EMT marker, Vimentin. Unpaired t-test (two-tailed) analysis was used 
for comparing between these groups.  
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3.10.5 Genomic analysis of NSCLC patient CTC samples using Fluorescence in situ 
hybridization (FISH) analysis 
To investigate whether CTCs isolated by Labyrinth carry the genomic 
signature of the primary tumor, we analyzed CTCs for genomic alterations in 
ROS1, ALK, and RET. A 5’ deletion of ROS1 was detected by FISH in recovered 
CTCs from a patient with a known ROS1 rearrangement in the primary tumor (P 
03) (Figure  3-64A). Similarly, an ALK rearrangement was noted in the CTCs, 
matching the patient’s primary tumor (P 17) (Figure  3-64B) and a 3’deletion of 
RET was found in recovered CTCs from a patient with a RET rearranged tumor 
(P 21) (Figure  3-64C).  
             
Figure ‎3-64: Genomic analysis of NSCLC patient samples using Fluorescence in situ hybridization (FISH) 
analysis. A-C) Recovered CTCs from selected patient samples with different mutation (ROS1, ALK, and RET) were 
evaluated A) A patient with ROS1 rearrangement showed 5’ deletion is some of the cells. B) A patient with aberration 
in ALK showed ALK rearrangement C) A patient with aberration in RET showed 3’ deletion. Arrows indicate specific 
aberration in each gene. D) Box plot of the total number of CTCs recovered from patients with different mutation 
(EGFR (n=11), ROS1 (n=6), ALK (n=4) and RET (n=1)).  
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The total numbers of CTCs mL-1 in all patients with respect to their 
EGFR/ALK/ROS1 status are shown in Figure  3-64D. NSCLC patients with ROS1 
rearrangements (n=6) had an average of 277.2 total CTCs mL-1 (45.2-631.4). 
Patients with ALK rearrangements (n=4) had an average of 188.3 total CTC mL-1 
(70.4-402.6), and patients with EGFR mutations (n=11) had an average 124 total 
CTCs mL-1 (10.2-286.3). However, the differences in the number of CTCs 
according to genotype were not statistically significant.  
3.11 Patient-derived CTC expansion  
3.11.1 Optimization of CTC expansion methods 
To be able to expand the recovered CTCs from NSCLC patients for ex vivo drug 
testing, different CTC culture methods were tested. Sixteen samples were seeded in 
three conditions including, a plain 48-well plate (plastic), a “Fibronectin coated” 48-well 
plate (2D), and a “Matrigel-Collagen” coated 48-well plate (3D). After 3-4 weeks the 
expanded CTCs were passaged and then seeded onto 2D 48-well plates. The “possible 
CTCs” were counted and the results showed that the growth rate was significantly 
higher in the 3D model (Figure  3-65).  
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Figure ‎3-65: Patient-derived CTC expansion utilizing different culture conditions. Enriched CTCs separated 
from Labyrinth were cultured on A) uncoated 48-well plate B) Fibronectin coated 48-well plate), and C) Martigel-
collagen coated 48-well plate. D) The box plot of these 3 conditions shows significantly higher growth rate in the 
Martigel condition. 
Small portion of expanded CTCs were seeded in 96-well plate to check the cell 
viability. Cells were labeled with IncuCyte NucLight Rapid Red (IncuCyte) reagent for 30 
min prior visualization with fluorescence microscopy (Figure  3-66). The NucLight Rapid 
Red reagent labels the nucleus of cells and their growth rate can be tracked for 72 hr. 
Alive cells show dim, and dead cells show bright fluorescent. Some bright field and 
fluorescently labeled images of expanded CTCs were shown in Figure  3-66A-B.    
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Figure ‎3-66: Cell viability check on the patient-derived expanded CTC using 3D models. A) Bright field images 
of possible expanded patient-derived CTCs. B) Possible expanded CTCs from different patient samples were labeled 
with IncuCyte NucLight Rapid Red. Alive cells show dim, and dead cells show bright fluorescent.    
3.11.1.1     Red blood cells (RBCs) removal techniques 
To be able to expand patient-derived CTCs in vitro, it is necessary to reduce the 
off-target cells (mostly RBCs) after CTCs enrichment. Even though by utility of Dextran, 
the majority of the RBCs are depleted at the first place, the high numbers of remain 
RBCs may still disturb the CTC expansion in vitro. Hence, we attempted to optimize the 
RBCs depletion methods while maintaining the numbers of the recovered CTCs from 
NSCLC patient.  
3.11.1.1.1     Double Labyrinth 
In the first attempt, we processed the second outlet’s products of the Labyrinth 
(single) through another Labyrinth (double). The CTCs recovered from single vs. double 
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Labyrinth of 4 different patient samples were collected and stained with PanCK and 
CD45. The CTC lost was observed across all the samples (n=4) using the double 
Labyrinth (Figure  3-67A). For further investigation of the CTC lost in double Labyrinth 
using one NSCLC patient sample, the recovered CTCs from single Labyrinth compared 
to the ones recovered from different outlets (1, 2, and 3) of double Labyrinth. The 
results showed that the majority of the CTCs separated in the first outlet (Figure  3-67B).  
3.11.1.1.2     RBC lysis buffer 
Since the use of double Labyrinth was not a success, in the second attempt the 
RBC lysis buffer was used for further RBC depletion. The effects of both single vs. 
double, with or without RBC lysis buffer on the CTC counts were analyzed. The CTC 
numbers showed CTCs lost using both double Labyrinth and RBC lysis buffer 
(Figure  3-67C-D). In another attempt, the recovered CTCs from two patients divided into 
2 groups; in one set the effect of RBC lysis buffer was checked on the CTC lost, and in 
the other set, the recovered CTCs (suspended into the media) sat overnight inside the 
refrigerator to allow the larger cells (CTCs) form a pellet. The following day, the media 
was removed and the pellet was resuspended. A small portion of the sample was 
checked for the CTC counts. The results showed that the number of CTCs decreased 
using the RBC lysis buffer/fridge compared to the CTC counts from Labyrinth without 
any post processing (After single) (Figure  3-67E).  
3.11.1.1.3     Microbubbles  
We further tested the RBC Depletion Kit (Akadeum) which is a microbubble-
based cell isolation product designed to clean up samples with red blood cell 
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contamination. We tested 2 different concentrations of the bubbles and compared with 
the CTC count without any post processing. However, due to the steps of centrifugation 
we lost many CTCs (Figure  3-67F).  
3.11.1.1.4     Cell strainer  
Due to the CTC lost using the stated techniques which contains centrifugation 
steps, we decided to investigate the cell strainer technology for the RBC removal. The 
cell strainer (pluriselect) is a size-based sterile sieving device to separate cells of 
interest from the other cells. Any cell smaller than the pores, will go through the filter 
while the larger cells will remain on top of the filter. In theory, this method should allow 
RBCs/WBCs (smaller cells) pass through the filter and CTCs (larger cells) remain on 
top of the filter. The filter can then be inverted to recover the CTCs on top to obtain a 
more purified sample.  
The experiment we conducted involved using two different types of cell strainers 
(Uber and Pluri (Figure  3-68C-D)), three different pore sizes (1, 5, and 10 m), and two 
sample retrieval methods (washing from the top or from the bottom of the filter). Pluri 
uses a vacuum to send the sample through the filter and Uber uses pressure to send 
the sample through the filter. 
1000 green CellTracker cell lines (A549) spiked into 1 mL treated blood with 
dextran were prepared to test RBCs depletion. Samples sent through different cell 
strainers and both waste and recovered samples were collected for further analysis. 
The results showed that the 1 m Pluri cell strainer has the highest recovery compared 
to the Uber (>61% vs. 25%) and other filter sizes (>61% vs.1% and 26%) 
(Figure  3-68A). 
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Figure ‎3-67: RBC removal techniques optimization. A) CTC numbers from single vs. double in different patient 
samples (n=4). CTC lost was observed using double Labyrinth. B) CTC numbers of different outlets from double 
Labyrinth vs single Labyrinth. C-D) The effect of using double Labyrinth, with or without RBC lysis buffer on the CTC 
counts. E) The effect of RBC lysis buffer and no post-processing (in the fridge) of the product from 2
nd
 outlet of 
Labyrinth on the CTC counts. F) The effect of using microbubbles on the CTC counts. All the mentioned methods 
result in losing CTCs. 
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The 1 m Pluri cell strainer was utilized with one patient sample to confirm their 
effectiveness and compatibility but no CTCs were collected after using the filter. Using 1 
m Pluri, the diameter of the cell lines in both waste and the recovered samples showed 
that the size of cells passing through or remaining on top of the filter are almost similar 
(16m vs 14m) (Figure  3-68B). This could be a reason for CTC loss using this 
technology.  
 
Figure ‎3-68: RBC removal techniques optimization using cell strainer. A) % of recovered cells from the sample 
and waste for each cell strainer. B) Cell diameter in both waste and the recovered samples. C-D) A representative 
image of Uber (C) and Pluri (D) strainer.  
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3.11.1.1.5     Ficoll-Paque ™‎PLUS‎Media 
In another attempt, we applied Ficoll-Paque™ PLUS Media (GE Healthcare) for 
the RBC removal purpose before the CTC enrichment. Different NSCLC patient 
samples were treated with both Dextran and Ficoll before the enrichment (n=10). A 
small portion of the processed samples was stained for enumeration purposes, and the 
rest were seeded for the CTC expansion. The CTC numbers were higher in 6/10 of 
patient samples using Ficoll and the number of RBC was reduced significantly using 
Ficoll (Figure  3-69). Hence, this technique was carried on for the CTC expansion 
application for the rest of processed NSCLS patient samples.  
 
Figure ‎3-69: RBC removal techniques optimization using Ficoll. CTC numbers from Dextran vs. Ficoll from 10 
different patient samples indicated higher CTC numbers in 6/10 of patients using Ficoll.  
3.11.2 Recovered CTCs were expanded from NSCLC patient samples (n=2) using 3D 
model 
We were able to successfully expand isolated CTCs from 2 patient samples (P 
03 at visit 6 and P 022 at visit 8). A small portion of the expanded “potential CTCs” were 
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stained for the CTC panel of antibodies (PanCK, EpCAM, Vimentin, and CD45). Since 
the majority of the RBCs and WBCs are gone at this time, the cells expansions are 
faster. Eventually, we were able to expand CTCs from a 48-well plate to T175 flasks. 
Figure  3-70 and Figure  3-72 are representative images of the bright field and 
fluorescent images of the expanded CTCs from P 03 (Figure  3-70) and P 22 
(Figure  3-72).  
 
Figure ‎3-70: Representative images of the NSCLC patient-derived expanded CTCs (P 03). A-B) Bright filed 
images of expanded CTCs in single cell forms on a well plate culture (A) and in cluster forms in a low attachment well 
plate (B). C) Expanded CTCs are stained with DAPI (blue), CD45 (green), PanCK (red), EpCAM (orange), and 
Vimentin (pink). 
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To be able to verify the genomic signature (ROS-1 rearrangement) from the 
CTCs at day 0 vs. the expanded CTCs, the cells were analyzed using FISH 
(Figure  3-71A). Similar to the results of FISH analysis on the tumor from the clinic, the 
FISH analysis on the CTCs expanded demonstrated the loss of 5’ probe in some cells 
confirming ROS-1 rearrangement (Figure  3-71B).  
 
Figure ‎3-71: Genomic analysis of NSCLC patient sample (P 03) using FISH analysis. A) Recovered day 0 CTCs 
from patient P 03 with ROS-1 rearrangement were evaluated. Patient P 03 showed 5’ deletion is some of the cells. B) 
Expanded CTCs from same patient showed the loss of 5’ probe in some cells. 
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Figure ‎3-72: Representative images of the NSCLC patient-derived expanded CTCs (P 22). A-B) Bright filed 
images of the expanded CTCs in single cell forms on a well plate culture and in cluster forms. C) Expanded CTCs are 
stained with DAPI (blue), CD45 (green), PanCK (red), EpCAM (orange), and Vimentin (pink). 
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3.12 CTC enumeration of follow-up NSCLC patient samples 
Blood samples were collected during subsequent clinic visits in addition to the 
baseline. The relevant clinical information for patients P 03 and P 22 over the course of 
treatment is shown in detail in appendix section (Table  9-15).  
Ten consecutive samples from patient P 03 were collected during different 
treatment regimes. The numbers of CTCs were analyzed during the follow-up visits 
(Figure  3-73A). This patient enrolled at this study on 12/6/2016 while she was on 
Crizotinib treatment. The progression in the brain was observed after 350 days. Higher 
numbers of CTCs were observed in her 3rd visit compared to first and second visits. 
After 412 days (visit 5), a slight increase in fullness of L frontal brain tumor was 
observed. Then, the treatment regime was switched to Entrectinib. Cancer progression 
at several spots in the brain was detected after 468 days and Entrectinib continued as 
treatment. The CTC numbers increased 3 folds at this visit (V6) compared to the 
previous visit (V5). We were able to establish the CTC cell line from the recovered 
CTCs at this visit (Figure  3-70). In summary, according to the available clinical 
information, the CTC numbers tracked the patient’s outcome over the course of 
treatment.  
Nine follow-up samples were collected during different treatments from patient P 
22 and the CTC numbers were analyzed (Figure  3-73B). This patient enrolled at this 
study on 10/21/2016 and after one-week treatment with Docetaxel along with 
Ramucirumab was started. After 525 days at her 8th visit, the CTC numbers increased 
from the previous visits and we were able to expand CTCs from this visit (V8) 
(Figure  3-72). Due to fatigue and taste changes Docetaxel was discontinued after 539 
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days. After 602 days due to the progression on MR brain with two new lesions, her 
treatment regime was switched from Ramucirumab to Osimertinib.  
 
Figure ‎3-73: CTC enumeration of two NSCLC patients over the treatment regime. A) 10 different follow-up 
samples from patient P 03 (A) and P 22 (B) were collected and the CTC numbers were evaluated over different 
treatments.  
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3.13 Drug testing  
3.13.1 Optimization of drug testing methods using NSCLC cell lines 
To analyze the effect of each drug on different NSCLC cell lines including, both 
sensitive and resistant cell lines to drugs, the half maximal inhibitory concentration 
(IC50) analysis using different methods was conducted.  
3.13.1.1     CellTiter 96® Aqueous One Solution Cell Proliferation Assay 
The tetrazolium-based MTS assay, CellTiter 96® aqueous one solution cell 
proliferation assay, was used to analyze IC50 of each different drugs against potential 
sensitive or resistant NSCLC cell lines. 2000 cells were seeded in each well of a 96-well 
plate in triplicates.  
Using a sensitive cell line (H3122) to Crizotinib and Ceritinib the IC50 values 
were 151.8 nM and 14.3 nM respectively. The resistant cell line (A549) showed IC50 of 
6642 nM and 3761 nM for these two drugs respectively (Figure  3-74A-B). IC50 of 
Erlotinib for the sensitive cell line (PC-9) was 112.2 nM, while the resistant cell line 
A549 showed IC50 of 3761 nM (Figure  3-74C). HCC827 cell line was 2.6 fold more 
sensitive to Afatinib (IC50= 332.1 nM) than the resistant cell line, A549 (IC50=854.4 nM) 
(Figure  3-74D). The IC50 of the sensitive cell line to Osimertinib (EGFR L858R/T790M 
double mutation cell line, H1975) was 139.8 nM compared to the resistant cell line 
(A549) which was 1790 nM (Figure  3-74E). The efficacy of Cetuximab, at inhibiting 
growth of EGFR mutant cell line, HCC827 (IC50=8957 ng/mL) is more effective than the 
resistant cell line, A549 (IC50=111287 ng/mL) (Figure  3-74F).  
The IC50 results of drug-testing studies conducted with Crizotinib, Ceritinib, 
Erlotiinb, Afatinib, Osimertinib, and Cetuximab are summarized in   
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Table  3-4. 
 
Figure ‎3-74: IC50 values of different drugs on NSCLC cell lines using CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay. A) H3122, A549 cell lines treated by Crizotinib; B) H3122, A549 cell lines treated by 
Ceritinib; C) PC-9, A549 cell lines treated by Erlotinib; D) HCC827, A549 cell lines treated by Afatinib; E) H1975, 
A549 cell lines treated by Osimertinib; F) HCC827, A549 cell lines treated by Cetuximab. 
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Table ‎3-4: The effects of different drugs on of NSCLC cell lines. 
Compound 
Range of 
concentration of 
compound 
Sensitive cell 
line 
IC50 of 
sensitive cell 
line 
Resistant cell 
line 
IC50 of 
resistant cell 
line 
Crizotinib 100~10000 nM H3122 151.8 nM A549 6642 nM 
Ceritinib 5~5000 nM H3122 14.3 nM A549 3761 nM 
Erlotiinib 5~5000 nM PC-9 112.2 nM A549 4894 nM 
Afatinib 5~5000 nM HCC827 332.1 nM A549 854.4 nM 
Osimertinib 5~5000 nM H1975 139.8 nM A549 1790 nM 
Cetuximab 10~50000 ng/mL HCC827 8957 ng/mL A549 111287 ng/mL 
3.13.1.2     CellTiter-Glo® luminescent cell viability assay (2D kit)  
To assess IC50 values with a lower seeding density, we utilized the CellTiter-
Glo® luminescent cell viability assay. All cell lines were seeded at a density of 400 cells 
well-1 on 384-well plates. After treatment, each well was incubated with CellTiter-Glo® 
luminescent cell viability assay for 10 min. Absorbance was measured with LUM mode 
of Biotek-Synergy Neo-plate Reader.  
Similar to the IC50 results we observed using CellTiter 96® aqueous one solution 
cell proliferation assay with 2000 cell well-1 density in 96 well plate, we obtained 
comparable IC50 values using  CellTiter-Glo® luminescent cell viability assay using 400 
cells well-1 in 384-well plate (Figure  3-75, Table  3-5). 
Table ‎3-5: Comparison of IC50 values with two different cell viability assays. 
Drugs Cell lines 
Concentrations 
nM 
IC50 (nM) using  
CellTiter-Glo®  
Luminescent   
Cell Viability Assay 
IC50 (nM) using  
CellTiter 96® 
Aqueous One 
Solution Cell 
Proliferation Assay 
Crizotinib 
Sensitive 
cell line 
H3122 100~10000 243 151.8 
Ceritinib H3122 5~5000 44 14.3 
Erlotinib HCC827 5~5000  97 112.2 
Afatinib HCC827 5~5000  95 332.1 
Osimertinib H1975 5~10000  37 139.8 
Crizotinib 
Resistant 
cell line 
A549 100~10000 1502 6642 
Ceritinib A549 5~5000  1357 3761 
Erlotinib A549 5~5000  1064 4894 
Afatinib A549 5~5000  505 854.4 
Osimertinib A549 5~10000  1899 1790 
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Figure ‎3-75: IC50 values of different drugs on NSCLC cell lines using CellTiter-Glo® Luminescent Cell 
Viability Assay. A) H3122 and A549 cell lines treated with Crizotinib; B) H3122 and A549 cell lines treated with 
Ceritinib; C) PC-9 and A549 cell lines treated with Erlotinib; D) HCC827 and A549 cell lines treated with Afatinib; E) 
H1975 and A549 cell lines treated with Osimertinib. 
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3.13.1.3     CellTiter-Glo luminescent cell viability assay (2D kit) vs. CellTiter-Glo 3D Cell 
Viability Assay (3D kit) 
To be able to expedite testing the effect of each drug on the recovered-seeded 
CTCs on the 3D culture model, the utilizing of the CellTiter-Glo 3D cell viability assay 
(3D) which is formulated with more robust lytic capacity to spheroids was investigated. 
We studied the IC50 values of 2D and 3D cell viability kits with 2D and 3D cell culture 
conditions using sensitive (H3122) and resistant (A549) cell lines. 
Utilizing Crizotinib on the 2D culture model using the 2D cell viability kit, the IC50 
of H3122 was 297 nM, and A549 was 2173 nM (Figure  3-76A). Expectedly, 3D culture 
with 2D cell viability kit showed IC50 of 1565 nM for H3122 cell line. However, utilizing 
the 3D cell viability kit on 3D cells culture model drops the IC50 to 291 nM 
(Figure  3-76B). The IC50 values of this experiment are summarized in Table  3-6. 
 
Figure ‎3-76: IC50 values of crizotinib on NSCLC cell lines using CellTiter-Glo luminescent cell viability assay 
(2D kit) vs. CellTiter-Glo 3D Cell Viability Assay (3D kit). A) H3122 cells B) and A549 were cultured in 2D or 3D 
conditions and IC50 values were analyzed by the 2D vs. 3D kit.  
Table ‎3-6: Comparison of IC50 values with two different cell viability assays 2D vs. 3D 
Cell Culture and Cell Viability 
Kits 
Cell lines IC50 for crizotinib (nM) 
2D culture, 2D kit 
H3122 297 
A549 2173 
3D culture, 2D kit 
H3122 1565 
A549 7097 
3D culture, 3D kit 
H3122 291 
A549 6524 
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3.13.1.4     LIVE/DEAD viability/cytotoxicity kit optimization 
Given that enrichment of a large number of CTCs in vitro is still a challenge, we 
investigated the LIVE/DEAD cell viability assays to assess drug efficacy tests by 
seeding less cell numbers (50-200 cells well-1). The LIVE/DEAD viability/cytotoxicity kit 
(Thermo Fisher Scientific) was used to analyze IC50 of tyrosine kinase inhibitors (TKIs) 
with directly counting live cells using Calcein AM (green) and dead cells using ethidium 
homodimer (EthD-1) (red) under fluorescence microscope from lower number of cells. 
The optimal dye concentrations for NSCLC cell lines H3122 and A549 were 10 μM 
calcein AM /3 μM EthD-1 (Figure  3-77A), and 20 μM calcein AM /3 μM EthD-1 
(Figure  3-77B) respectively. 
 
Figure ‎3-77:  LIVE/DEAD viability/cytotoxicity kit optimization using different NSCLC cell lines. A) H3122 and 
B) A549 were cultured in 2D condition in 384-well plate. Treat and stain cells following manufacture's protocol and 
take picture under fluorescent microscope with amplification 20x.  
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3.13.2 Drug testing on the patient-derived expanded CTCs 
As mentioned above, we have successfully expanded the isolated CTCs from 2 
patient samples (P 03 at follow up visits of 6 and P 22 at follow up visits of 8). The drug 
screening was done subsequently with 2D kit using various TKIs directed against the 
genomic drivers. Appropriate positive and negative controls were used and experiments 
were confirmed in triplicates.  
The first patient (P 03) had a ROS1 rearranged NSCLC on Entrectinib therapy. 
The IC50 value of this drug on the expanded CTCs is 2357 nM (Figure  3-78). Patient P 
03 showed CNS progression on scans on Entrectinib, hence Loralatinib was selected to 
test on her expanded CTCs (IC50=15979 nM) (Figure  3-78). The third tested drug on 
her CTCs was TPX-0005 which has been shown overcoming a broad spectrum of 
mutations in ALK and TRKA (tropomyosin receptor kinase A) kinases (IC50=278 nM) 
(Figure  3-78). The IC50 values of different drug tested on this patient’s expanded CTCs 
are summarized in Table  3-7.    
 
Figure ‎3-78:‎IC50 values of different drugs on the expanded CTCs from patient P 03-V6. The expanded CTCs 
were treated with Entrectinib, Lorlatinib, and TPX-0005. The cells were resistant to both Entrectinib and Loralatinib, 
but sensitive to TPX-0005.  
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Table ‎3-7: IC50 values of different drugs on the expanded CTCs from patient P 03-V6. Data are means ± 
standard deviation of three independent experiments. 
The second patient (P 22) had an EGFR mutant NSCLC, on Osimertinib therapy. 
Following successful expansion during visit 8, we tested this patient’s CTCs against 
Osimertinib, and a sensitive NSCLC cell line to this drug (PC-9) (deletion in exon 19 of 
the EGFR gene). Karachaliou N et al. has been reported that TPX-0005 was synergistic 
with Osimertinib in EGFR-mutated NSCLC cells.199 Therefore, TPX-0005 was selected 
to test on the expanded CTCs from P 22, as well as evaluating whether a co-activation 
trait was shown between TPX-0005 and EGFR TKIs in treatment of EGFR-mutation-
positive NSCLC patients.   
Our results showed that PC-9 was more sensitive to Osimertinib (IC50=135nM) 
than TPX-0005 (IC50=830nM) (Figure  3-79B, Table  3-8). Meanwhile, the IC50 of 
combining both TKIs displayed similar value (71 nM) as the one of Osimertinib 
treatment alone (135 nM). On the contrary, the expanded CTCs of P 22-V8 were 
resistant to Osimertinib (IC50=34617 nM), but exhibited a modest sensitivity to TPX-
0005 (IC50=339 nM), as well as TPX-0005 + Osimertinib (IC50=392 nM) (Figure  3-79A, 
Table  3-8). 
Table ‎3-8:‎ IC50‎ values‎ of‎ TKIs‎ tested‎ in‎ patients’‎ CTCs‎ or‎ NSCLC‎ cell‎ line.‎ Data‎ are‎ means‎ ±‎ standard‎
deviation of three independent experiments. 
  
                                 TKI 
CTC or Cell Line  
IC50 (nM) 
TPX-0005 Entrectinib Lorlatinib 
Expanded CTCs from 
P 03-V6  
278±140 2357±802 12175±8324 
                                 TKI 
CTC or Cell Line  
IC50 (nM) 
TPX-0005 Osimertinib TPX-0005+Osimertinib 
Expanded CTCs from 
P 22-V8  
339±113 34617±7938 392±223 
PC-9 830±30 135±19 71±43 
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Figure ‎3-79: IC50 values of different drugs on the expanded CTCs from patient P 22-V8. A) The expanded 
CTCs and B) PC-9 cell line were treated with Osimertinib alone or the combination and TPX-0005. The expanded 
CTCs were resistant to Osimertinib but sensitive to TPX-0005.  
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4 Discussion 
In the past decade, circulating tumor cells (CTCs) have been the subject of 
intense research as blood based biomarkers of diagnosis and prognosis in various 
cancers. In fact, CTCs have now been proposed as surrogate biomarkers in over 270 
clinical trials.200   
Many techniques have been developed to detect CTCs in the circulatory system, 
making them promising biomarkers for detection of different types of cancer. However, 
to date, CTCs have not been incorporated into clinical practice for management of 
patients with cancer. The main challenges to this field include sensitivity and specificity 
of various proposed approaches in detecting these cells which often number between 1-
10 cells per 10 mL of blood. 
Microfluidic isolation techniques have become attractive since the development 
of the first microfluidic CTC Chip due to their high sensitivity, high throughput, low cost, 
and enhanced spatio-temporal control abilities.4, 9 Immunoaffinity-based microfluidic 
technologies are capable of isolating CTCs from peripheral blood without pre-
processing and with high specificity of the recovered assorted pool of CTCs.102 The 
main approach for enrichment thus far has been to capture cells of interest by using 
specific epithelial markers such as EpCAM on the cell surface to distinguish CTCs from 
leukocytes.1 These technologies provide high purity, allowing for improved downstream 
analysis. However, they suffer from low throughput and bias in capturing specific 
subpopulations of CTCs.61, 102 Another drawback of immunoaffinity technologies is their 
inability to easily release cells from the device,30 which can limit downstream 
applications such as single-cell analysis and CTC-derived xenografts assays.102  
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During cancer progression, cancer cells undergo an epithelial-to-mesenchymal 
transition (EMT) process, whereby epithelial markers on the cell surface are down-
regulated and mesenchymal markers are upregulated.154, 201 As such, CTC detection 
based only on EpCAM (EpCAM+) might miss a substantial number of other CTCs have 
lost expression of epithelial markers and have undergone the process of EMT (EpCAM-
).21, 154, 202 
In this presented work, immunoaffinity-based and label-free microfluidic 
technologies have been developed to investigate heterogeneous CTC populations from 
pancreatic cancer and non-small cell lung cancer (NSCLC) patients.  
The most prevalent form of pancreatic cancer, PDAC, displays a particularly 
aggressive biology with resistance to both conventional and targeted therapeutics. By 
the time a patient receives diagnosis, the disease has already advanced to an incurable 
state in the vast majority of patients.135 These facts highlight the unmet challenge of 
identifying the lethal cells that survive and thrive even after treatment and predispose 
patients to recur, even after seemingly curative surgery.  
Although isolation of CTCs from pancreatic cancer patients is feasible, 
investigating their clinical utility has proven less successful than other cancers due to 
limitations of epithelial cellular adhesion molecule (EpCAM)-only based CTC assays. 
CTC detection based only on EpCAM may miss a substantial number of other CTCs, 
which might have an aggressive phenotype such as EMT-like CTCs.21, 154 The only 
FDA-cleared CTC isolation technology, CellSearch,63 suffers from drawbacks including 
low efficiency, low purity, and extremely low abundance of CTCs (0-1 CTC per 7.5 mL 
of blood) in pancreatic cancer patients.203 To our knowledge, there is no technique 
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available for detecting different cell populations of interest simultaneously from 
peripheral blood of pancreatic cancer patients. Herein, we present two different 
technologies to study heterogeneous CTCs in pancreatic cancer.   
We developed an integrated technology and biology based translational 
approach, the immunoaffinity-based microfluidic, “CTC Carpet Chip” to study the 
biological relevance of rare circulating cells from pancreatic cancer patients (n=35). We 
have focused on a novel strategy based on obtaining separate populations of 
phenotypically distinct CTCs. Both circulating epithelial CTCs (EpCs) and EMT-like 
CTCs (EMTCs) were simultaneously isolated from the peripheral blood of pancreatic 
cancer patients by using multiple markers of interest. Sequential microfluidic devices 
were set up using antibodies against EpCAM, to capture EpCAM+ CTCs (detected by 
anti-cytokeratin), and antibodies against CD133 to capture more stem-like cells, 
potentially EpCAM- CTCs (detected by Vimentin) in pancreatic cancer patients.1, 27, 31, 32, 
155, 204, 205 Among the genes involved in EMT, Vimentin has been studied most in our 
work. It has been shown that pancreatic cancer has greater than threefold higher 
expression of Vimentin compared to other cancers.27, 204 
The EpCAM CTC Carpet Chip could capture ≥5 EpCs mL-1 in 97.5% of 
pancreatic cancer patients assayed (mean 22.4±17.7 CTCs mL-1). Moreover, 100% of 
those individuals showed ≥15 EMTCs/mL (mean 85.7±59.5 CTCs mL-1) in the CD133 
chip. We found the numbers of EMTCs were significantly higher compared to the 
number of EpCs within the stages from early stages to metastatic, and more 
interestingly, the ratio of EMTCs to total CTCs has an increasing trend toward late 
stages. The stage IV group patients showed higher number of EMTCs than EpCs 
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(p=0.0008), suggesting the strong role of EMT process in the progression of pancreatic 
cancer.2, 5, 20, 25, 36, 206 Moreover, we observed that pancreatic cancer patients with lymph 
node involvement had significantly higher numbers of EMTCs compared to the patients 
without. This supports the observations from other studies, where the associations of 
EMT with lymph node metastasis have been reported.207-209 However, we were not able 
to observe any significant correlation between CTC abundance, disease stage, tumor 
size, metastatic burden, operability, and survival rate in this group, which could be due 
to the limited sample size.  
The comparison between the EpCAM and CD133 chips in terms of gene 
expression profiling showed that CXCR1 was significantly upregulated in CTCs isolated 
by the EpCAM chip while POU5F1 (or OCT-4) and MYC were significantly elevated in 
the CTCs captured on the CD133 chip. Given the phenotypic differences we have 
observed between EpCs and EMTCs, it is not surprising that the stem cell related gene 
POU5F1 is highly expressed in EMTCs. Based on our results, over expression of this 
gene was significantly correlated with worse PFS.  
 It has been reported that the expression of the chemokine gene, CXCR1 is 
correlated with lymph node metastasis in pancreatic cancer.210 The presence of 
POU5F1 has been reported in adult human pancreatic stem cells during differentiation 
and in pancreatic cancer cells and plays a crucial role in proliferation, cell cycle, 
stemness, and metastasis.211 Based on our results, over expression of this gene was 
significantly correlated with worse PFS (p=0.04). There are several studies showing that 
expression of the oncogene MYC is elevated in pancreatic cancer, the activation of 
which may be essential during carcinogenesis.212, 213 Signaling pathways based on 
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analysis of captured CTCs on EpCAM vs. CD133 chip with iPathwayGuide using a p 
value threshold of 0.05, suggested that these two genes were involved in signaling 
pathways regulating pluripotency of stem cells (p=0.056).  
We found that the expression of ATL1, BMi1, CD14, CDH2, ERCC1, MKi67, 
TTF1, and Vimentin were significantly higher in our early stage pancreatic cancer 
patient cohort compared to the rest of the stages. Among these genes, BMi1, CDH2, 
ERCC1, and TTF1 genes were significantly associated with the prolonged OS and/or 
PFS. BMi1 has been implicated in progression of PDAC by the regulation of pancreatic 
cancer CSCs,37, 214 conversely, our results showed over expression of these genes lead 
to significantly prolonged OS and PFS. It has been shown that over expression of CDH2 
(N-Cadherin) is associated with invasiveness in cancer and poor outcomes in 
pancreatic cancer patients,215, 216 however our results showed higher expression of this 
gene in early stage patients with longer OS.  
ERCC1 has a key role in the removal of adducts from genomic DNA through the 
NER pathway and over expression of this gene enables DNA repair in tumor cells that 
promotes their viability and growth.217 Similar to our findings, over expression of this 
gene has been reported in PDAC with better OS and outcomes.218 TTF1 has been 
reported in PDAC with a prolonged disease control (≥10 months).219  
We observed genes including, ALDH1A3, ESR1, KRT18, KRT19, AKT1, and 
CD3D were significantly higher in stage IIB&III pancreatic cancer patients. Among these 
genes, AKT1 was significantly associated with PFS. AKT1 is increased in many types of 
cancer including pancreatic cancer, which is related to apoptosis resistance and cell 
proliferation, growth and energy metabolism.220, 221  
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We also observed the expression of CDH1, DCN, KRT19, PGR, and PIK3CA 
genes significantly elevated in the stage IV pancreatic cancer patients cohort. Collagen-
associated proteoglycan decorin (DCN) is an important component of extracellular 
matrix (ECM) and over expression of this gene has been reported in PDAC.222 Somatic 
mutation in PIK3CA gene has been reported in several types of cancer including 
colorectal, gastric, thyroid, and breast.223 It has not been reported in conventional PDAC 
to date; however the presence of this gene has been reported in IPMN and MCN.223, 224  
Further, gene expression profiling revealed that IL8 and TP53 were significantly 
over expressed in patients with higher OS and/or PFS. IL8 (CXCL8) is a chemokine 
which is associated with cell proliferation, migration, invasion and cancer stem cells 
population in many types of cancers including pancreatic cancer.225 The TP53 tumor 
suppressor gene is a well-considered deregulated gene in pancreatic cancer.226 
However, pancreatic cancer patients with higher expression of metastatic marker, 
GEMIN2 and stem marker, POU5F1 showed worse OS or PFS respectively.  
Although the immunoaffinity CTC Carpet Chip enables us to isolate different CTC 
populations from pancreatic cancer patients, it’s still a low throughput and biased CTC 
isolation system. Therefore, refinements including increasing throughput and using 
biomaterials and reversible conjugation of antibodies for CTC release of off the chip 
may be the important steps toward improving immunoaffinity technologies.102   
The other current challenge is to increase the yield and detection of CTCs that 
have undergone phenotypic changes such as EMT.227 To enable identification and 
enrichment of heterogeneous populations of CTCs, biomarker-independent 
technologies have been developed. Label-free technologies present high throughput 
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approaches with the ability to release and expand CTCs using off-chip standard cell 
culture techniques. However, they share some disadvantages including, limited 
recovery, throughput, purity, and the ability to couple with conventional biological 
assays or platforms for other downstream analyses.94, 163, 170, 176, 188, 228 Therefore, a high 
throughput microfluidic-based biomarker-independent CTC isolation technology with 
high sensitivity, specificity, and efficiency is needed to enable the study of 
heterogeneous CTC populations. 
 The size-based, label-free inertial microfluidic device, Labyrinth, uses the 
delicate balance of inertial and dean forces to differentially focus cells within microfluidic 
channels.198 Particles are focused by inertial forces which can be considered as the 
driving forces, while particle migrates away from the center of the channel by drag 
forces from dean flow, leading to size-based separation.103 It also induces fluidic path 
directional shifts by incorporating 56 high curvature turns.198 The multi-course path 
traversing across inner loops to outer loops yields an increased hydrodynamic path 
length to enhance the focusing of both CTCs and WBCs, resulting in greater purity.198 
Herein, using this novel technology, we have isolated heterogeneous populations of 
CTCs expressing epithelial and mesenchymal markers in both pancreatic cancer 
patients and advanced non-small cell lung cancer patients (NSCLC). 
As mentioned above, the treatment options for pancreatic cancer are limited to 
surgery, chemotherapy and radiotherapy. Only 15% of patients are qualified for surgery, 
which may result in increasing patient’s survival only 10-20%. The efficiencies of 
chemotherapy and radiotherapy are also limited. Hence, the need of a biomarker for 
detecting and monitoring this disease is an urgent need.  
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Therefore, in order to study the efficacy of CTCs as tumor biomarkers,141 
treatment naïve pancreatic cancer patients samples were studied for heterogeneous 
CTC populations including epithelial CTCs and EMT-like CTCs. Using Labyrinth, CTCs 
were detected in 94.3% of treatment naïve pancreatic cancer patients ranging from 0-
117 total CTCs mL-1. This cohort was further stratified based on their cancer stage: 
resectable, borderline resectable, locally advanced, and metastasis. Patients with 
borderline resectable disease had significantly higher numbers of total CTCs compared 
to the other categories. Our results showed the potential of cancer dissemination even 
in the earlier stage, as has been previously reported by other groups.154   
The CTC counts were analyzed for the patients who were under surgery and it 
compared with the CTC numbers before surgery. The total CTC numbers showed a 
slight decrease in post-surgery patients. However, when this cohort grouped based on 
their stages, significantly higher decrease change on the CTC counts was observed in 
the more advanced stage group of patients (borderline resettable). The correlation of 
overall survival of patients with a decrease compared to an increase or constant CTC 
counts shows a better OS in the patients who lost CTCs due to the treatment. 
The effect of chemotherapy on CTC numbers was evaluated on pre-/on- 
chemotherapy cohort, and pre-/post-chemotherapy group. The numbers of epithelial, 
EMT-like, and total CTCs were significantly decreases in on-chemotherapy cohort. 
Patients who had a decrease in their CTC numbers show an improved on their OS. 
Furthermore, post-chemotherapy group of patients showed significantly lower number of 
total and epithelial CTCs, suggesting the effect of chemotherapy treatment on 
decreasing the CTC numbers in the circulatory system and result in a longer probability 
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survival. Furthermore, the effects of radiotherapy were studied on patients where the 
total CTCs counts significantly declined in response to treatment which is associated 
with prolonged OS. 
Lung cancer causes aproximately one fifth of all cancer-related deaths in the 
world. Most lung cancer patients are diagnosed when their disease is too advanced for 
surgical intervention. A small minority of patients with lung adenocarcinoma present to 
the clinic with oncogenic driver mutations in the EGFR (epidermal growth factor 
receptor) gene, or rearrangements in the ALK (anaplastic lymphoma kinase) or ROS1 
gene.164, 229 Additional genomic aberrations include fusions in the RET 
protooncogene.230 
Over the last decade, a number of new therapies targeting signaling pathways 
that control cell growth and survival have been developed. The discovery and 
development of small molecule tyrosine kinase inhibitors (TKIs) has revolutionized 
therapy for specific molecular subsets of NSCLC patients. TKIs competitively bind in the 
ATP-binding pocket of kinases, thus interfering with tumor growth.231 Examples include 
Erlotinib, Osimertinib, Gefitinib, and Afatinib for EGFR-mutant lung cancers and more 
recently, Alectinib, Certinib, and Crizotinib for lung cancers harboring chromosomal 
rearrangements of ALK.  
Erlotinib is one of reversible EGFR-TKIs and recommended as first line treatments for 
NSCLCs harboring an activating EGFR mutation such as an exon 19 deletion or an 
L858R mutation. Afatinib belongs to a class of irreversible inhibitors of the human 
epidermal receptor family. However, EGFR T790M mutation leads to resistance to most 
EGFR TKIs such as Erlotinib or Afatinib. Osimertinib is the third-generation EGFR TKI 
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and it has shown effects against the T790M mutation. Cetuximab is a monoclonal 
antibody (mAb) against EGFR extracellular domain. Crizotinib is a non-specific small 
molecule ALK inhibitor and Ceritinib is the second-generation ALK inhibitor. 
These therapies often induce marked responses and clinical remissions. 
However, the majority of patients will develop resistance to TKIs within a few years.232, 
233
 The resistance is often mediated by a secondary mutation in the target gene or 
alternative pathways that supervene and bypass the original signaling pathway.234  
Presently, the only way to ascertain mechanism of resistance is to perform 
a re-biopsy.235, 236 Once the resistance mechanism is identified, there are newer 
therapies available to target the resistance mechanism. However, there is no 
definitive method to identify which one of the various drugs that target the 
“resistance causing mutation” might be the most effective for that individual 
patient.234 There is therefore an unmet need, not only to identify resistance early 
and without a tissue biopsy, but also for drug sensitivity assays that predict 
response ex vivo. 
CTC isolation as a non-invasive method could help to identify primary and 
secondary resistance mutations and allow for ex vivo drug testing to direct therapy 
specific to the patient. Current methods for isolation of lung CTCs mostly rely on 
biomarker dependent antibody-based capture, missing populations that may be stem-
like in nature. Therefore, our technology needs to be highly sensitive and highly specific 
in order to test isolated cells for driver mutations and resistance mutations, as well as 
culture cells for ex vivo drug testing. Therefore, we utilized the Labyrinth technology to 
identify and study the CTCs recovering from non-small cell lung cancer patients.  
 159 
We were able to detect CTCs in all analyzed NSCLC patients whose lung 
cancers exhibited specific driver mutations/rearrangements. CTCs were detected at 
numbers of ≥10 CTCs mL-1 in 100%, ≥50 in 81%, ≥100 in 57%, ≥200 in 29%, ≥400 in 
14%, and ≥600 in 5% of NSCLC patient samples. We have also found that the number 
of recovered EpCAM- CTCs (115.7 CTCs mL-1) was significantly higher than the 
EpCAM+ CTCs (39.1 CTCs mL-1) (p=0.01). As such, CTC detection based only on 
EpCAM (EpCAM+) might miss a substantial number of tumor cells.21, 154 
CTC clusters have been observed rarely in various cancers, including lung 
cancer.70, 127 We have previously demonstrated the presence of CTCs in clusters from 
patients with early-stage lung cancer.172 To investigate the ability of Labyrinth to isolate 
CTCs in cluster form, we analyzed the CTCs isolated from advanced NSCLC patients 
for the presence of clusters. In addition to the single CTCs (28.9±27 CTCs mL-1) 
recovered from these patients, we were able to isolate CTCs in clusters (125.9±138.9 
CTCs mL-1) from 95% of patients (p=0.005). Of 19 patient samples, 17 had ≥2 clusters, 
16 had ≥3 clusters, 7 had 4 clusters, 4 had 5 clusters, 1 had 6 clusters, and 2 had 7 
clusters. It has been reported that the CTC clusters have a high propensity for survival 
in circulation and development of metastases.127 We found that significantly higher 
numbers of recovered clusters were EpCAM- (p=0.009) and 36% of them displayed 
mesenchymal markers, suggestive of a preponderance of an EMT phenotype in CTC 
clusters.237, 238 
It has been shown previously that matched EGFR mutations were detected 
in CTCs in 84% of patients carrying EGFR mutations in their primary tumors.239 In 
another study, all NSCLC patients with ALK rearranged tumors had detectable 
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CTCs in their baseline blood samples.240 We utilized FISH analysis to explore 
whether the recovered CTCs from driver mutant lung adenocarcinoma patients 
with aberration in ROS1, ALK, and RET carry the genomic signature of the 
primary tumor. Our results revealed that a 5’ deletion of ROS1 in the recovered 
CTCs from a patient with a known ROS1 rearrangement in the primary tumor, an 
ALK rearrangement in the CTCs, matching the patient’s primary tumor, and a 
3’deletion of RET in recovered CTCs from a patient with a RET rearranged 
tumor. 
To be able to expand patient-derived CTCs for ex vivo drug testing, it is 
necessary to reduce the off-target cells (mostly RBCs and WBCs) after CTCs 
enrichment. We utilized many techniques for the RBCs removals including, RBC 
lysis buffer, cell strainer, and microbubbles. However, applying these techniques 
resulted in excessive loss of CTCs. Although, utilizing Ficoll-Paque showed a 
great promise on higher CTC enrichment and lower RBC numbers after 
Labyrinth, the need of a faster, reliable, and more robust system still is a 
challenge.   
Patient-derived CTCs could be a useful method for therapeutic testing, but to date it 
has been difficult to expand this population of cells. To date, only few groups have been 
able to expand CTCs in ex vivo.125, 241-244 The challenge of culturing CTCs comes from 
not only the rarity of the captured population, but also from the physical distance 
between the cells. Therefore, the environment imposes stresses that may prevent cells 
from growing and instead, induce them to undergo apoptosis. To overcome these 
challenges, a Matrigel-Collagen culture model supplemented with conditional media 
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from human pancreatic cancer associated fibroblast cells, and human platelet lysates 
were utilized for the NSCLC patient-derived CTC expansion ex vivo. 
The half maximal inhibitory concentration (IC50) analysis is the most commonly 
used technique for drug testing analysis. The IC50 numbers may be influenced by 
several conditions such as, number of cells, cell culture conditions, and the viability 
assay kits (for example the metabolism-based or DNA synthesis-based). Various 
NSCLC cell lines were used simultaneously as positive/negative controls along with the 
expanded CTCs for drug testing. The drug testing was performed on theses expanded 
CTC using various TKIs directed against the genomic drivers.  
The first patient (P 03) had a ROS1 rearranged NSCLC on Entrectinib 
therapy. Following successful expansion during visit 6, we tested this patient’s 
CTCs against Entrectinib, Lorlatinib, and TPX-0005. The IC50 data could echo 
the clinical inefficiency of Entrectinib on this patient. Her expanded CTCs were 
not sensitive to Lorlatinib either. However, TPX-0005 could direct her to a clinical 
trial. Concurrently, it was noted that the patient was noted to have CNS 
progression on scans on Entrectinib. Given the relative sensitivity to TPX-0005, 
this patient could be directed to a clinical trial using this compound.  
The second patient (P 22) had an EGFR mutant NSCLC, on Osimertinib 
therapy. Following successful expansion during visit 8, we tested this patient’s 
CTCs against various EGFR TKIs as well as TPX-0005. We found that the 
expanded CTCs were resistant to Osimertinib, but sensitive to TPX-0005 as well 
as to the combination of Osimertinib and TPX-0005. Given the relative sensitivity 
to TPX-0005, this patient could be directed to a clinical trial using this compound. 
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5 Conclusion 
Primary tumors are constituted of heterogeneous populations of cells from which 
circulating tumor cells (CTCs) are derived.245 Hence, CTCs may allow for dynamic, 
continual assessment of the tumor’s biological activity and provide a relatively facile 
means of monitoring the important yet poorly understood epithelial-to-mesenchymal 
transition (EMT) of disseminated cells. Therefore, CTCs have emerged as important 
blood-based surrogate markers of primary tumors. By detecting and analyzing primary 
tumor-derived CTCs, we would obtain useful information about disease status 
noninvasively. The field of study involving CTCs has evolved at a rapid pace that may 
eventually provide a valuable point of care assessment of cancer prognosis and 
prediction of the effectiveness of therapy.  
To develop the clinical applications of CTCs for personalized therapy in many 
types of cancers, there is a compelling need for sensitive and accurate approaches to 
distinguish CTCs from other blood cells. Microfluidic-based technologies have changed 
the existing paradigm for the recovery of CTCs from cancer patients. Two main 
approaches for the isolation of CTCs utilizing microfluidic devices are immunoaffinity 
capture and label-free size-based methods. We have developed and utilized both of 
these approaches in various cancer types including pancreatic, breast, prostate and 
lung cancer.69, 72, 103, 133, 168, 246  
Pancreatic cancer has one of the lowest survival rates among all cancers. Tumor 
invasion to other organs has often already occurred by the time of diagnosis. Hence, 
there is an urgent need for methods that enable early detection.  
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We presented an integrated technology and biology-based approach using a 
microfluidic “Carpet Chip” with different spacing between posts and arrays to study the 
biological relevance of heterogeneous CTC populations in pancreatic cancer.133 Both 
epithelial CTCs (EpCs) and EMT-like CTCs (EMTCs) are isolated simultaneously from 
whole blood of pancreatic cancer patients (n=35) by separately targeting two surface 
markers: EpCAM to capture EpCAM+ CTCs, and CD133 to capture more stem cell like 
cells, or putative EpCAM- CTCs. 133, 155 
Different spacing between posts and arrays, enabled us to increase the capture 
efficiencies (>97%) and purity (>76%), which is crucial for downstream gene analysis. 
Thirty-four patients had ≥5 EpCs mL−1 and 35 patients had ≥15 EMTCs mL−1. Overall, 
significantly higher numbers of EMTCs than EpCs are recovered, reflecting the 
aggressive nature of pancreatic cancer. Furthermore, higher numbers of EMTCs are 
observed in patients with lymph node involvement compared to patients without. Our 
results indicate that enumeration, detection, and molecular characterization of these 
CTC populations show a great promise as a diagnostic and therapeutic tool for 
detection of cancer and metastasis. 
Gene expression profiling of CTCs from 17 patients reveals that CXCR1 is 
significantly upregulated in EpCs, while known stem cell markers POU5F1 and MYC are 
upregulated in EMTCs. Our findings on gene expression profiling of CTCs from early 
stage pancreatic cancer patients may improve prediction of survival and outcomes. 
Based on our observations on EMTCs and lymph node involvement, targeting the 
genes involved in the EMT process and individualized therapy could reduce metastasis, 
thereby increasing the survival rate of pancreatic cancer patients.36   
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Among the analyzed genes, BMi1, CDH2, ERCC1, and TTF1 showed higher 
expression in early stage patients (stage IIA) compared to the rest of stages which were 
also significantly associated with prolonged OS and/or PFS. However, pancreatic 
cancer patients with higher expression of stem marker POU5F1 showed worse PFS. In 
this study, successful isolation and genomic profiling of heterogeneous CTC populations 
are demonstrated, revealing genetic signatures relevant to patient outcomes. Overall, 
isolating different CTC populations separately may help us predict the patient’s 
outcome.  
Among the existing CTC isolation technologies, high throughput, label-free, 
microfluidic devices have advantages compared with other available techniques. By 
removing the bias of using molecular markers for CTC isolation, heterogeneous CTC 
subpopulations can be recovered using label-free isolation. Each different population 
may carry distinct, important information that could predict patient outcomes. Herein, we 
utilized a high throughput, continuous, biomarker-independent, and size-based 
microfluidic separation technology, Labyrinth, to isolate CTCs from whole blood of 
pancreatic and non-small cell lung cancer patients.198   
Using Labyrinth, we were able to isolate epithelial CTCs (9.7±15.7 CTCs mL-1) 
and EMT-like CTCs (9±9.8 CTCs mL-1) from treatment naïve pancreatic cancer patients 
(n=141). This cohort was stratified based on their tumor staging: resectable, borderline 
resectable, locally advanced, and metastatic. The CTC numbers were significantly 
higher in the borderline resectable group. This cohort was further stratified by each 
patient’s treatment options, surgery, chemotherapy, and radiotherapy. For all the 
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treatment options, we observed a statistically significant decrease in CTC counts after 
treatment completion, which was associated with prolonged OS.   
Lung cancer is the leading cause of cancer-related death in the world. CTCs 
have shown tremendous promise in lung cancer for therapeutic monitoring, especially in 
predicting drug resistance. We evaluated the detection of heterogeneous CTC 
populations isolated from NSCLC patient blood samples (n=19) using the Labyrinth 
device. The Labyrinth device was optimized and tested for inertial separation of cancer 
cells using the human lung cancer cell line H1650. The recovery and purity were >82% 
and >78%, respectively, operating at a flow rate of 2.5 mL min-1.  
Heterogeneous CTC populations were detected, including CTCs (PanCK+ and 
CD45-), CTCs expressing EpCAM or Vimentin, and CTCs expressing both markers 
representing an EMT-like population of CTCs. Using Labyrinth, we were able to isolate 
CTCs from 100% of patients with an average yield of 180±168 CTCs mL-1, while the 
healty control group showed 1±1.7 total CTCs mL-1 (p=0.001). Among the captured 
CTCs, EpCAM- CTCs were significantly more common than EpCAM+ CTCs (115.7 vs. 
39.1 CTCs mL-1 respectively). Of recovered CTCs, on average, only 28.7% of CTCs 
expressed some level of EpCAM, emphasizing the need for label-free approaches for 
studying lung CTCs. In addition, an average 39.6% of CTCs expressed Vimentin. 
Among 21 analyzed patient samples, 20 samples had Vimentin+ CTCs, indicating the 
presence of Vimentin+ EMT-like cells in circulation in NSCLC. 
In addition to single CTCs, we have observed CTC clusters (≥2 CTCs) in 95% of 
NSCLC patients. Among the total number of clusters (905.2 clusters mL-1) recovered 
from all 19 patient samples, 79% of cell-clusters were negative for EpCAM expression, 
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whereas 35% of clusters expressed the EMT marker Vimentin, suggestive of an EMT 
phenotype in CTC clusters. These findings indicate the advantage of the label-free 
approach for isolating CTC subpopulations in both single and cluster forms. 
We have been able to detect tumor related-mutations in the recovered CTCs 
from patients with driver mutant lung adenocarcinoma. Recovered CTCs from patients 
with RET, ROS1, and ALK rearranged tumors showed aberrations matching with the 
primary tumor for each gene using FISH analysis. The label-free Labyrinth device 
demonstrated the advantages of marker-independent separation methods in identifying 
heterogonous CTC sub-population in lung cancer. 
The isolated CTCs were successfully expanded ex vivo from two patients and 
were screened for therapeutic efficacy. A Matrigel-Collagen (3D) model was utilized for 
ex vivo expansion and the drug testing was performed using various TKIs directed 
against known genomic drivers of lung cancer. We found that the expanded CTCs from 
a NSCLC patient with ROS1 rearrangement were resistant to Entrectinib (IC50=2357 
nM) and loralatinib (IC50=15979 nM). The second successful expanded CTCs from 
NSCLS patient with EGFR mutation were resistant to Osimertinib  (IC50=34167 nM). 
The IC50 results on the expanded CTCs were consistent with patients clinical 
outcomes. We have successfully found a new potential TKI, TPX-0005 (IC50=278 nM 
for the patient with ROS1 rearrangement, and IC50=392 nM for the patient with EGFR 
mutation) which might be effective in these patients and would direct them to a clinical 
trial using this compound.  
There is an unmet need to diagnose any kind of cancers by non-invasive 
methods as well as to develop methods to predict drug sensitivity, ex vivo. Although in 
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vivo applications of label-free technologies are still very limited, the capability of 
collecting recovered CTCs from the device using a continuous processing technique 
while in a suspension state opens the opportunities not only for CTC expansion off-chip 
but also for ex vivo drug testing to direct patient-specific therapies. The specificity of 
genomic aberration, as well as defined therapies for lung cancers, make them ideally 
suited to test our CTC platform for diagnosis, CTC expansion, and drug testing. 
However, in order to perform the drug testing for each patient samples, we still need to 
optimize the CTC expansion methods.   
Moreover, single-cell diagnostics including those based on CTCs, are predicted 
to be instrumental for the realization of personalized medicine and for the development 
of completely novel therapeutic concepts. The single cell workflow process allows rapid 
and reliable isolation, processing, and profiling of individual cells for multiple genomics 
applications.  
In order for CTCs to become a routine clinical test for personalized therapy in 
lung and other cancers that are associated with specific genomic alterations, there is a 
compelling need for sensitive, accurate, and validated approaches. There is currently no 
way to predict which of the many early phase compounds that target resistance 
mechanisms will actually lead to further response in the patient. Having the ability to 
culture CTCs ex vivo reproducibly and without loss of genetic fidelity may allow us to 
perform ex vivo drug testing as a parallel “co-clinical” trial. 
Our recent and encouraging breakthroughs in optimizing conditions for CTC 
expansion and ex vivo drug testing in NSCLC patients (n=2) needs to be validated in 
additional patients in a prospective manner. We still need to understand molecular 
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mechanisms underlying therapeutic resistance in lung cancer as observed by CTCs’ 
response to therapy. It is also beneficial to understand aberrations in intracellular RNA 
silencing pathways at a single cell level in the CTCs during the course of therapy in 
these specific driver mutant lung cancers. The expanded CTCs yet need to be validated 
via genomic characterization, as well as, test the patient derived CTCs for drug 
resistance. Furthermore, in order to validate the utility of the expanded CTCs, CTC-
derived xenograft mice (Nod/Scid) model need to be utilized, which could serve as a 
method to examine expanded CTCs in vitro properties including tumorigenicity and drug 
susceptibility (Figure  5-1).  
Due to the CTC enrichment and expansion challenges new approaches for CTC 
drug screening need to be established such as 3D single-cell analysis based on 3D 
culture platform. High throughput screening approaches for single CTCs will give further 
advance individually drug administration. However, breaking through the bottlenecks for 
single cell in 3D long-term culture still is a critical factor to overcome.  
Last but not the least, we need to validate more CTCs from a variety of patients 
by variant TKIs in a prospective manner which might give benefit to optimize the 
systemic therapy and enable early decision-making to tailor effective antitumor 
strategies. 
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Figure ‎5-1: Biomarker independent microfluidics strategy and the future direction for CTC based tumor 
models in lung cancer.
247-249
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6 Summary 
Circulating tumor cells (CTCs) are cancerous cells that shed from a primary 
tumor, intravasate into blood, travel through the blood circulation, and then extravasate 
to distant organs and form secondary tumors. Hence, CTCs are critical to understand 
the biological process of metastasis and could serve as potential blood-based surrogate 
markers to noninvasively evaluate tumor progression and response to treatment.  
Although isolation of CTCs from pancreatic adenocarcinoma (PDAC) patients is 
feasible, investigating their clinical utility has proven less successful than in other 
cancers due to limitations of epithelial cellular adhesion molecule (EpCAM)-only based 
CTC assays. We developed a "Carpet Chip” using sequential immunoaffinity-based 
microfluidics to study the biological relevance of heterogeneous CTCs. Both epithelial 
(EpCs) and epithelial-to-mesenchymal transition (EMT)-like CTCs (EMTCs) were 
detected from the blood of PDAC patients (n=35). Thirty-four patients had ≥5 EpCs 
mL−1 and 35 patients had ≥15 EMTCs mL−1. Overall, significantly higher numbers of 
EMTCs than EpCs were recovered, reflecting the aggressive nature of PDAC. 
Furthermore, higher numbers of EMTCs were observed in patients with lymph node 
involvement compared to patients without. Gene expression profiling of CTCs from 17 
patients revealed that CXCR1 is significantly upregulated in EpCs, while known stem 
cell markers POU5F1, or Oct-4 and MYC were upregulated in EMTCs. Thus, successful 
isolation and genomic profiling of heterogeneous CTC populations were demonstrated, 
revealing genetic signatures relevant to patient outcomes. Individualizing therapies 
targeting genes involved in EMT could reduce metastasis and improve patient survival.  
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In further studies on PDAC patients, the utility of CTCs as a tool was validated for 
assessing tumor response to the only three therapy options currently available: surgery, 
chemotherapy, and radiotherapy. For all treatment options, we observed a statistically 
significant decrease in CTC counts after treatment completion, which was associated 
with prolonged OS.   
Orthogonally, in an effort to develop label-free technologies for CTC isolation, a 
microfluidic Labyrinth device for high throughput, label-free, size-based isolation of 
CTCs was applied to study CTCs from metastatic non-small cell lung cancer patients 
(NSCLC). Current methods for isolation of lung CTCs mostly rely on biomarker 
dependent antibody-based capture, missing populations that may be stem-like in 
nature. Using Labyrinth operating at a flow rate of 2.5 mL/min, heterogeneous CTC 
populations were isolated from NSCLC patients (n=21). Detected populations included 
CTCs (PanCK+ and CD45-), CTCs expressing EpCAM or Vimentin, and CTCs 
expressing both markers representing an EMT-like population of CTCs. We were able 
to isolate CTCs from 100% of patients with an average yield of 180±168 CTCs mL-1. 
Among captured CTCs, EpCAM- CTCs were significantly more common than EpCAM+ 
CTCs (115.7 vs. 39.1 CTCs mL-1 respectively). Cell clusters of 2 or more CTCs were 
also observed in 95% of patients; 79% of these clusters were negative for EpCAM 
expression, whereas 35% expressed Vimentin, suggestive of an EMT phenotype. 
Recovered CTCs from patients with RET, ROS1 and ALK rearrangements in tumors 
showed aberrations matching the primary tumor for each gene using FISH analysis. We 
successfully expanded CTCs in vitro and the cultured cells carried matched mutations. 
The Labyrinth device demonstrated the advantages of marker-independent separation 
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methods for isolation of heterogonous CTC sub-populations in lung cancer for CTC 
expansion, allowing drug testing for therapies targeting specific driver mutations. 
The capability of collecting recovered CTCs from the device using a continuous 
processing technique opens up opportunities for not only CTC expansion off-chip, but 
also ex-vivo drug testing to direct patient-specific therapies.  
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7 ZUSAMMENFASSUNG 
Zirkulierende Tumorzellen (CTCs) sind Krebszellen, die aus einem Primärtumor 
ausgeschieden werden, sich in Blut intravasieren, durch den Blutkreislauf wandern und 
dann in entfernte Organe extravasieren und sekundäre Tumore bilden. Daher sind 
CTCs für das Verständnis des biologischen Prozesses der Metastasierung von 
entscheidender Bedeutung und könnten als mögliche Ersatzmarker auf Blutbasis 
dienen, um die Tumorprogression und das Ansprechen auf die Behandlung nicht-
invasiv zu bewerten. Obwohl die Isolierung von CTCs aus Patienten mit 
Pankreasadenokarzinom (PDAC) durchführbar ist, hat sich die Untersuchung ihres 
klinischen Nutzens aufgrund von Einschränkungen der nur auf EpCAM-basierenden 
CTC-Tests auf Epithelzellen (EpCAM) basierenden Tests als weniger erfolgreich 
erwiesen. 
Wir entwickelten einen "Carpet-Chip" mit sequenziellen Mikrofluidik auf 
Immunoaffinitätsbasis, um die biologische Relevanz heterogener CTCs zu untersuchen. 
Sowohl epitheliale (EpCs) als auch epithelial-mesenchymale Übergangs (EMT) -
ähnliche CTCs (EMTCs) wurden aus dem Blut von PDAC Patienten (n = 35) detektiert. 
Vierunddreißig Patienten hatten ≥5 EpCs mL-1 und 35 Patienten hatten ≥15 EMTCs 
mL-1. Insgesamt wurden deutlich mehr EMTCs als EpCs gewonnen, was die 
Aggressivität von PDAC widerspiegelt. Darüber hinaus wurden bei Patienten mit 
Lymphknotenbefall im Vergleich zu Patienten ohne EMTC eine höhere Anzahl von 
EMTCs beobachtet. Genexpressionsprofile von CTCs von 17 Patienten zeigten, dass 
CXCR1 in EpCs signifikant hochreguliert ist, während bekannte Stammzellmarker 
POU5F1 oder Oct-4 und MYC in EMTCs hochreguliert wurden. So wurde die 
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erfolgreiche Isolierung und das genomische Profiling heterogener CTC-Populationen 
demonstriert, was genetische Signaturen aufzeigt, die für die Patientenergebnisse 
relevant sind. Durch die Individualisierung von Therapien, die auf Gene abzielen, die an 
der EMT beteiligt sind, könnte die Metastasierung verringert und das Überleben der 
Patienten verbessert werden. 
In weiteren Studien an PDAC-Patienten wurde der Nutzen von CTCs als 
Instrument für die Bewertung der Tumorreaktion auf die drei derzeit verfügbaren 
Therapiemöglichkeiten validiert: Operation, Chemotherapie und Strahlentherapie. Bei 
allen Behandlungsoptionen beobachteten wir eine statistisch signifikante Abnahme der 
CTC-Werte nach Abschluss der Behandlung, die mit einem verlängerten OS verbunden 
war.  
In dem Bestreben, kennzeichnungsfreie Technologien für die CTC-Isolierung zu 
entwickeln, wurde orthogonal ein mikrofluidisches Labyrinth-Gerät für die 
markierungsfreie, größenbasierte Isolierung von CTCs mit hohem Durchsatz 
angewendet, um CTCs von Patienten mit metastasiertem nicht kleinzelligem 
Lungenkrebs (NSCLC) zu untersuchen . Derzeitige Methoden zur Isolierung von 
Lungen-CTCs basieren meistens auf Biomarker-abhängiger Erfassung von Antikörpern, 
wobei Populationen fehlen, die möglicherweise stammähnlich sind. Unter Verwendung 
von Labyrinthbetrieb, das mit einer Flussrate von 2,5 ml / min betrieben wurde, wurden 
heterogene CTC-Populationen aus NSCLC-Patienten (n = 21) isoliert. Zu den 
entdeckten Populationen gehörten CTCs (PanCK + und CD45-), CTCs, die EpCAM 
oder Vimentin exprimieren, und CTCs, die beide Marker exprimieren, die eine EMT-
ähnliche Population von CTCs darstellen. Wir konnten CTCs von 100% der Patienten 
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mit einer durchschnittlichen Ausbeute von 180 ± 168 CTCsmL-1 isolieren. Unter den 
erfassten CTCs waren EpCAM-CTCs signifikant häufiger als EpCAM + CTCs (115,7 vs. 
39,1 CTCsmL-1). Bei 95% der Patienten wurden auch Zellcluster von 2 oder mehr 
CTCs beobachtet. 79% dieser Cluster waren für die EpCAM-Expression negativ, 
während 35% Vimentin exprimierten, was auf einen EMT-Phänotyp hindeutet. 
Wiederhergestellte CTCs von Patienten mit RET-, ROS1- und ALK-Umlagerungen in 
Tumoren zeigten unter Verwendung der FISH-Analyse für jedes Gen Abbildungsfehler, 
die mit dem Primärtumor übereinstimmen. 
Wir konnten CTCs in vitro erfolgreich ausbauen und die kultivierten Zellen 
übereinstimmende Mutationen tragen. Die Labyrinth-Vorrichtung demonstrierte die 
Vorteile von markerunabhängigen Trennungsverfahren für heterogonale CTC-
Subpopulationen in einer CGD für die CTC-Dilatation, wodurch Medikamententests für 
Therapien durchgeführt werden können, die auf spezifische Treibermutationen abzielen. 
Die Möglichkeit, gewonnene CTCs mithilfe einer kontinuierlichen Verarbeitungstechnik 
vom Gerät zu sammeln, eröffnet nicht nur Möglichkeiten für die CTC-Erweiterung 
außerhalb des Chips, sondern auch Ex-vivo-Drogentests, um patientenspezifische 
Therapien zu steuern. 
 
  
 176 
8 References  
1. Alunni-Fabbroni, M, Sandri, MT: Circulating tumour cells in clinical practice: Methods of detection and 
possible characterization. Methods, 50: 289-297, 2010. 
2. Tjensvoll, K, Nordgard, O, Smaaland, R: Circulating tumor cells in pancreatic cancer patients: Methods 
of detection and clinical implications. International Journal of Cancer, 134: 1-8, 2014. 
3. Torphy, RJ, Tignanelli, CJ, Moffitt, RA, Soper, SA, Yeh, JJ: Circulating tumor cells as a biomarker of 
response to treatment in patient derived xenograft mouse models of pancreatic 
adenocarcinoma. Journal of the American College of Surgeons, 217: S30-S30, 2013. 
4. Nagrath, S, Sequist, LV, Maheswaran, S, Bell, DW, Irimia, D, Ulkus, L, Smith, MR, Kwak, EL, Digumarthy, 
S, Muzikansky, A, Ryan, P, Balis, UJ, Tompkins, RG, Haber, DA, Toner, M: Isolation of rare 
circulating tumour cells in cancer patients by microchip technology. Nature, 450: 1235-U1210, 
2007. 
5. Bednarz-Knoll, N, Alix-Panabieres, C, Pantel, K: Plasticity of disseminating cancer cells in patients with 
epithelial malignancies. Cancer and Metastasis Reviews, 31: 673-687, 2012. 
6. Kurihara, T, Itoi, T, Sofuni, A, Itokawa, F, Tsuchiya, T, Tsuji, S, Ishii, K, Ikeuchi, N, Tsuchida, A, Kasuya, K, 
Kawai, T, Sakai, Y, Moriyasu, F: Detection of circulating tumor cells in patients with pancreatic 
cancer: a preliminary result. Journal of Hepato-Biliary-Pancreatic Surgery, 15: 189-195, 2008. 
7. Kanwar, N, Done, S: Circulating Tumour Cells: Implications and Methods of Detection. 2011. 
8. Stott, SL, Hsu, CH, Tsukrov, DI, Yu, M, Miyamoto, DT, Waltman, BA, Rothenberg, SM, Shah, AM, Smas, 
ME, Korir, GK, Floyd, FP, Gilman, AJ, Lord, JB, Winokur, D, Springer, S, Irimia, D, Nagrath, S, 
Sequist, LV, Lee, RJ, Isselbacher, KJ, Maheswaran, S, Haber, DA, Toner, M: Isolation of circulating 
tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National 
Academy of Sciences of the United States of America, 107: 18392-18397, 2010. 
9. Zhang, Z, Nagrath, S: Microfluidics and cancer: are we there yet? Biomedical microdevices, 15: 595-
609, 29 January 2013. 
10. Khoja, L, Backen, A, Sloane, R, Menasce, L, Ryder, D, Krebs, M, Board, R, Clack, G, Hughes, A, 
Blackhall, F, Valle, JW, Dive, C: A pilot study to explore circulating tumour cells in pancreatic 
cancer as a novel biomarker. British journal of cancer, 106: 508-516, 2012. 
11. Yu, M, Ting, DT, Stott, SL, Wittner, BS, Ozsolak, F, Paul, S, Ciciliano, JC, Smas, ME, Winokur, D, 
Gilman, AJ, Ulman, MJ, Xega, K, Contino, G, Alagesan, B, Brannigan, BW, Milos, PM, Ryan, DP, 
Sequist, LV, Bardeesy, N, Ramaswamy, S, Toner, M, Maheswaran, S, Haber, DA: RNA sequencing 
of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature, 487: 510-
U130, 2012. 
12. Armstrong, AJ, Marengo, MS, Oltean, S, Kemeny, G, Bitting, RL, Turnbull, JD, Herold, CI, Marcom, PK, 
George, DJ, Garcia-Blanco, MA: Circulating Tumor Cells from Patients with Advanced Prostate 
and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer 
Research, 9: 997-1007, 2011. 
13. Stott, SL, Lee, RJ, Nagrath, S, Yu, M, Miyamoto, DT, Ulkus, L, Inserra, EJ, Ulman, M, Springer, S, 
Nakamura, Z, Moore, AL, Tsukrov, DI, Kempner, ME, Dahl, DM, Wu, CL, Iafrate, AJ, Smith, MR, 
Tompkins, RG, Sequist, LV, Toner, M, Haber, DA, Maheswaran, S: Isolation and Characterization 
of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer. Science 
Translational Medicine, 2, 2010. 
14. Cen, P, Ni, X, Yang, J, Graham, DY, Li, M: Circulating tumor cells in the diagnosis and management of 
pancreatic cancer. Biochimica et biophysica acta, 1826: 350-356, 2012. 
15. de Albuquerque, A, Kubisch, I, Breier, G, Stamminger, G, Fersis, N, Eichler, A, Kaul, S, Stolzel, U: 
Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility 
study. Oncology, 82: 3-10, 2012. 
 177 
16. Ren, CL, Han, CX, Zhang, JQ, He, P, Wang, DX, Wang, BH, Zhao, P, Zhao, XH: Detection of apoptotic 
circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. 
Cancer Biology & Therapy, 12: 700-706, 2011. 
17. Han, L, Chen, W, Zhao, Q: Prognostic value of circulating tumor cells in patients with pancreatic 
cancer: a meta-analysis. Tumour Biol, 2013. 
18. Crowley, E, Di Nicolantonio, F, Loupakis, F, Bardelli, A: Liquid biopsy: monitoring cancer-genetics in 
the blood. Nature Reviews Clinical Oncology, 10: 472-484, 2013. 
19. M. Liberko, K. Kolostova, V. Bobek: Essentials of circulating tumor cells for clinical research and 
practice. Critical reviews in oncology/hematology, vol. 88, Nov. 2013. 
20. Chen, CL, Mahalingam, D, Osmulski, P, Jadhav, RR, Wang, CM, Leach, RJ, Chang, TC, Weitman, SD, 
Kumar, AP, Sun, LZ, Gaczynska, ME, Thompson, IM, Huang, THM: Single-cell analysis of 
circulating tumor cells identifies cumulative expression patterns of EMT-related genes in 
metastatic prostate cancer. Prostate, 73: 813-826, 2013. 
21. Pantel, K, Alix-Panabieres, C: Circulating tumour cells in cancer patients: challenges and perspectives. 
Trends in Molecular Medicine, 16: 398-406, 2010. 
22. Ashworth, TR: A case of cancer in which cells similar to those in the tumours were seen in the blood 
after death. The Medical Journal of Australia, 14: 146–147, 1869. 
23. Paget, S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev, 
8: 98-101, 1989. 
24. Yu, M, Bardia, A, Wittner, B, Stott, SL, Smas, ME, Ting, DT, Isakoff, SJ, Ciciliano, JC, Wells, MN, Shah, 
AM, Concannon, KF, Donaldson, MC, Sequist, LV, Brachtel, E, Sgroi, D, Baselga, J, Ramaswamy, S, 
Toner, M, Haber, DA, Maheswaran, S: Circulating Breast Tumor Cells Exhibit Dynamic Changes in 
Epithelial and Mesenchymal Composition. Science, 339: 580-584, 2013. 
25. Zhang, ZY, Ge, HY: Micrometastasis in gastric cancer. Cancer Lett, 336: 34-45, 2013. 
26. E., K: Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor 
Budding the Missing Link? Frontiers in oncology, 2013 Sep 17. 
27. Satelli, A, Li, SL: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular 
and Molecular Life Sciences, 68: 3033-3046, 2011. 
28. Sarrio, D, Rodriguez-Pinilla, SM, Hardisson, D, Cano, A, Moreno-Bueno, G, Palacios, J: Epithelial-
mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research, 
68: 989-997, 2008. 
29. Lee, JM, Dedhar, S, Kalluri, R, Thompson, EW: The epithelial-mesenchymal transition: new insights in 
signaling, development, and disease. J Cell Biol, 172: 973-981, 2006. 
30. Kallergi, G, Papadaki, MA, Politaki, E, Mavroudis, D, Georgoulias, V, Agelaki, S: Epithelial to 
mesenchymal transition markers expressed in circulating tumour cells of early and metastatic 
breast cancer patients. Breast Cancer Research, 13, 2011. 
31. Mendez, MG, Kojima, SI, Goldman, RD: Vimentin induces changes in cell shape, motility, and 
adhesion during the epithelial to mesenchymal transition. Faseb Journal, 24: 1838-1851, 2010. 
32. Ivaska, J: Vimentin: Central hub in EMT induction? Small GTPases, 2: 51-53, 2011. 
33. Kokkinos, MI, Wafai, R, Wong, MK, Newgreen, DF, Thompson, EW, Waltham, M: Vimentin and 
epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo. 
Cells Tissues Organs, 185: 191-203, 2007. 
34. Kalluri, R, Weinberg, RA: The basics of epithelial-mesenchymal transition. J Clin Invest, 119: 1420-
1428, 2009. 
35. Kalluri, R: EMT: When epithelial cells decide to become mesenchymal-like cells. 2015. 
36. Beuran, M, Negoi, I, Paun, S, Ion, AD, Bleotu, C, Negoi, RI, Hostiuc, S: The epithelial to mesenchymal 
transition in pancreatic cancer: A systematic review. Pancreatology, 2015. 
 178 
37. Lee, CJ, Dosch, J, Simeone, DM: Pancreatic cancer stem cells. Journal of Clinical Oncology, 26: 2806-
2812, 2008. 
38. Ischenko, I, Seeliger, H, Kleespies, A, Angele, MK, Eichhorn, ME, Jauch, KW, Bruns, CJ: Pancreatic 
cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks 
Archives of Surgery, 395: 1-10, 2010. 
39. Nel, I, Jehn, U, Gauler, T, Hoffmann, A-C: Individual profiling of circulating tumor cell composition in 
patients with non-small cell lung cancer receiving platinum based treatment. Translational Lung 
Cancer Research, 3: 100-106, 2014. 
40. Xu, L: Cancer stem cell in the progression and therapy of pancreatic cancer. Frontiers in Bioscience-
Landmark, 18: 795-802, 2013. 
41. Low, WS, Kadri, NA, Abas, WA: Computational fluid dynamics modelling of microfluidic channel for 
dielectrophoretic BioMEMS application. ScientificWorldJournal, 2014: 961301, 2014. 
42. Polla, DL: BioMEMS Applications in Medicine. 2001. 
43. Saliterman, SS: Fundamentals of BioMEMS and Medical Microdecices. 2006. 
44. Daneshvar, ED: Conjugated Polymer Actuators for Articulating Neural Probes and Electrode 
Interfaces. 2014. 
45. Borenstein, JT: BioMEMS Technologies for Regenerative Medicine. Materials Research Society, 1139, 
2009. 
46. B. Lin: Microfluidics, Technologies and Application. Springer, New York, NY, USA,, 2011. 
47. Qin, G, Liu, Y, Liu, H, Ding, Y, Qi, X, Du, R: Fabrication of bio-microelectrodes for deep-brain 
stimulation using microfabrication and electroplating process. Microsystem Technologies, 15: 
933-939, 2009. 
48. Guber, AE, Herrmann, D, Mühlberger, H, Hoffmann, W, Gerlach, A, Gottschlich, N: Lab-on-a-Chip-
Systeme für die Online-Analytik. Chemie Ingenieur Technik, 76: 1332-1332, 2004. 
49. Saem, S, Zhu, Y, Luu, H, Moran-Mirabal, J: Bench-Top Fabrication of an All-PDMS Microfluidic 
Electrochemical Cell Sensor Integrating Micro/Nanostructured Electrodes. Sensors (Basel, 
Switzerland), 17: 732, 2017. 
50. Yung-Chieh Tan, aJSF, a Alan I. Lee,a Vittorio Cristiniab and Abraham Phillip, Lee: Design of 
microfluidic channel geometries for the control of droplet volume, chemical concentration, and 
sorting. 2004. 
51. Samuel K. Sia, GMW: Microfluidic devices fabricated in poly(dimethylsiloxane) for biological studies. 
Electrophoresis, 24, 3563–3576, 2003. 
52. Liberko, M, Kolostova, K, Bobek, V: Essentials of circulating tumor cells for clinical research and 
practice. Crit Rev Oncol Hemat, 88: 338-356, 2013. 
53. Gorges, TM, Pantel, K: Circulating tumor cells as therapy-related biomarkers in cancer patients. 
Cancer immunology, immunotherapy : CII, 62: 931-939, 2013. 
54. Fiegl, M, Kircher, B, Zojer, N: Correspondence re: T. Fehm et al., cytogenetic evidence that circulating 
epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res., 8: 2073-2084, 2002. 
Clinical Cancer Research, 9: 1224-1225, 2003. 
55. Moreno, JG, O'Hara, SM, Gross, S, Doyle, G, Fritsche, H, Gomella, LG, Terstappen, LW: Changes in 
circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease 
status. Urology, 58: 386-392, 2001. 
56. Moreno, JG, Miller, MC, Gross, S, Allard, WJ, Gomella, LG, Terstappen, LW: Circulating tumor cells 
predict survival in patients with metastatic prostate cancer. Urology, 65: 713-718, 2005. 
57. Fizazi, K, Morat, L, Chauveinc, L, Prapotnich, D, De Crevoisier, R, Escudier, B, Cathelineau, X, Rozet, F, 
Vallancien, G, Sabatier, L, Soria, JC: High detection rate of circulating tumor cells in blood of 
patients with prostate cancer using telomerase activity. Annals of Oncology, 18: 518-521, 2007. 
 179 
58. Danila, DC, Heller, G, Gignac, GA, Gonzalez-Espinoza, R, Anand, A, Tanaka, E, Lilja, H, Schwartz, L, 
Larson, S, Fleisher, M, Scher, HI: Circulating tumor cell number and prognosis in progressive 
castration-resistant prostate cancer. Clinical Cancer Research, 13: 7053-7058, 2007. 
59. Wang, ZP, Eisenberger, MA, Carducci, MA, Partin, AW, Scher, HI, Ts'o, POP: Identification and 
characterization of circulating prostate carcinoma cells. Cancer, 88: 2787-2795, 2000. 
60. Talasaz, AH, Powell, AA, Huber, DE, Berbee, JG, Roh, KH, Yu, W, Xiao, WZ, Davis, MM, Pease, RF, 
Mindrinos, MN, Jeffrey, SS, Davis, RW: Isolating highly enriched populations of circulating 
epithelial cells and other rare cells from blood using a magnetic sweeper device. Proceedings of 
the National Academy of Sciences of the United States of America, 106: 3970-3975, 2009. 
61. Ferreira, MM, Ramani, VC, Jeffrey, SS: Circulating tumor cell technologies. Molecular Oncology, 10: 
374-394, 2016. 
62. Pantel, K, Alix-Panabieres, C: Functional Studies on Viable Circulating Tumor Cells. Clin Chem, 62: 
328-334, 2016. 
63. Allard, WJ, Matera, J, Miller, MC, Repollet, M, Connelly, MC, Rao, C, Tibbe, AGJ, Uhr, JW, Terstappen, 
LWMM: Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy 
Subjects or Patients With Nonmalignant Diseases. Clinical Cancer Research, 10: 6897-6904, 
2004. 
64. Miltenyi, S, Muller, W, Weichel, W, Radbruch, A: High gradient magnetic cell separation with MACS. 
Cytometry, 11: 231-238, 1990. 
65. Peters, CE, Woodside, SM, Eaves, AC: Isolation of subsets of immune cells. Methods Mol Biol, 302: 
95-116, 2005. 
66. Neurauter, AA, Bonyhadi, M, Lien, E, Nokleby, L, Ruud, E, Camacho, S, Aarvak, T: Cell isolation and 
expansion using Dynabeads((R)). Cell Separation: Fundamentals, Analytical and Preparative 
Methods, 106: 41-73, 2007. 
67. Gleghorn, JP, Pratt, ED, Denning, D, Liu, H, Bander, NH, Tagawa, ST, Nanus, DM, Giannakakou, PA, 
Kirby, BJ: Capture of circulating tumor cells from whole blood of prostate cancer patients using 
geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab 
on a Chip, 10: 27-29, 2010. 
68. Mikolajczyk, SD, Millar, LS, Tsinberg, P, Coutts, SM, Zomorrodi, M, Pham, T, Bischoff, FZ, Pircher, TJ: 
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral 
Blood. J Oncol, 2011: 252361, 2011. 
69. Murlidhar, V, Zeinali, M, Grabauskiene, S, Ghannad-Rezaie, M, Wicha, MS, Simeone, DM, Ramnath, 
N, Reddy, RM, Nagrath, S: A Radial Flow Microfluidic Device for Ultra-High-Throughput Affinity-
Based Isolation of Circulating Tumor Cells. Small, 10: 4895-4904, 2014. 
70. Stott, SL, Hsu, C-H, Tsukrov, DI, Yu, M, Miyamoto, DT, Waltman, BA, Rothenberg, SM, Shah, AM, 
Smas, ME, Korir, GK, Floyd, FP, Gilman, AJ, Lord, JB, Winokur, D, Springer, S, Irimia, D, Nagrath, S, 
Sequist, LV, Lee, RJ, Isselbacher, KJ, Maheswaran, S, Haber, DA, Toner, M: Isolation of circulating 
tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National 
Academy of Sciences of the United States of America, 107: 18392-18397, 2010. 
71. Sheng, WA, Ogunwobi, OO, Chen, T, Zhang, JL, George, TJ, Liu, C, Fan, ZH: Capture, release and 
culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. 
Lab on a Chip, 14: 89-98, 2014. 
72. Yoon, HJ, Kim, TH, Zhang, Z, Azizi, E, Pham, TM, Paoletti, C, Lin, J, Ramnath, N, Wicha, MS, Hayes, DF, 
Simeone, DM, Nagrath, S: Sensitive capture of circulating tumour cells by functionalized 
graphene oxide nanosheets. Nat Nanotechnol, 8: 735-741, 2013. 
73. Kamande, JW, Hupert, ML, Witek, MA, Wang, H, Torphy, RJ, Dharmasiri, U, Njoroge, SK, Jackson, JM, 
Aufforth, RD, Snavely, A, Yeh, JJ, Soper, SA: Modular microsystem for the isolation, enumeration, 
 180 
and phenotyping of circulating tumor cells in patients with pancreatic cancer. Analytical 
chemistry, 85: 9092-9100, 2013. 
74. Saliba, AE, Saias, L, Psychari, E, Minc, N, Simon, D, Bidard, FC, Mathiot, C, Pierga, JY, Fraisier, V, 
Salamero, J, Saada, V, Farace, F, Vielh, P, Malaquin, L, Viovy, JL: Microfluidic sorting and 
multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci U S A, 
107: 14524-14529, 2010. 
75. Earhart, CM, Hughes, CE, Gaster, RS, Ooi, CC, Wilson, RJ, Zhou, LY, Humke, EW, Xu, L, Wong, DJ, 
Willingham, SB, Schwartz, EJ, Weissman, IL, Jeffrey, SS, Neal, JW, Rohatgi, R, Wakelee, HA, 
Wang, SX: Isolation and mutational analysis of circulating tumor cells from lung cancer patients 
with magnetic sifters and biochips. Lab Chip, 14: 78-88, 2014. 
76. Winer-Jones, JP, Vahidi, B, Arquilevich, N, Fang, C, Ferguson, S, Harkins, D, Hill, C, Klem, E, Pagano, 
PC, Peasley, C, Romero, J, Shartle, R, Vasko, RC, Strauss, WM, Dempsey, PW: Circulating tumor 
cells: clinically relevant molecular access based on a novel CTC flow cell. PLoS One, 9: e86717, 
2014. 
77. Harb, W, Fan, A, Tran, T, Danila, DC, Keys, D, Schwartz, M, Ionescu-Zanetti, C: Mutational Analysis of 
Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. 
Translational oncology, 6: 528-538, 2013. 
78. Ozkumur, E, Shah, AM, Ciciliano, JC, Emmink, BL, Miyamoto, DT, Brachtel, E, Yu, M, Chen, PI, 
Morgan, B, Trautwein, J, Kimura, A, Sengupta, S, Stott, SL, Karabacak, NM, Barber, TA, Walsh, JR, 
Smith, K, Spuhler, PS, Sullivan, JP, Lee, RJ, Ting, DT, Luo, X, Shaw, AT, Bardia, A, Sequist, LV, 
Louis, DN, Maheswaran, S, Kapur, R, Haber, DA, Toner, M: Inertial Focusing for Tumor Antigen-
Dependent and -Independent Sorting of Rare Circulating Tumor Cells. Science Translational 
Medicine, 5, 2013. 
79. Saucedo-Zeni, N, Mewes, S, Niestroj, R, Gasiorowski, L, Murawa, D, Nowaczyk, P, Tomasi, T, Weber, 
E, Dworacki, G, Morgenthaler, NG, Jansen, H, Propping, C, Sterzynska, K, Dyszkiewicz, W, Zabel, 
M, Kiechle, M, Reuning, U, Schmitt, M, Lucke, K: A novel method for the in vivo isolation of 
circulating tumor cells from peripheral blood of cancer patients using a functionalized and 
structured medical wire. Int J Oncol, 41: 1241-1250, 2012. 
80. Liu, Z, Fusi, A, Klopocki, E, Schmittel, A, Tinhofer, I, Nonnenmacher, A, Keilholz, U: Negative 
enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor 
cells from peripheral blood of cancer patients. Journal of translational medicine, 9: 70, 2011. 
81. Lara, O, Tong, X, Zborowski, M, Chalmers, JJ: Enrichment of rare cancer cells through depletion of 
normal cells using density and flow-through, immunomagnetic cell separation. Experimental 
hematology, 32: 891-904, 2004. 
82. Lara, O, Tong, X, Zborowski, M, Farag, SS, Chalmers, JJ: Comparison of two immunomagnetic 
separation technologies to deplete T cells from human blood samples. Biotechnology and 
bioengineering, 94: 66-80, 2006. 
83. Chen, CL, Chen, KC, Pan, YC, Lee, TP, Hsiung, LC, Lin, CM, Chen, CY, Lin, CH, Chiang, BL, Wo, AM: 
Separation and detection of rare cells in a microfluidic disk via negative selection. Lab Chip, 11: 
474-483, 2011. 
84. Harouaka, RA, Nisic, M, Zheng, SY: Circulating tumor cell enrichment based on physical properties. 
Journal of laboratory automation, 18: 455-468, 2013. 
85. Sollier, E, Go, DE, Che, J, Gossett, DR, O'Byrne, S, Weaver, WM, Kummer, N, Rettig, M, Goldman, J, 
Nickols, N, McCloskey, S, Kulkarni, RP, Di Carlo, D: Size-selective collection of circulating tumor 
cells using Vortex technology. Lab Chip, 14: 63-77, 2014. 
86. Seal, SH: Silicone flotation: a simple quantitative method for the isolation of free-floating cancer cells 
from the blood. Cancer, 12: 590-595, 1959. 
 181 
87. Rosenberg, R, Gertler, R, Friederichs, J, Fuehrer, K, Dahm, M, Phelps, R, Thorban, S, Nekarda, H, 
Siewert, JR: Comparison of two density gradient centrifugation systems for the enrichment of 
disseminated tumor cells in blood. Cytometry, 49: 150-158, 2002. 
88. Muller, V, Stahmann, N, Riethdorf, S, Rau, T, Zabel, T, Goetz, A, Janicke, F, Pantel, K: Circulating 
tumor cells in breast cancer: Correlation to bone marrow micrometastases, heterogeneous 
response to systemic therapy and low proliferative activity. Clinical Cancer Research, 11: 3678-
3685, 2005. 
89. He, W, Kularatne, SA, Kalli, KR, Prendergast, FG, Amato, RJ, Klee, GG, Hartmann, LC, Low, PS: 
Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer 
patients using tumor-specific fluorescent ligands. Int J Cancer, 123: 1968-1973, 2008. 
90. Campton, DE, Ramirez, AB, Nordberg, JJ, Drovetto, N, Clein, AC, Varshavskaya, P, Friemel, BH, 
Quarre, S, Breman, A, Dorschner, M, Blau, S, Blau, CA, Sabath, DE, Stilwell, JL, Kaldjian, EP: High-
recovery visual identification and single-cell retrieval of circulating tumor cells for genomic 
analysis using a dual-technology platform integrated with automated immunofluorescence 
staining. BMC Cancer, 15: 360, 2015. 
91. Gertler, R, Rosenberg, R, Fuehrer, K, Dahm, M, Nekarda, H, Siewert, JR: Detection of circulating 
tumor cells in blood using an optimized density gradient centrifugation. Molecular Staging of 
Cancer, 162: 149-155, 2003. 
92. Naume, B, Borgen, E, Tossvik, S, Pavlak, N, Oates, D, Nesland, JM: Detection of isolated tumor cells in 
peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy, 6: 244-252, 
2004. 
93. Hayes, GM, Busch, R, Voogt, J, Siah, IM, Gee, TA, Hellerstein, MK, Chiorazzi, N, Rai, KR, Murphy, EJ: 
Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis 
of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. 
Leuk Res, 34: 809-815, 2010. 
94. Vona, G, Sabile, A, Louha, M, Sitruk, V, Romana, S, Schutze, K, Capron, F, Franco, D, Pazzagli, M, 
Vekemans, M, Lacour, B, Brechot, C, Paterlini-Brechot, P: Isolation by size of epithelial tumor 
cells - A new method for the immunomorphological and molecular characterization of 
circulating tumor cells. American Journal of Pathology, 156: 57-63, 2000. 
95. Desitter, I, Guerrouahen, BS, Benali-Furet, N, Wechsler, J, Janne, PA, Kuang, Y, Yanagita, M, Wang, L, 
Berkowitz, JA, Distel, RJ, Cayre, YE: A new device for rapid isolation by size and characterization 
of rare circulating tumor cells. Anticancer research, 31: 427-441, 2011. 
96. Adams, AA, Okagbare, PI, Feng, J, Hupert, ML, Patterson, D, Gottert, J, McCarley, RL, Nikitopoulos, D, 
Murphy, MC, Soper, SA: Highly efficient circulating tumor cell isolation from whole blood and 
label-free enumeration using polymer-based microfluidics with an integrated conductivity 
sensor. Journal of the American Chemical Society, 130: 8633-8641, 2008. 
97. Harouaka, RA, Zhou, MD, Yeh, YT, Khan, WJ, Das, A, Liu, X, Christ, CC, Dicker, DT, Baney, TS, Kaifi, JT, 
Belani, CP, Truica, CI, El-Deiry, WS, Allerton, JP, Zheng, SY: Flexible micro spring array device for 
high-throughput enrichment of viable circulating tumor cells. Clin Chem, 60: 323-333, 2014. 
98. Zhou, MD, Hao, S, Williams, AJ, Harouaka, RA, Schrand, B, Rawal, S, Ao, Z, Brenneman, R, Gilboa, E, 
Lu, B, Wang, S, Zhu, J, Datar, R, Cote, R, Tai, YC, Zheng, SY: Separable bilayer microfiltration 
device for viable label-free enrichment of circulating tumour cells. Sci Rep, 4: 7392, 2014. 
99. Qin, X, Park, S, Duffy, SP, Matthews, K, Ang, RR, Todenhofer, T, Abdi, H, Azad, A, Bazov, J, Chi, KN, 
Black, PC, Ma, H: Size and deformability based separation of circulating tumor cells from 
castrate resistant prostate cancer patients using resettable cell traps. Lab Chip, 15: 2278-2286, 
2015. 
100. Sarioglu, AF, Aceto, N, Kojic, N, Donaldson, MC, Zeinali, M, Hamza, B, Engstrom, A, Zhu, H, 
Sundaresan, TK, Miyamoto, DT, Luo, X, Bardia, A, Wittner, BS, Ramaswamy, S, Shioda, T, Ting, 
 182 
DT, Stott, SL, Kapur, R, Maheswaran, S, Haber, DA, Toner, M: A microfluidic device for label-free, 
physical capture of circulating tumor cell clusters. Nature methods, 12: 685-691, 2015. 
101. Kuo, JS, Zhao, Y, Schiro, PG, Ng, L, Lim, DS, Shelby, JP, Chiu, DT: Deformability considerations in 
filtration of biological cells. Lab Chip, 10: 837-842, 2010. 
102. Vasudha, M, Lianette, RB, Sunitha, N: Affinity Versus Label‐Free Isolation of Circulating Tumor Cells: 
Who Wins? Small, 12: 4450-4463, 2016. 
103. Lin, E, Rivera-Báez, L, Fouladdel, S, Yoon, HJ, Guthrie, S, Wieger, J, Deol, Y, Keller, E, Sahai, V, 
Simeone, DM, Burness, ML, Azizi, E, Wicha, MS, Nagrath, S: High-Throughput Microfluidic 
Labyrinth for the Label-free Isolation of Circulating Tumor Cells. Cell Systems, 5: 295-304.e294. 
104. Warkiani, ME, Guan, G, Luan, KB, Lee, WC, Bhagat, AA, Chaudhuri, PK, Tan, DS, Lim, WT, Lee, SC, 
Chen, PC, Lim, CT, Han, J: Slanted spiral microfluidics for the ultra-fast, label-free isolation of 
circulating tumor cells. Lab Chip, 14: 128-137, 2014. 
105. Becker, FF, Wang, XB, Huang, Y, Pethig, R, Vykoukal, J, Gascoyne, PR: Separation of human breast 
cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A, 92: 860-864, 
1995. 
106. Stoy, RD, Foster, KR, Schwan, HP: Dielectric properties of mammalian tissues from 0.1 to 100 MHz: 
a summary of recent data. Physics in medicine and biology, 27: 501-513, 1982. 
107. Gupta, V, Jafferji, I, Garza, M, Melnikova, VO, Hasegawa, DK, Pethig, R, Davis, DW: ApoStream(), a 
new dielectrophoretic device for antibody independent isolation and recovery of viable cancer 
cells from blood. Biomicrofluidics, 6: 24133, 2012. 
108. Polzer, B, Medoro, G, Pasch, S, Fontana, F, Zorzino, L, Pestka, A, Andergassen, U, Meier-Stiegen, F, 
Czyz, ZT, Alberter, B, Treitschke, S, Schamberger, T, Sergio, M, Bregola, G, Doffini, A, Gianni, S, 
Calanca, A, Signorini, G, Bolognesi, C, Hartmann, A, Fasching, PA, Sandri, MT, Rack, B, Fehm, T, 
Giorgini, G, Manaresi, N, Klein, CA: Molecular profiling of single circulating tumor cells with 
diagnostic intention. EMBO molecular medicine, 6: 1371-1386, 2014. 
109. Moon, HS, Kwon, K, Kim, SI, Han, H, Sohn, J, Lee, S, Jung, HI: Continuous separation of breast cancer 
cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis 
(DEP). Lab Chip, 11: 1118-1125, 2011. 
110. Peeters, DJ, De Laere, B, Van den Eynden, GG, Van Laere, SJ, Rothe, F, Ignatiadis, M, Sieuwerts, AM, 
Lambrechts, D, Rutten, A, van Dam, PA, Pauwels, P, Peeters, M, Vermeulen, PB, Dirix, LY: 
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells 
from CellSearch enriched blood samples using dielectrophoretic cell sorting. British journal of 
cancer, 108: 1358-1367, 2013. 
111. Augustsson, P, Magnusson, C, Nordin, M, Lilja, H, Laurell, T: Microfluidic, label-free enrichment of 
prostate cancer cells in blood based on acoustophoresis. Analytical chemistry, 84: 7954-7962, 
2012. 
112. Casavant, BP, Mosher, R, Warrick, JW, Maccoux, LJ, Berry, SM, Becker, JT, Chen, V, Lang, JM, 
McNeel, DG, Beebe, DJ: A negative selection methodology using a microfluidic platform for the 
isolation and enumeration of circulating tumor cells. Methods, 64: 137-143, 2013. 
113. Zuba-Surma, EK, Ratajczak, MZ: Analytical capabilities of the ImageStream cytometer. Methods in 
cell biology, 102: 207-230, 2011. 
114. Nieva, J, Wendel, M, Luttgen, MS, Marrinucci, D, Bazhenova, L, Kolatkar, A, Santala, R, 
Whittenberger, B, Burke, J, Torrey, M, Bethel, K, Kuhn, P: High-definition imaging of circulating 
tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal 
analysis. Physical biology, 9: 016004, 2012. 
115. Krivacic, RT, Ladanyi, A, Curry, DN, Hsieh, HB, Kuhn, P, Bergsrud, DE, Kepros, JF, Barbera, T, Ho, MY, 
Chen, LB, Lerner, RA, Bruce, RH: A rare-cell detector for cancer. Proc Natl Acad Sci U S A, 101: 
10501-10504, 2004. 
 183 
116. Hillig, T, Horn, P, Nygaard, AB, Haugaard, AS, Nejlund, S, Brandslund, I, Soletormos, G: In vitro 
detection of circulating tumor cells compared by the CytoTrack and CellSearch methods. Tumour 
Biol, 36: 4597-4601, 2015. 
117. Galanzha, EI, Zharov, VP: Circulating Tumor Cell Detection and Capture by Photoacoustic Flow 
Cytometry in Vivo and ex Vivo. Cancers (Basel), 5: 1691-1738, 2013. 
118. Lopez-Riquelme, N, Minguela, A, Villar-Permuy, F, Ciprian, D, Castillejo, A, Alvarez-Lopez, MR, Soto, 
JL: Imaging cytometry for counting circulating tumor cells: comparative analysis of the 
CellSearch vs ImageStream systems. APMIS : acta pathologica, microbiologica, et immunologica 
Scandinavica, 121: 1139-1143, 2013. 
119. Marrinucci, D, Bethel, K, Kolatkar, A, Luttgen, MS, Malchiodi, M, Baehring, F, Voigt, K, Lazar, D, 
Nieva, J, Bazhenova, L, Ko, AH, Korn, WM, Schram, E, Coward, M, Yang, X, Metzner, T, Lamy, R, 
Honnatti, M, Yoshioka, C, Kunken, J, Petrova, Y, Sok, D, Nelson, D, Kuhn, P: Fluid biopsy in 
patients with metastatic prostate, pancreatic and breast cancers. Physical biology, 9: 016003-
016003, 2012. 
120. Das, M, Riess, JW, Frankel, P, Schwartz, E, Bennis, R, Hsieh, HB, Liu, X, Ly, JC, Zhou, L, Nieva, JJ, 
Wakelee, HA, Bruce, RH: ERCC1 expression in circulating tumor cells (CTCs) using a novel 
detection platform correlates with progression-free survival (PFS) in patients with metastatic 
non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung cancer (Amsterdam, 
Netherlands), 77: 421-426, 2012. 
121. Alix-Panabieres, C: EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent 
results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le 
cancer, 195: 69-76, 2012. 
122. Lu, J, Fan, T, Zhao, Q, Zeng, W, Zaslavsky, E, Chen, JJ, Frohman, MA, Golightly, MG, Madajewicz, S, 
Chen, WT: Isolation of circulating epithelial and tumor progenitor cells with an invasive 
phenotype from breast cancer patients. Int J Cancer, 126: 669-683, 2010. 
123. Ramirez, JM, Fehm, T, Orsini, M, Cayrefourcq, L, Maudelonde, T, Pantel, K, Alix-Panabieres, C: 
Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast 
cancer patients. Clin Chem, 60: 214-221, 2014. 
124. Alix-Panabieres, C, Pantel, K: Liquid biopsy in cancer patients: advances in capturing viable CTCs for 
functional studies using the EPISPOT assay. Expert review of molecular diagnostics, 15: 1411-
1417, 2015. 
125. Cayrefourcq, L, Mazard, T, Joosse, S, Solassol, J, Ramos, J, Assenat, E, Schumacher, U, Costes, V, 
Maudelonde, T, Pantel, K, Alix-Panabieres, C: Establishment and characterization of a cell line 
from human circulating colon cancer cells. Cancer Res, 75: 892-901, 2015. 
126. Dong, Y, Skelley, AM, Merdek, KD, Sprott, KM, Jiang, C, Pierceall, WE, Lin, J, Stocum, M, Carney, WP, 
Smirnov, DA: Microfluidics and circulating tumor cells. The Journal of molecular diagnostics : 
JMD, 15: 149-157, 2013. 
127. Aceto, N, Bardia, A, Miyamoto, DT, Donaldson, MC, Wittner, BS, Spencer, JA, Yu, M, Pely, A, 
Engstrom, A, Zhu, H, Brannigan, BW, Kapur, R, Stott, SL, Shioda, T, Ramaswamy, S, Ting, DT, Lin, 
CP, Toner, M, Haber, DA, Maheswaran, S: Circulating tumor cell clusters are oligoclonal 
precursors of breast cancer metastasis. Cell, 158: 1110-1122, 2014. 
128. Shah, AM, Yu, M, Nakamura, Z, Ciciliano, J, Ulman, M, Kotz, K, Stott, SL, Maheswaran, S, Haber, DA, 
Toner, M: Biopolymer system for cell recovery from microfluidic cell capture devices. Analytical 
chemistry, 84: 3682-3688, 2012. 
129. Gossett, DR, Weaver, WM, Mach, AJ, Hur, SC, Tse, HT, Lee, W, Amini, H, Di Carlo, D: Label-free cell 
separation and sorting in microfluidic systems. Analytical and bioanalytical chemistry, 397: 
3249-3267, 2010. 
 184 
130. Marrinucci, D, Bethel, K, Lazar, D, Fisher, J, Huynh, E, Clark, P, Bruce, R, Nieva, J, Kuhn, P: 
Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol, 2010: 861341, 
2010. 
131. Cristofanilli, M, Budd, GT, Ellis, MJ, Stopeck, A, Matera, J, Miller, MC, Reuben, JM, Doyle, GV, Allard, 
WJ, Terstappen, LWMM, Hayes, DF: Circulating tumor cells, disease progression, and survival in 
metastatic breast cancer. New England Journal of Medicine, 351: 781-791, 2004. 
132. Andreopoulou, E, Yang, LY, Rangel, KM, Reuben, JM, Hsu, L, Krishnamurthy, S, Valero, V, Fritsche, 
HA, Cristofanilli, M: Comparison of assay methods for detection of circulating tumor cells in 
metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex 
CellSearch system. Int J Cancer, 130: 1590-1597, 2012. 
133. Zeinali, M, Murlidhar, V, Fouladdel, S, Shao, S, Zhao, L, Cameron, H, Bankhead, A, Shi, J, Cuneo, KC, 
Sahai, V, Azizi, E, Wicha, MS, Hafner, M, Simeone, DM, Nagrath, S: Profiling Heterogeneous 
Circulating Tumor Cells (CTC) Populations in Pancreatic Cancer Using a Serial Microfluidic CTC 
Carpet Chip. Advanced Biosystems, 0: 1800228, 2018. 
134. L., SR, D., MK, Ahmedin, J: Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68: 7-30, 
2018. 
135. Hezel, AF, Kimmelman, AC, Stanger, BZ, Bardeesy, N, DePinho, RA: Genetics and biology of 
pancreatic ductal adenocarcinoma. Genes & Development, 20: 1218-1249, 2006. 
136. Hidalgo, M: Pancreatic Cancer. New England Journal of Medicine, 362: 1605-1617, 2010. 
137. Chu, GC, Kimmelman, AC, Hezel, AF, DePinho, RA: Stromal biology of pancreatic cancer. Journal of 
Cellular Biochemistry, 101: 887-907, 2007. 
138. Vogelstein, B, , K, K. W.: Cancer genes and the pathways they control. Nature Medicine, 10: 789-
799, 2004. 
139. Hingorani, SR, Wang, LF, Multani, AS, Combs, C, Deramaudt, TB, Hruban, RH, Rustgi, AK, Chang, S, 
Tuveson, DA: Trp53(R172H) and KraS(G12D) cooperate to promote chromosomal instability and 
widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7: 469-483, 2005. 
140. Guerra, C, Schuhmacher, AJ, Canamero, M, Grippo, PJ, Verdaguer, L, Perez-Gallego, L, Dubus, P, 
Sandgren, EP, Barbacid, M: Chronic pancreatitis is essential for induction of pancreatic ductal 
adenocarcinorna by k-Ras Oncogenes in adult mice. Cancer Cell, 11: 291-302, 2007. 
141. Bardeesy, N, Aguirre, AJ, Chu, GC, Cheng, KH, Lopez, LV, Hezel, AF, Feng, B, Brennan, C, Weissleder, 
R, Mahmood, U, Hanahan, D, Redston, MS, Chin, L, DePinho, RA: Both p16(Ink4a) and the 
p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. 
Proceedings of the National Academy of Sciences of the United States of America, 103: 5947-
5952, 2006. 
142. Jones, S, Zhang, XS, Parsons, DW, Lin, JCH, Leary, RJ, Angenendt, P, Mankoo, P, Carter, H, 
Kamiyama, H, Jimeno, A, Hong, SM, Fu, BJ, Lin, MT, Calhoun, ES, Kamiyama, M, Walter, K, 
Nikolskaya, T, Nikolsky, Y, Hartigan, J, Smith, DR, Hidalgo, M, Leach, SD, Klein, AP, Jaffee, EM, 
Goggins, M, Maitra, A, Iacobuzio-Donahue, C, Eshleman, JR, Kern, SE, Hruban, RH, Karchin, R, 
Papadopoulos, N, Parmigiani, G, Vogelstein, B, Velculescu, VE, Kinzler, KW: Core signaling 
pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321: 1801-
1806, 2008. 
143. Mahadevan, D, Von Hoff, DD: Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol 
Cancer Ther, 6: 1186-1197, 2007. 
144. Adwan, H, Zhivkova-Galunska, M, Georges, R, Eyol, E, Kleeff, J, Giese, NA, Friess, H, Bergmann, F, 
Berger, MR: Expression of HOXC8 is inversely related to the progression and metastasis of 
pancreatic ductal adenocarcinoma. British journal of cancer, 105: 288-295, 2011. 
145. Miura, F, Takada, T, Amano, H, Yoshida, M, Furui, S, Takeshita, K: Diagnosis of pancreatic cancer. 
HPB (Oxford), 8: 337-342, 2006. 
 185 
146. Pierantoni, C, Pagliacci, A, Scartozzi, M, Berardi, R, Bianconi, M, Cascinu, S: Pancreatic cancer: 
progress in cancer therapy. Crit Rev Oncol Hematol, 67: 27-38, 2008. 
147. Matsuda, Y, Hagio, M, Ishiwata, T: Nestin: a novel angiogenesis marker and possible target for 
tumor angiogenesis. World J Gastroenterol, 19: 42-48, 2013. 
148. Malafa, JKaMP: “Early Detection of Pancreatic Cancer : Why , Who , and How to Screen,”. vol. 15, 
2008. 
149. Greenhalf, W, Grocock, C, Harcus, M, Neoptolemos, J: Screening of High-Risk Families for 
Pancreatic Cancer. Pancreatology, 9: 215-222, 2009. 
150. Larghi, A, Verna, EC, Lecca, PG, Costamagna, G: Screening for Pancreatic Cancer in High-Risk 
Individuals: A Call for Endoscopic Ultrasound. Clinical Cancer Research, 15: 1907-1914, 2009. 
151. Faca, VM, Song, KS, Wang, H, Zhang, Q, Krasnoselsky, AL, Newcomb, LF, Plentz, RR, Gurumurthy, S, 
Redston, MS, Pitteri, SJ, Pereira-Faca, SR, Ireton, RC, Katayama, H, Glukhova, V, Phanstiel, D, 
Brenner, DE, Anderson, MA, Misek, D, Scholler, N, Urban, ND, Barnett, MJ, Edelstein, C, 
Goodman, GE, Thornquist, MD, McIntosh, MW, DePinho, RA, Bardeesy, N, Hanash, SM: A mouse 
to human search for plasma Proteome changes associated with pancreatic tumor development. 
Plos Medicine, 5: 953-967, 2008. 
152. Bidard, FC, Huguet, F, Louvet, C, Mineur, L, Bouché, O, Chibaudel, B, Artru, P, Desseigne, F, Bachet, 
JB, Mathiot, C, Pierga, JY, Hammel, P: Circulating tumor cells in locally advanced pancreatic 
adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Annals of Oncology, 24: 2057-
2061, 2013. 
153. Bissolati, M, Sandri, MT, Burtulo, G, Zorzino, L, Balzano, G, Braga, M: Portal vein-circulating tumor 
cells predict liver metastases in patients with resectable pancreatic cancer. Tumour Biol, 36: 
991-996, 2015. 
154. Rhim, AD, Mirek, ET, Aiello, NM, Maitra, A, Bailey, JM, McAllister, F, Reichert, M, Beatty, GL, Rustgi, 
AK, Vonderheide, RH, Leach, SD, Stanger, BZ: EMT and dissemination precede pancreatic tumor 
formation. Cell, 148: 349-361, 2012. 
155. Qiang Ding, Yumi Miyazaki, Koichiro Tsukasa, Shyuichiro Matsubara, Makoto Yoshimitsu, Takao, S: 
CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in 
pancreatic cancer metastasis. Molecular Cancer, 2014. 
156. Hori, Y: Prominin-1 (CD133) Reveals New Faces of Pancreatic Progenitor Cells and Cancer Stem 
Cells: Current Knowledge and Therapeutic Perspectives. Adv Exp Med Biol, 777: 185-196, 2013. 
157. Hatina, J: The dynamics of cancer stem cells. Neoplasma, 59: 700-707, 2012. 
158. Hatina, J, Schulz, WA, Fischer, J, Wahl, J, Debatin, KM, Beltinger, C: Tumour stem cells - a new 
concept in tumour biology. Deutsche Medizinische Wochenschrift, 132: 1629-1632, 2007. 
159. Moriyama, T, Ohuchida, K, Mizumoto, K, Cui, L, Ikenaga, N, Sato, N, Tanaka, M: Enhanced cell 
migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal 
cells. Cancer, 116: 3357-3368, 2010. 
160. Zhang, Y, Wei, JS, Wang, H, Xue, XF, An, Y, Tang, D, Yuan, ZX, Wang, FT, Wu, JL, Zhang, JJ, Miao, Y: 
Epithelial mesenchymal transition correlates with CD24(+)CD44(+) and CD133(+) cells in 
pancreatic cancer. Oncology Reports, 27: 1599-1605, 2012. 
161. Ding, Q, Yoshimitsu, M, Kuwahata, T, Maeda, K, Hayashi, T, Obara, T, Miyazaki, Y, Matsubara, S, 
Natsugoe, S, Takao, S: Establishment of a highly migratory subclone reveals that CD133 
contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic 
cancer. Human Cell, 25: 1-8, 2012. 
162. Li, Y, Cheng, X, Chen, Z, Liu, Y, Liu, Z, Xu, S: Circulating tumor cells in peripheral and pulmonary 
venous blood predict poor long-term survival in resected non-small cell lung cancer patients. 
Scientific Reports, 7: 4971, 2017. 
 186 
163. Zhang, Z, Ramnath, N, Nagrath, S: Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future 
Directions. Frontiers in oncology, 5: 209, 2015. 
164. Santarpia, M, Liguori, A, D'Aveni, A, Karachaliou, N, Gonzalez-Cao, M, Daffina, MG, Lazzari, C, 
Altavilla, G, Rosell, R: Liquid biopsy for lung cancer early detection. Journal of thoracic disease, 
10: S882-s897, 2018. 
165. Faugeroux, V, Pailler, E, Auger, N, Taylor, M, Farace, F: Clinical Utility of Circulating Tumor Cells in 
ALK-Positive Non-Small-Cell Lung Cancer. Frontiers in Oncology, 4, 2014. 
166. Cancer.Lung., AJCo: Non-Small Cell Lung Cancer Early, Detection, Diagnosis, and Staging. In: AJCC 
Cancer Staging Manual 8th ed New York, NY: Springer, 2017. 
167. Wiener, RS, Schwartz, LM, Woloshin, S, Welch, HG: Population-based risk for complications after 
transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Annals 
of internal medicine, 155: 137-144, 2011. 
168. Murlidhar, V, Ramnath, N, Nagrath, S, Reddy, R: Optimizing the Detection of Circulating Markers to 
Aid in Early Lung Cancer Detection. Cancers, 8: 61, 2016. 
169. van Zandwijk, N: Neoadjuvant strategies for non-small cell lung cancer. Lung cancer (Amsterdam, 
Netherlands), 34 Suppl 2: S145-150, 2001. 
170. Ilie, M, Hofman, V, Long, E, Bordone, O, Selva, E, Washetine, K, Marquette, CH, Hofman, P: Current 
challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and 
their characterization in non-small cell lung carcinoma patients. What is the best blood 
substrate for personalized medicine? Annals of translational medicine, 2: 107, 2014. 
171. Pantel, K, Speicher, MR: The biology of circulating tumor cells. Oncogene, 35: 1216-1224, 2016. 
172. Murlidhar, V, Reddy, RM, Fouladdel, S, Zhao, L, Ishikawa, MK, Grabauskiene, S, Zhang, Z, Lin, J, 
Chang, AC, Carrott, P, Lynch, WR, Orringer, MB, Kumar-Sinha, C, Palanisamy, N, Beer, DG, Wicha, 
MS, Ramnath, N, Azizi, E, Nagrath, S: Poor Prognosis Indicated by Venous Circulating Tumor Cell 
Clusters in Early-Stage Lung Cancers. Cancer Research, 77: 5194-5206, 2017. 
173. Zhang, Z, Shiratsuchi, H, Palanisamy, N, Nagrath, S, Ramnath, N: Expanded Circulating Tumor Cells 
from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with 
Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. Journal of Thoracic 
Oncology, 12: 397-402, 2017. 
174. Tanaka, F, Yoneda, K, Kondo, N, Hashimoto, M, Takuwa, T, Matsumoto, S, Okumura, Y, Rahman, S, 
Tsubota, N, Tsujimura, T, Kuribayashi, K, Fukuoka, K, Nakano, T, Hasegawa, S: Circulating tumor 
cell as a diagnostic marker in primary lung cancer. Clin Cancer Res, 15: 6980-6986, 2009. 
175. Rolfo, C, Castiglia, M, Hong, D, Alessandro, R, Mertens, I, Baggerman, G, Zwaenepoel, K, Gil-Bazo, I, 
Passiglia, F, Carreca, AP, Taverna, S, Vento, R, Santini, D, Peeters, M, Russo, A, Pauwels, P: Liquid 
biopsies in lung cancer: the new ambrosia of researchers. Biochimica et biophysica acta, 1846: 
539-546, 2014. 
176. Perez-Callejo, D, Romero, A, Provencio, M, Torrente, M: Liquid biopsy based biomarkers in non-
small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res, 5: 455-
465, 2016. 
177. Hou, JM, Krebs, M, Ward, T, Sloane, R, Priest, L, Hughes, A, Clack, G, Ranson, M, Blackhall, F, Dive, 
C: Circulating tumor cells as a window on metastasis biology in lung cancer. The American 
journal of pathology, 178: 989-996, 2011. 
178. Tong, B, Xu, Y, Zhao, J, Chen, M, Xing, J, Zhong, W, Wang, M: Prognostic significance of circulating 
tumor cells in non-small cell lung cancer patients undergoing chemotherapy. Oncotarget, 8: 
86615-86624, 2017. 
179. Fiorelli, A, Accardo, M, Carelli, E, Angioletti, D, Santini, M, Di Domenico, M: Circulating Tumor Cells 
in Diagnosing Lung Cancer: Clinical and Morphologic Analysis. The Annals of thoracic surgery, 99: 
1899-1905, 2015. 
 187 
180. Ilie, M, Hofman, V, Long-Mira, E, Selva, E, Vignaud, JM, Padovani, B, Mouroux, J, Marquette, CH, 
Hofman, P: "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with 
chronic obstructive pulmonary disease. PLoS One, 9: e111597, 2014. 
181. Krebs, MG, Sloane, R, Priest, L, Lancashire, L, Hou, JM, Greystoke, A, Ward, TH, Ferraldeschi, R, 
Hughes, A, Clack, G, Ranson, M, Dive, C, Blackhall, FH: Evaluation and prognostic significance of 
circulating tumor cells in patients with non-small-cell lung cancer. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology, 29: 1556-1563, 2011. 
182. Hofman, V, Ilie, MI, Long, E, Selva, E, Bonnetaud, C, Molina, T, Venissac, N, Mouroux, J, Vielh, P, 
Hofman, P: Detection of circulating tumor cells as a prognostic factor in patients undergoing 
radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch 
Assay (TM) and the isolation by size of epithelial tumor cell method. International Journal of 
Cancer, 129: 1651-1660, 2011. 
183. Isobe, K, Hata, Y, Kobayashi, K, Hirota, N, Sato, K, Sano, G, Sugino, K, Sakamoto, S, Takai, Y, Shibuya, 
K, Takagi, K, Homma, S: Clinical significance of circulating tumor cells and free DNA in non-small 
cell lung cancer. Anticancer research, 32: 3339-3344, 2012. 
184. Hirose, T, Murata, Y, Oki, Y, Sugiyama, T, Kusumoto, S, Ishida, H, Shirai, T, Nakashima, M, Yamaoka, 
T, Okuda, K, Ohnishi, T, Ohmori, T: Relationship of circulating tumor cells to the effectiveness of 
cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncology 
research, 20: 131-137, 2012. 
185. Ke, Z, Lin, M, Chen, J-F, Choi, J-s, Zhang, Y, Fong, A, Liang, A-J, Chen, S-F, Li, Q, Fang, W, Zhang, P, 
Garcia, MA, Lee, T, Song, M, Lin, H-A, Zhao, H, Luo, S-C, Hou, S, Yu, H-h, Tseng, H-R: 
Programming Thermoresponsiveness of NanoVelcro Substrates Enables Effective Purification of 
Circulating Tumor Cells in Lung Cancer Patients. ACS Nano, 9: 62-70, 2015. 
186. Kallergi, G, Vetsika, EK, Aggouraki, D, Lagoudaki, E, Koutsopoulos, A, Koinis, F, Katsarlinos, P, 
Trypaki, M, Messaritakis, I, Stournaras, C, Georgoulias, V, Kotsakis, A: Evaluation of PD-L1/PD-1 
on circulating tumor cells in patients with advanced non-small cell lung cancer. Therapeutic 
advances in medical oncology, 10: 1758834017750121, 2018. 
187. Ilie, M, Hofman, V, Leroy, S, Cohen, C, Heeke, S, Cattet, F, Bence, C, Lalvee, S, Mouroux, J, 
Marquette, CH, Hofman, P: Use of circulating tumor cells in prospective clinical trials for NSCLC 
patients - standardization of the pre-analytical conditions. Clinical chemistry and laboratory 
medicine, 56: 980-989, 2018. 
188. Hou, HW, Warkiani, ME, Khoo, BL, Li, ZR, Soo, RA, Tan, DS, Lim, WT, Han, J, Bhagat, AA, Lim, CT: 
Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep, 3: 1259, 2013. 
189. McDonald, JC, Duffy, DC, Anderson, JR, Chiu, DT, Wu, H, Schueller, OJ, Whitesides, GM: Fabrication 
of microfluidic systems in poly(dimethylsiloxane). Electrophoresis, 21: 27-40, 2000. 
190. Campo, Ad, Greiner, C: SU-8: a photoresist for high-aspect-ratio and 3D submicron lithography. 
Journal of Micromechanics and Microengineering, 17: R81-R95, 2007. 
191. Zhou, J, Ellis, AV, Voelcker, NH: Recent developments in PDMS surface modification for microfluidic 
devices. Electrophoresis, 31: 2-16, 2010. 
192. Meghna Waghray, MY, Michele Dziubinski, Mina Zeinali, Marguerite Erkkinen,, Huibin Yang, KAS, 
Sumithra Urs, Marina Pasca Di Magliano, Theodore H. Welling,, Phillip L. Palmbos, EVA, Vaibhav 
Sahai, Sunitha Nagrath, Lidong Wang, Diane M. Simeone.: GM-CSF Mediates Mesenchymal–
Epithelial Cross-talk in Pancreatic Cancer. cancer discovery, May 16, 2016. 
193. Han, B, Mehra, R, Dhanasekaran, SM, Yu, J, Menon, A, Lonigro, RJ, Wang, X, Gong, Y, Wang, L, 
Shankar, S, Laxman, B, Shah, RB, Varambally, S, Palanisamy, N, Tomlins, SA, Kumar-Sinha, C, 
Chinnaiyan, AM: A fluorescence in situ hybridization screen for E26 transformation-specific 
aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res, 68: 7629-
7637, 2008. 
 188 
194. Han, B, Mehra, R, Suleman, K, Tomlins, SA, Wang, L, Singhal, N, Linetzky, KA, Palanisamy, N, Zhou, 
M, Chinnaiyan, AM, Shah, RB: Characterization of ETS Gene Aberrations in Select Histologic 
Variants of Prostate Carcinoma. Modern pathology : an official journal of the United States and 
Canadian Academy of Pathology, Inc, 22: 1176-1185, 2009. 
195. Bhalla, R, Kunju, LP, Tomlins, SA, Christopherson, K, Cortez, C, Carskadon, S, Siddiqui, J, Park, K, 
Mosquera, JM, Pestano, GA, Rubin, MA, Chinnaiyan, AM, Palanisamy, N: Novel dual-color 
immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate 
carcinoma. Mod Pathol, 26: 835-848, 2013. 
196. Lee, HJ, You, DD, Choi, DW, Choi, YS, Kim, SJ, Won, YS, Moon, HJ: Significance of CD133 as a cancer 
stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. Journal of the 
Korean Surgical Society, 81: 263-270, 2011. 
197. Waghray, M, Yalamanchili, M, Dziubinski, M, Zeinali, M, Erkkinen, M, Yang, H, Schradle, KA, Urs, S, 
Pasca Di Magliano, M, Welling, TH, Palmbos, PL, Abel, EV, Sahai, V, Nagrath, S, Wang, L, 
Simeone, DM: GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. Cancer 
Discov, 6: 886-899, 2016. 
198. Báez, LR: Application of Label-free Microfluidic Technologies for the Enrichment, Expansion and 
Characterization of Circulating Tumor Cells in Pancreatic Cancer. 2017. 
199. Karachaliou, N, Chaib, I, Cardona, AF, Berenguer, J, Bracht, JWP, Yang, J, Cai, X, Wang, Z, Hu, C, 
Drozdowskyj, A, Servat, CC, Servat, JC, Ito, M, Attili, I, Aldeguer, E, Capitan, AG, Rodriguez, J, 
Rojas, L, Viteri, S, Molina-Vila, MA, Ou, SI, Okada, M, Mok, TS, Bivona, TG, Ono, M, Cui, J, Cajal, 
SRY, Frias, A, Cao, P, Rosell, R: Common Co-activation of AXL and CDCP1 in EGFR-mutation-
positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine, 29: 112-127, 
2018. 
200. Alix-Panabieres, C, Pantel, K: Challenges in circulating tumour cell research. Nat Rev Cancer, 14: 
623-631, 2014. 
201. Xiao, D, He, J: Epithelial mesenchymal transition and lung cancer. Journal of thoracic disease, 2: 
154-159, 2010. 
202. Gorges, TM, Tinhofer, I, Drosch, M, Rose, L, Zollner, TM, Krahn, T, von Ahsen, O: Circulating tumour 
cells escape from EpCAMbased detection due to epithelial-tomesenchymal transition. BMC 
Cancer, 12: 178, 2012. 
203. Sieuwerts, AM, Kraan, J, Bolt, J, van der Spoel, P, Elstrodt, F, Schutte, M, Martens, JW, Gratama, JW, 
Sleijfer, S, Foekens, JA: Anti-epithelial cell adhesion molecule antibodies and the detection of 
circulating normal-like breast tumor cells. J Natl Cancer Inst, 101: 61-66, 2009. 
204. Hong SH, Misek DE, Wang H, Puravs E, Hinderer R, Giordano TJ, al, GJe: Identiﬁcation of a speciﬁc 
vimentin isoform that induces an antibody response in pancreatic cancer. Biomark Insights, 
2006. 
205. Ren, C, Chen, H, Han, C, Jin, G, Wang, D, Tang, D: Detection and molecular analysis of circulating 
tumor cells for early diagnosis of pancreatic cancer. Med Hypotheses, 80: 833-836, 2013. 
206. Fazlul H. Sarkar, Yiwei Li, Zhiwei Wang, Kong, D: Pancreatic cancer stem cells and EMT in drug 
resistance and metastasis. Minerva chirurgica, 64: 489-500, Oct. 2009. 
207. Yamada, S, Fuchs, BC, Fujii, T, Shimoyama, Y, Sugimoto, H, Nomoto, S, Takeda, S, Tanabe, KK, 
Kodera, Y, Nakao, A: Epithelial-to-mesenchymal transition predicts prognosis of pancreatic 
cancer. Surgery, 154: 946-954, 2013. 
208. Lahat, G, Lubezky, N, Loewenstein, S, Nizri, E, Gan, S, Pasmanik-Chor, M, Hayman, L, Barazowsky, E, 
Ben-Haim, M, Klausner, JM: Epithelial-to-Mesenchymal Transition (EMT) in Intraductal Papillary 
Mucinous Neoplasm (IPMN) is Associated with High Tumor Grade and Adverse Outcomes. 
Annals of Surgical Oncology, 21: 750-757, 2014. 
 189 
209. Hiroshi, K, Sonshin, T, Kosei, M, Yuko, M, Taisaku, K, Koki, M, Qiang, D, Masahiko, S, Satoshi, I, 
Sumiya, I, Shinichi, U, Hiroyuki, S, Shoji, N: Epithelial–mesenchymal transition and 
mesenchymal–epithelial transition via regulation of ZEB‐1 and ZEB‐2 expression in pancreatic 
cancer. Journal of Surgical Oncology, 105: 655-661, 2012. 
210. Lianyu Chen1, Jie Fan3, , HC, 2, Zhiqiang Meng1,2, Zhen Chen1,2, Peng Wang1,2 & Luming Liu1,2: 
The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with 
clinical prognosis in human pancreatic cancer cases. Sci Rep, Aug 2014. 
211. Tai, MH, Chang, CC, Kiupel, M, Webster, JD, Olson, LK, Trosko, JE: Oct4 expression in adult human 
stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis, 26: 
495-502, 2005. 
212. Chengzhi He1, Hua Jiang1, Shasha Geng1, Haihui Sheng3, Xiaoying Shen3, Xiaoyan Zhang3, 
Shizhang, Zhu3, XC, Changqing Yang2, HengJun Gao2,3: Expression of c-Myc and Fas correlates 
with perineural invasion of pancreatic cancer. May 30, 2012. 
213. Yu-Jun Li, Z-MW, Yun-Xiao Meng, Xiang-Rui Ji: -catenin up-regulates the expression of cyclinD1, c-
myc and MMP-7 in human pancreatic cancer: Relationships with carcinogenesis and metastasis. 
World J Gastroenterol 2004. 
214. Proctor, E, , W, M., , L, C. J., , H, D. G., , Y, M., , L, C., , B, F., , S, D. M.: Bmi1 enhances tumorigenicity 
and cancer stem cell function in pancreatic adenocarcinoma. PLoS One, 8: e55820, 2013. 
215. Nakajima, S, Doi, R, Toyoda, E, Tsuji, S, Wada, M, Koizumi, M, Tulachan, SS, Ito, D, Kami, K, Mori, T, 
Kawaguchi, Y, Fujimoto, K, Hosotani, R, Imamura, M: N-Cadherin Expression and Epithelial-
Mesenchymal Transition in Pancreatic Carcinoma. Clinical Cancer Research, 10: 4125, 2004. 
216. Gagliano, N, Celesti, G, Tacchini, L, Pluchino, S, Sforza, C, Rasile, M, Valerio, V, Laghi, L, Conte, V, 
Procacci, P: Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: 
Characterization in a 3D-cell culture model. World Journal of Gastroenterology, 22: 4466-4483, 
2016. 
217. Maithel, SK, Coban, I, Kneuertz, PJ, Kooby, DA, El-Rayes, BF, Kauh, JS, Sarmiento, J, Staley, CA, 3rd, 
Volkan Adsay, N: Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor 
expression is associated with earlier recurrence and shortened survival after resection. Ann Surg 
Oncol, 18: 2699-2705, 2011. 
218. Akita, H, Zheng, Z, Takeda, Y, Kim, C, Kittaka, N, Kobayashi, S, Marubashi, S, Takemasa, I, Nagano, H, 
Dono, K, Nakamori, S, Monden, M, Mori, M, Doki, Y, Bepler, G: Significance of RRM1 and ERCC1 
expression in resectable pancreatic adenocarcinoma. Oncogene, 28: 2903-2909, 2009. 
219. Ormanns, S, Siveke, JT, Heinemann, V, Haas, M, Sipos, B, Schlitter, AM, Esposito, I, Jung, A, 
Laubender, RP, Kruger, S, Vehling-Kaiser, U, Winkelmann, C, Fischer von Weikersthal, L, 
Clemens, MR, Gauler, TC, Märten, A, Geissler, M, Greten, TF, Kirchner, T, Boeck, S: pERK, pAKT 
and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a 
translational subgroup analysis from AIO-PK0104. BMC Cancer, 14: 624, 2014. 
220. Hay, N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 8: 179-183, 2005. 
221. Si, L, Xu, L, Yin, L, Qi, Y, Han, X, Xu, Y, Zhao, Y, Liu, K, Peng, J: Potent effects of dioscin against 
pancreatic cancer via miR‐149‐3P‐mediated inhibition of the Akt1 signalling pathway. British 
Journal of Pharmacology, 174: 553-568, 2017. 
222. Köninger, J, Giese, NA, di Mola, FF, Berberat, P, Giese, T, Esposito, I, Bachem, MG, Büchler, MW, 
Friess, H: Overexpressed Decorin in Pancreatic Cancer. Clinical Cancer Research, 10: 4776, 2004. 
223. Schonleben, F, Qiu, W, Remotti, HE, Hohenberger, W, Su, GH: PIK3CA, KRAS, and BRAF mutations in 
intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks 
Arch Surg, 393: 289-296, 2008. 
224. Garcia-Carracedo, D, Chen, ZM, Qiu, W, Huang, AS, Tang, SM, Hruban, RH, Su, GH: PIK3CA 
mutations in mucinous cystic neoplasms of the pancreas. Pancreas, 43: 245-249, 2014. 
 190 
225. Chen, L, Fan, J, Chen, H, Meng, Z, Chen, Z, Wang, P, Liu, L: The IL-8/CXCR1 axis is associated with 
cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic 
cancer cases. Scientific Reports, 4: 5911, 2014. 
226. Hollstein, M, Moeckel, G, Hergenhahn, M, Spiegelhalder, B, Keil, M, Werle-Schneider, G, Bartsch, H, 
Brickmann, J: On the origins of tumor mutations in cancer genes: insights from the p53 gene. 
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 405: 145-154, 
1998. 
227. Gorges, TM, Tinhofer, I, Drosch, M, Rose, L, Zollner, TM, Krahn, T, von Ahsen, O: Circulating tumour 
cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC 
Cancer, 12: 178, 2012. 
228. Krebs, MG, Hou, JM, Sloane, R, Lancashire, L, Priest, L, Nonaka, D, Ward, TH, Backen, A, Clack, G, 
Hughes, A, Ranson, M, Blackhall, FH, Dive, C: Analysis of circulating tumor cells in patients with 
non-small cell lung cancer using epithelial marker-dependent and -independent approaches. 
Journal of thoracic oncology : official publication of the International Association for the Study of 
Lung Cancer, 7: 306-315, 2012. 
229. The Cancer Genome Atlas Research, N: Comprehensive molecular profiling of lung 
adenocarcinoma. Nature, 511: 543, 2014. 
230. The Cancer Genome Atlas Research, N: Comprehensive genomic characterization of squamous cell 
lung cancers. Nature, 489: 519, 2012. 
231. Arora, A, Scholar, EM: Role of tyrosine kinase inhibitors in cancer therapy. The Journal of 
pharmacology and experimental therapeutics, 315: 971-979, 2005. 
232. Ahn, MJ, Sun, JM, Lee, SH, Ahn, JS, Park, K: EGFR TKI combination with immunotherapy in non-small 
cell lung cancer. Expert opinion on drug safety, 16: 465-469, 2017. 
233. Gerber, DE, Gandhi, L, Costa, DB: Management and future directions in non-small cell lung cancer 
with known activating mutations. American Society of Clinical Oncology educational book 
American Society of Clinical Oncology Annual Meeting: e353-365, 2014. 
234. Socinski, MA, Villaruz, LC, Ross, J: Understanding Mechanisms of Resistance in the Epithelial Growth 
Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. The 
oncologist, 22: 3-11, 2017. 
235. Arcila, ME, Oxnard, GR, Nafa, K, Riely, GJ, Solomon, SB, Zakowski, MF, Kris, MG, Pao, W, Miller, VA, 
Ladanyi, M: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and 
enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical 
cancer research : an official journal of the American Association for Cancer Research, 17: 1169-
1180, 2011. 
236. Yoon, HJ, Lee, HY, Lee, KS, Choi, Y-L, Ahn, M-J, Park, K, Ahn, JS, Sun, J-M, Kim, J, Kim, TS, Chung, MJ, 
Yi, CA: Repeat Biopsy for Mutational Analysis of Non–Small Cell Lung Cancers Resistant to 
Previous Chemotherapy: Adequacy and Complications. Radiology, 265: 939-948, 2012. 
237. Lecharpentier, A, Vielh, P, Perez-Moreno, P, Planchard, D, Soria, JC, Farace, F: Detection of 
circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with 
metastatic non-small cell lung cancer. British journal of cancer, 105: 1338-1341, 2011. 
238. Hong, Y, Fang, F, Zhang, Q: Circulating tumor cell clusters: What we know and what we expect 
(Review). International Journal of Oncology, 49: 2206-2216, 2016. 
239. Marchetti, A, Del Grammastro, M, Felicioni, L, Malatesta, S, Filice, G, Centi, I, De Pas, T, Santoro, A, 
Chella, A, Brandes, AA, Venturino, P, Cuccurullo, F, Crino, L, Buttitta, F: Assessment of EGFR 
mutations in circulating tumor cell preparations from NSCLC patients by next generation 
sequencing: toward a real-time liquid biopsy for treatment. PLoS One, 9: e103883, 2014. 
240. Provencio, M, Pérez-Callejo, D, Torrente, M, Martin, P, Calvo, V, Gutiérrez, L, Franco, F, Coronado, 
MJ, Cruz-Bermúdez, JL, Ruiz-Valdepeñas, AM, Cruz-Bermúdez, A, Sánchez-Beato, M, Romero, A, 
 191 
García-Grande, A: Concordance between circulating tumor cells and clinical status during follow-
up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients. Oncotarget, 8: 
59408-59416, 2017. 
241. Kang, JH, Krause, S, Tobin, H, Mammoto, A, Kanapathipillai, M, Ingber, DE: A combined 
micromagnetic-microfluidic device for rapid capture and culture of rare circulating tumor cells. 
Lab Chip, 12: 2175-2181, 2012. 
242. Zhang, L, Ridgway, LD, Wetzel, MD, Ngo, J, Yin, W, Kumar, D, Goodman, JC, Groves, MD, Marchetti, 
D: The identification and characterization of breast cancer CTCs competent for brain metastasis. 
Sci Transl Med, 5: 180ra148, 2013. 
243. Yu, M, Bardia, A, Aceto, N, Bersani, F, Madden, MW, Donaldson, MC, Desai, R, Zhu, H, Comaills, V, 
Zheng, Z, Wittner, BS, Stojanov, P, Brachtel, E, Sgroi, D, Kapur, R, Shioda, T, Ting, DT, 
Ramaswamy, S, Getz, G, Iafrate, AJ, Benes, C, Toner, M, Maheswaran, S, Haber, DA: Cancer 
therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug 
susceptibility. Science, 345: 216-220, 2014. 
244. Zhang, Z, Shiratsuchi, H, Lin, J, Chen, G, Reddy, RM, Azizi, E, Fouladdel, S, Chang, AC, Lin, L, Jiang, H, 
Waghray, M, Luker, G, Simeone, DM, Wicha, MS, Beer, DG, Ramnath, N, Nagrath, S: Expansion 
of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget, 
5: 12383-12397, 2014. 
245. Costello, E, Greenhalf, W, Neoptolemos, JP: New biomarkers and targets in pancreatic cancer and 
their application to treatment. Nat Rev Gastroenterol Hepatol, 9: 435-444, 2012. 
246. Jack, RM, Grafton, MM, Rodrigues, D, Giraldez, MD, Griffith, C, Cieslak, R, Zeinali, M, Kumar Sinha, 
C, Azizi, E, Wicha, M, Tewari, M, Simeone, DM, Nagrath, S: Ultra-Specific Isolation of Circulating 
Tumor Cells Enables Rare-Cell RNA Profiling. Advanced science (Weinheim, Baden-Wurttemberg, 
Germany), 3: 1600063, 2016. 
247. MD-Anderson: Personalized Cancer Therapy. 
248. Perkel, JM: Single-cell biology: The power of one. 2015  
249. Care-for-a-Cure: New Drug Testing Method Could Speed Up Development of Breast Cancer 
Treatments. 2016. 
250. Bilimoria, KY, Bentrem, DJ, Ko, CY, Ritchey, J, Stewart, AK, Winchester, DP, Talamonti, MS: 
Validation of the 6th Edition AJCC Pancreatic Cancer Staging System - Report from the National 
Cancer Database. Cancer, 110: 738-744, 2007. 
251. Nagrath, S, Jack, RM, Sahai, V, Simeone, DM: Opportunities and Challenges for Pancreatic 
Circulating Tumor Cells. Gastroenterology, 151: 412-426, 2016. 
252. Zhang, Y, Wang, F, Ning, N, Chen, Q, Yang, Z, Guo, Y, Xu, D, Zhang, D, Zhan, T, Cui, W: Patterns of 
circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. International 
Journal of Cancer, 136: 1228-1233, 2015. 
253. Ankeny, JS, Hou, S, Lin, M, OuYang, H, Song, M, Rochefort, MM, Girgis, MD, Isacoff, WH, Wainberg, 
ZA, Tseng, H-R, Tomlinson, JS: Pancreatic circulating tumor cells as a diagnostic adjunct in 
pancreatic cancer. Journal of Clinical Oncology, 32: 175-175, 2014. 
254. Kulemann, B, Pitman, MB, Liss, AS, Valsangkar, N, Fernández-del Castillo, C, Lillemoe, KD, 
Hoeppner, J, Mino-Kenudson, M, Warshaw, AL, Thayer, SP: Circulating Tumor Cells Found in 
Patients With Localized and Advanced Pancreatic Cancer. Pancreas, 44: 547-550, 2015. 
255. Vladimir Bobek, Robert Gurlich, Petra Eliasova, Kolostova, K: Circulating tumor cells in pancreatic 
cancer patients: Enrichment and cultivation. 2014 December. 
256. Hanssen, A, Loges, S, Pantel, K, Wikman, H: Detection of Circulating Tumor Cells in Non-Small Cell 
Lung Cancer. Frontiers in oncology, 5: 207, 2015. 
257. Pailler, E, Adam, J, Barthelemy, A, Oulhen, M, Auger, N, Valent, A, Borget, I, Planchard, D, Taylor, M, 
Andre, F, Soria, JC, Vielh, P, Besse, B, Farace, F: Detection of circulating tumor cells harboring a 
 192 
unique ALK rearrangement in ALK-positive non-small-cell lung cancer. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology, 31: 2273-2281, 2013. 
258. Dorsey, JF, Kao, GD, MacArthur, KM, Ju, M, Steinmetz, D, Wileyto, EP, Simone, CB, 2nd, Hahn, SM: 
Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung 
cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer, 121: 
139-149, 2015. 
259. Hosokawa, M, Kenmotsu, H, Koh, Y, Yoshino, T, Yoshikawa, T, Naito, T, Takahashi, T, Murakami, H, 
Nakamura, Y, Tsuya, A, Shukuya, T, Ono, A, Akamatsu, H, Watanabe, R, Ono, S, Mori, K, Kanbara, 
H, Yamaguchi, K, Tanaka, T, Matsunaga, T, Yamamoto, N: Size-based isolation of circulating 
tumor cells in lung cancer patients using a microcavity array system. PLoS One, 8: e67466, 2013. 
 
  
 193 
9 Appendix 
9.1 Different design configurations of immunoaffinity microfluidic 
devices  
We undertook a pilot exploratory study comparing five different immunoaffinity 
CTC Chip devices to determine the highest capture efficiencies. Different micropost 
distributions and arrangement were tested in this study including, CTC Original, Split, 
Modified, Rotated, and Carpet Chip.  
9.1.1 Original vs. Split CTC chip 
The Original CTC Chip was modified to a Split chamber CTC Chip to enhance 
the % capture efficiencies. The expression of EpCAM on PC-3 cell line was checked 
prior to the experiments with western blot analysis (section  3.3.1) (Figure  3-13). 1000 
fluorescently-labeled with green CellTracker PC-3 cell line were spiked into buffer and 
the % capture efficiencies of EpCAM on the CTC Original and Split Chip at 10 mL hr-1 
flow rate were analyzed. The results showed higher capture efficiencies in the Original 
(20.1%) compared to the Split Chip (12.4%) (Figure  9-1). 
 
Figure ‎9-1: Original vs. Split CTC Chip. A) AutoCAD design of the Original CTC Chip, B) and the Split CTC Chip. 
C) % Capture efficiency of EpCAM with 1,000 spiked pre-labeled PC-3 cell line into buffer at 10 mL hr
-1
 flow rate 
showed higher %capture efficiency in the Original CTC Chip (20.1%) compare to the Split device (12.4%). 
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9.1.2 Original vs. Modified CTC Chip  
Original Chip was re-designed to Modified Chip to make it more refined for 
capturing purpose. 1000 fluorescently-labeled with green CellTracker PC-3 cell line 
were spiked into buffer and blood. % Capture efficiencies of EpCAM with the CTC 
Original and Modified Chips at 1 mL hr-1 flow rates were analyzed. % Capture 
efficiencies in blood were slightly higher in the Modified device compare to the Original 
device (71.9% vs. 67%) (Figure  9-2). 
 
Figure ‎9-2: Original vs. Modified CTC Chip. A) AutoCAD design of the Original CTC Chip, B) and the Modified 
CTC Chip. C) %  Capture efficiencies of EpCAM with spiked pre-labeled PC-3 cell line into buffer and blood at 1 mL 
hr
-1
 flow rate. The CTC Modified Chip showed 71.9% capture efficiency with the PC-3 cell line into blood. 
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9.1.3 Modified vs. Rotated CTC Chip 
Due to low capture efficiencies of the Modified Chip, the Rotated device had 
been designed based on the rotating the arrays 10˚ relative to the previous array until 
reaching a total rotation of 180° and then decreasing rotation from 180° to 0° for the 
subsequent row. By this new configuration, capture efficiencies of pre-labeled PC-3 
cells spiked into blood increased 11.8% at 1 mL hr-1 flow rate compare to the Modified 
CTC Chip (83.7% vs.71.9%) (Figure  9-3).  
 
Figure ‎9-3: Modified vs. Rotated CTC Chip. A) AutoCAD design of the Modified CTC Chip, B) and the Rotated 
CTC Chip.  C) % Capture efficiency of EpCAM with spiked pre-labeled PC-3 cell line into buffer and blood at 1 mL hr
-
1
 flow rate. The CTC Rotated Chip showed 83.7% capture efficiency with the PC-3 cell line into blood. 
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9.1.4 Rotated vs. Carpet CTC chip 
In order to increase the specificity and sensitivity of capturing CTCs, CTC Carpet 
Chip was designed based on an 18° rotation of hexagonal arrays of 100 μm posts, by 
which capture efficiencies increased to 87.7% with pre-labeled PC-3 cell line spiked into 
blood at 1 mL hr-1 flow rate compare to the Rotated Chip (83.7%) (Figure  9-4).  
 
Figure ‎9-4: Rotated vs. Carpet CTC Chip. A) AutoCAD design of the Rotated CTC Chip, B) and the Carpet CTC 
Chip. C) % Capture efficiency of EpCAM with spiked pre-labeled PC-3 cell line into buffer and blood at 1 mL hr
-1
 flow 
rate. The CTC Carpet Chip showed 87.7% capture efficiency with the PC-3 cell line into blood.   
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9.2 List of Tables 
Table ‎9-1: Staging of pancreatic cancer 
250
 
Stage 
Tumor 
grade 
Nodal 
status 
Distant 
metastases 
Median 
survival 
Characteristics 
- TX NX MX - Primary tumor cannot be assessed 
- T0 N0 M0 - No evidence of primary tumor 
0 Tis N0 M0 - Carcinoma in situ 
IA T1 N0 M0 24.1 
Tumor limited to the pancreas, ≤2 cm in greatest diameter 
(localized within pancreas) 
IB T2 N0 M0 20.6 
Tumor limited to the pancreas, >2 cm in greatest diameter 
(localized within pancreas) 
IIA T N0 M0 15.4 
Tumor extends beyond the pancreas but does not involve 
the celiac 
axis or superior mesenteric artery 
(locally invasive, resectable) 
IIB T1/2/3 N1 M0 12.7 
Regional lymph-node metastasis 
(locally invasive, resectable) 
III T4 Any N M0 10.6 
Tumor involves the celiac axis or the superior mesenteric 
artery 
(locally advanced, unresectable) 
IV Any T Any N M1 4.5 Distant metastasis 
N; denotes regional lymph nodes, M; distant metastases, and T; primary tumor. 
NX; Regional nodes cannot be assessed, N0; No regional lymph node metastasis, N1; Regional lymph node 
metastasis 
MX; Distant metastasis cannot be assessed, M0; No distant metastasis, M1; Distant metastasis  
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  Table ‎9-2: CTC detection techniques in pancreatic cancer 
251
 
Platforms Enrichment technology Number of 
PDAC patients 
Detection rate (%) Reference 
CellSearch Immunomagnetic 16 2±6 CTCs 7.5mL
-1 63
 
26 42% 
6
 
79 11% 
152
 
20 45% 
153
 
Multi marker RT-PCR  Immunomagnetic 34 47.1% 
15
 
CTC-iChip Immunomagnetic, Inertial sorting 6 66.7% 
78
 
Ultra-specific CTC isolation platform Immunomagnetic, Inertial sorting 14 100% 
246
 
Immunofluorescence and in situ hybridization (FISH) of 
chromosome 8  
Negative Enrichment 40 90% 
252
 
CTC-Chip Immunoaffinity 15 100% 
4
 
Thermoplastic modular microsystem Immunoaffinity 12 100% 
73
 
GEDI Immunoaffinity 11 73% 
67
 
GEM Immunoaffinity 18 94.4% 
71
 
OncoBean Immunoaffinity 2 100% 
69
 
NanoVelcro Immunoaffinity 32 62.5% 
253
 
ISET Size-based filtration  93% 
10
 
ScreenCell Size-based filtration 11 73% 
254
 
MetaCell Size-based filtration 24 66.7% 
255
 
Immunocytogenetics  22 4 CTCs 7.5mL
-1
 
252
 
Immunocytochemistry  41 ≥1  CTCs 7.5mL
-1
 
16
 
HD-CTC  18 50% 
119
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   Table ‎9-3: Staging of Lung Cancer 
166
 
Stage 
Tumor 
grade 
Nodal 
status 
Distant 
metastases 
Characteristics 
 TX N0 M0 No evidence of primary tumor 
0 Tis N0 M0 Tumor is found in only the top layers of the cells lining the air passages 
IA1 T1mi/T1a N0 M0 Minimally invasive adenocarcinoma, tumor size <1 cm 
IA2 T1b N0 M0 Tumor size >1  cm  but not <2 cm 
IA3 T1c N0 M0 Tumor size >2  cm  but not <3 cm 
IB T2a N0 M0 
Tumor size >3  cm  but not <4 cm 
Grown into a main bronchus, visceral pleura, clogging the airways. 
IIA T2b N0 M0 
Tumor size >4  cm  but not <5 cm 
Grown into a main bronchus, visceral pleura, clogging the airways. 
IIB 
T1a/T1b/T1c 
 
T2a/T2b 
 
 
T3 
 
N1 
 
N1 
 
 
N0 
M0 
 
M0 
 
 
M0 
Tumor size <3  cm but has spread to lymph nodes 
 
Tumor size >3  cm  but not <5 cm 
Grown into a main bronchus, visceral pleura, clogging the airways(specific sizes).Cancer has spread to lymph nodes 
 
Tumor size >5  cm  but not <7 cm 
Grown into the chest wall, the phrenic nerve, or membrane of the sac surrounding the heart 
IIIA 
T2a/T2b 
 
 
 
T3 
 
 
 
T4 
 
 
 
T2a/T2b 
 
 
 
T3 
 
 
 
T4 
N2 
 
 
 
N1 
 
 
 
N0/N1 
 
 
 
N3 
 
 
 
N2 
 
 
 
N2 
M0 
 
 
 
M0 
 
 
 
M0 
 
 
 
M0 
 
 
 
M0 
 
 
 
M0 
Tumor size >3  cm  but not <5 cm 
Grown into a main bronchus, visceral pleura, and clogging the airways (specific sizes).  
Cancer has spread to lymph nodes around the carina or into the space between the lungs. 
 
Tumor size >5  cm  but not <7 cm 
Grown into the chest wall, partial pleura, the phrenic nerve, or membrane of the sac surrounding the heart.  
Cancer has spread to lymph nodes 
 
Tumor size >7  cm 
Grown into the space between lungs, the heart, aorta, trachea, esophagus, diaphragm, the backbone, or the carina. 
May or may not spread to the lymph nodes. 
 
Tumor size >3  cm  but not <5 cm 
Grown into the bronchus, visceral pleura, and clogging the airways (specific sizes).  
Cancer has spread to lymph nodes near the collarbone. 
 
Tumor size >5  cm  but not <7 cm 
Grown into the chest wall, partial pleura, the phrenic nerve, or membrane of the sac surrounding the heart.  
There are >2 separate tumor nodules. Has spread to lymph nodes around the carina 
 
Tumor size >7  cm 
Grown into the space between lungs, the heart, aorta, trachea, esophagus, diaphragm, the backbone, or the carina. 
There are >2 separate tumor nodules. Has spread to the lymph nodes around the carina. 
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IIIB 
T1a/T1b/T1c 
 
 
 
 
T2a/T2b 
 
 
 
 
T3 
 
 
 
T4 
N3 
 
 
 
 
N3 
 
 
 
 
N2 
 
 
 
N2 
M0 
 
 
 
 
M0 
 
 
 
 
M0 
 
 
 
M0 
Tumor size <3  cm 
Not grown into the membrane surrounded the lung. Cancer spread to lymph nodes near the collarbone on either side, 
or to hilar or mediastinal lymph nodes on the other side of the body from the main tumor.  
Cancer has not spread to distant sites 
 
Tumor size >3  cm  but not <5 cm 
Grown into a main bronchus, visceral pleura, and clogging the airways. Cancer has spread to lymph nodes near the 
collarbone on either side or to hilar or mediastinal lymph nodes on the other side of the body from the main tumor. 
Cancer has not spread to distant sites. 
 
Tumor size >5  cm  but not <7 cm 
Grown into the chest wall, partial pleura, and the phrenic nerve. There are >2 separate tumor nodules. 
Cancer has spread to lymph nodes around the carina or mediastinum. Cancer has not spread to distant sites. 
 
Tumor size >7  cm 
Grown into the space between lungs, the heart, the trachea, the esophagus, the diaphragm, the backbone, or the 
carina. There are >2 separate tumor nodules.  
Cancer has spread to the lymph nodes around the carina or mediastinum. Cancer has not spread to distant sites. 
IIIC 
T3 
 
 
 
T4 
N3 
 
 
 
N3 
M0 
 
 
 
M0 
Tumor size >5  cm  but not <7 cm 
Grown into the chest wall, partial pleura, the phrenic nerve, or membrane of the sac surrounding the heart. 
There are >2 separate tumor nodules. Cancer has spread to the lymph nodes around the collarbone. 
 
Tumor size >7  cm 
Grown into the space between lungs, the heart, aorta, trachea, esophagus, diaphragm, the backbone, or the carina. 
There are >2 separate tumor nodules. Cancer has spread to the lymph nodes around the carina. 
IVA 
Any T 
 
Any T 
Any N 
 
Any N 
M1a 
 
M1b 
Cancer has spread to the other lung, cancer cells are found in the fluid around the lung, and heart 
 
Has spread as a single tumor outside of the chest (lives, bones, or brain) 
IVB Any T Any N M1c Has spread as more than one tumor outside of the chest (lives, bones, or brain) 
N; denotes regional lymph nodes, M; distant metastases, and T; primary tumor. 
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Table ‎9-4: CTC detection technologies in NSCLC 
256
 
Platforms Enrichment technology Number of NSCLC patients Detection rate (%) Reference 
CellSearch Immunomagnetic  101 21 
181
 
210 39 
182
 
152 31 
174
 
24 33 
183
 
33 36 
184
 
CTC-Chip  Immunoaffinity 55 100 
4
 
Graphene oxide chip Immunoaffinity 4 100 
72
 
OncoBean Chip  Immunoaffinity 2 100 
69
 
35 83.3 
172
 
Vortex Chip   8 100 
85
 
Dean Flow Fractionation   20 100 
188
 
ISET Size-based filtration 210 50 
182
 
40 80 
228
 
32 100 
257
 
Negative depletion   43 100 
39
 
Telomerase-based   30 65 
258
 
MCA   22 77 
259
 
NanoVelcro Immunoaffinity 7 100 
185 
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Table ‎9-5: Optimization of panel of antibodies for CTCs detection in pancreatic cancer patients. 
Sample  EpCAM chip CD133 chip Antibodies 
 
EpCs EMTCs EpCs EMTCs Cytokeratin Vimentin 
S 01 0 NA 0 0 CK 7&8 (IgG2a/BD) Vimentin  (Rabbit mAb/Cell Signaling) 
S 02 0 NA 2 0 CK 7&8 (IgG2a/BD) Vimentin  (Rabbit mAb/ Cell Signaling) 
S 03 
0 
 
 
0 
0 
 
 
0 
0 
 
 
0 
0 
 
 
3 
CK 7&8 (IgG2a/BD) + 
CK 8/18/19 (IgG2a/Invitrogen) 
 
CK 7&8 (IgG2a/BD) 
Vimentin  (Rabbit pAb/ Santa Cruz) 
 
Vimentin (IgG1/BD) 
S 04 0 NA 0 6 CK 7&8 (IgG2a/BD) Vimentin (IgG1/BD) 
S 05 2 NA 0 6 CK 7&8 (IgG2a/BD) Vimentin (IgG1/BD) 
S 06 2 NA 0 4 CK 7&8 (IgG2a/BD) Vimentin (IgG1/BD) 
S 07 6 NA 0 7 CK 7&8 (IgG2a/BD) Vimentin (IgG1/BD) 
S 08 0 4 0 0 CK 7&8 (IgG2a/BD) Vimentin (IgG1/BD) 
S 09 0 0 0 2 CK 7&8(IgG2a/BD) Vimentin (IgG1/BD) 
S 10 0 0 0 0 CK 7&8 (IgG2a/BD) Vimentin (IgG1/BD) 
S 11 0 0 1 8 PanCK (IgG2a/Abcam) Vimentin (IgG1/BD) 
S 12 10 NA 0 3 
-PanCK (IgG2a/BioRad)  for EpCAM chip 
-CK 7&8 (IgG2a/BD) for CD133 chip 
Vimentin (IgG1/BD) 
S 13 4 NA 0 10 
-PanCK (IgG2a/ BioRad) for EpCAM chip 
-CK 7&8 (IgG2a/BD) for CD133 chip 
Vimentin (IgG1/BD) 
S 14 
2 
8 
NA 
NA 
NA 
NA 
NA 
NA 
-CK 7&8 (IgG2a/BD) 
-PanCK (IgG2a/ BioRad) 
NA 
NA 
S 15 
2 
7 
NA 
NA 
NA 
NA 
NA 
NA 
-CK 7&8 (IgG2a/BD) 
-PanCK (IgG2a/ BioRad) 
NA 
NA 
S 16 
6 
13 
NA 
NA 
NA 
NA 
NA 
NA 
-CK 7&8 (IgG2a/BD) 
-PanCK (IgG2a/ BioRad) 
NA 
NA 
EpCs; epithelial CTCs, EMTCs; EMT-like CTCs 
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Table ‎9-6: Clinical characterization of pancreatic cancer patients (n=40) (immunoaffinity CTC Carpet Chip study) 
Sample CTC EMT Gender Age Stage 
T 
(mm) 
N M Tumor status 
CA19-9 
U mL
-1
 
CEA  
ng mL
-1 Therapy 
Patholo
gy 
Death OS PFS 
P 01 30 26 F 74 IIA - N0 M0 Resected 2011 - Res AD Dead 463 279 
P 02 25 17 M 51 IIA - N0 M0 Resected 44 - 
Rad/ 
Res 
AD Dead 667 494 
P 03 ¶* 9 201 M 63 IIA 19 N0 M0 Resected 42 - Res AD Alive 1000 977 
P 04 ¶ 13 101 M 63 IIA 32 N0 M0 Locally Advanced 52 2 No AD Alive 907 208 
P 05 ¶* 44 73 M 71 IIA 24 N0 M0 Resected 16 - Res AD NA 181 169 
P 06 25 44 M 74 IIB 22 N1 M0 Resected 11 - No AD Alive 1508 1292 
P 07* 10 77 F 64 IIB 19 N1 M0 Resected 381 - No AD Alive 1314 835 
P 08 64 50 M 69 IIB - N1 M0 Resected 84 3.3 NA AD Alive 1245 1218 
P 09 ¶ 38 92 M 65 IIB 45 N1 M0 Locally Advanced 524 4 No AD Dead 612 612 
P 10 36 180 M 74 IIB 40 - M0 Locally Advanced 2128 5 No AD Dead 223 223 
P 11 ¶* 21 118 M 68 IIB 29 N1 M0 Resected 4 7 Res AD Dead 319 55 
P 12 ¶ 16 42 M 76 IIB 18 N1 M0 Locally Advanced 688 - No AD Dead 99 99 
P 13 ¶ 5 127 M 56 IIB 23 N1 M0 
Borderline 
Resectable 
1033 3 No AD Dead 539 471 
P 14 * 10 93 M 40 IIB 15 N1 M0 Resected 3 <1 
Chemo/
Res 
AD Alive 1112 1112 
P 15 ¶ 9 78 F 55 III 23 N0 M0 Locally advanced 21 2 No AD Alive 654 344 
P 16 0 15 F 53 III - N0 M0 Locally advanced 2485 - No AD Dead 670 573 
P 17 8 40 F 60 III - N0 M0 
Borderline 
Resectable 
27 - Chemo AD NA 364 161 
P 18 8 26 F 66 III - N0 M0 Locally Advanced 325 - NA AD Dead 321 321 
P 19 9 27 F 70 III - N1 M0 Locally advanced 3693 - No AD Dead 602 465 
P 20 8 183 F 60 III 13 N1 M0 Locally advanced 619 - No AD Dead 1363 373 
P 21 ¶ 39 87 F 55 III 17 N0 M0 Locally advanced 21 2 No AD Alive 723 351 
P 22 ¶ 57 73 M 64 III 27 N0 M0 Locally advanced 52 2 No AD Alive 1011 1005 
P 23 ¶ 30 15 M 63 III 44 - M0 Locally advanced - - No AD Dead 482 254 
P 24 9 48 F 81 IV 43 - M1-Liver Locally advanced 17408 - Chemo AD Dead 519 519 
P 25 9 21 M 66 IV - N0 M1 Metastatic 1109 - No AD Dead 130 91 
P 26 5 105 M 73 IV - N1 M1 Metastatic 145 - NA AD NA 14 14 
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P 27 67 66 F 50 IV 35 - M1-Liver Metastatic - - Chemo AD Dead 548 72 
P 28 ¶ 29 147 M 51 IV 34 N1 M1-Liver Metastatic 4 - No AD Dead 131 52 
P 29 31 36 F 58 IV 39 N1 M1-Breast Metastatic 56 29 No AD Dead 167 99 
P 30 ¶ 13 51 M 60 IV 44 N0 M1-Lung Metastatic 4232 - No AD Dead 367 137 
P 31 ¶ 35 236 M 66 IV 80 N1 M1-Liver Metastatic 3116 12 No AD Dead 450 55 
P 32 ¶ 13 128 M 74 IV 56 N1 
M1-
Peritoneum 
Metastatic 45 9 No AD Dead 169 139 
P 33 ¶ 9 83 M 65 IV 65 N1 M1-Liver Metastatic 652518 - No AD Dead 437 169 
P 34 ¶* 44 207 M 78 IV 60 N1 
M1-small 
bowel 
Metastatic 19712 26 No AD Dead 76 76 
P 35 7 85 F 58 IV 60 N1 
M1-Liver, 
Peritoneum 
Metastatic - - 
Chemo/
Rad 
AD Dead 734 143 
P 36* - - M 64 III 14 N1 M0 Locally advanced 204 1 Chemo AD Alive 1127 936 
P 37 * - - F 65 IIB 29 N1 M1-Liver Metastatic 97 - 
Chemo/
Rad 
AD Alive 496 265 
P 38 * - - F 78 IIB 15 N1 M1-Liver Metastatic 132 - Chemo Ad Alive 440 440 
P 39 * - - F 74 IIA 30 N0 M1-Liver Metastatic 29 <1 Chemo AD Dead 462 134 
P 40 * - - M 61 IIA 22 N0 M1-Liver Metastatic 21 <1 Chemo AD Dead 514 259 
HC 01 F 33 0 - - - - - - - - - HC Alive 
  
HC 02 F 27 2 - - - - - - - - - HC Alive   
HC 03 M 27 3 - - - - - - - - - HC Alive   
HC 04 M 24 1 - - - - - - - - - HC Alive   
HC 05 F 45 2 - - - - - - - - - HC Alive   
HC 06 M 40 0 - - - - - - - - - HC Alive   
HC 07 F 57 6 - - - - - - - - - HC Alive   
HC 08 M 90 3 - - - - - - - - - HC Alive   
HC 09 M 66 0 - - - - - - - - - HC Alive   
CA19-9, Carbohydrateantigen19-9; CEA, carcinoembryonic antigen; Chemo, Chemotherapy; Rad, Radiation; Res, Resected; AD, Adenocarcinoma; NA, not Available; HC, healthy 
controls; OS, overall survival; PFS, progression free survival. RNA analyses were done for patients marked with ¶. Tissues samples of patients marked with* were analyzed for IHC 
analysis.  
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Table ‎9-7: Treatment of pancreatic cancer patients in different visits (immunoaffinity CTC Carpet Chip study) 
Sample Gender Age Stage N M Visit 1 Visit 2 Visit 3 Visit 4 
P 04 Male 63 IIA N0 / 6/30/2014 
1/6/2015 / / 
Received clinical trial treatment UMCC, A 
Dose Escalation Trial of the Wee1 
Inhibitor MK1775, I in combination with 
gemcitabine (+radiation) - 6 cycles 
completed 
  
P 20 Female 60 III N1 / 6/17/2013 
9/22/2014 3/2/2015 6/1/2015 
Completed 4 cycles Folfirinox & 4 cycles 
of FOLFOX, then chemo+radiation (55 
Gy) and gastrojejunostomy 
On palliative treatment 
(Gemcitabine, Abraxane, 
Xeloda) 
Received previous 
treatment 
P 21 Female 39 III N0 / 7/14/2014 
8/7/2014 9/8/2014 12/8/2014 
Completed two weeks of gemcitabine 
with AZD1775 (wee1 inhibitor) 
Received 31.5 Gy (out of a 
planned 52.5 Gy) radiation with 
concurrent gemcitabine and 
AZD1775 
On chemotherapy with 
gemcitabine 
P 22 Male 57 III N0 / 7/28/2014 
8/14/2014 9/8/2014 4/14/2015 
Completed two weeks of gemcitabine 
with AZD1775 (wee1 inhibitor) 
Received 31.5 Gy (out of a 
planned 52.5 Gy) radiation with 
concurrent gemcitabine and 
AZD1775 
Off chemotherapy, last 
dose was 1/13/15 
P 29 Female 58 IV N1 BREAST 8/4/2014 
12/22/2014 4/28/2015 
 
Patient began Wee-1 inhibitor clinical trial 
( a dose escalation trial of the Wee1 
inhibitor MK1775, in combination with 
gemcitabine (+radiation)), the patient 
switched to FOLFIRI (completed 1 cycle) 
Received  FOLFIRI then 
switched to mFOLFIRINOX,  
currently on this tx at time of 
sample 
 
P 30 Male 60 IV N0 LUNG 8/4/2014 
1/12/2015 / / 
Received 6 cycles gemcitabine + 
Cisplatin 
  
P 31 Male 66 IV N1 LIVER 8/11/2014 
12/22/2014 / / 
Given Gemcitabine+Abraxane then 
began on FOLFOX (still on FOLFOX at 
time of sample) 
  
P 33 Male 65 IV N1 LIVER 8/18/2014 
1/20/2015 / / 
Completed 5 cycles of OMP-59R5 in 
Combination With Nab-Paclitaxel and 
Gemcitabine (APLINE trial) 
  
Visit 1: no prior treatment; different patients received different treatments in their visits 2, 3 and 4. 
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Table ‎9-8: Clinical characterization of treatment naïve patients with pancreatic cancer (Labyrinth) 
Sample Gender Age Tumor status 
CA19-9 
(U/mL) 
Name of chemotherapy received 
Type and Gy of 
Radiation 
received 
Total 
CTCs 
Epithelial 
CTCs 
EMT-
like 
CTCs 
P 01 M 64 Resectable 55 Gemcitabine, Abraxane 
 
0 0 0 
P 02 M 76 Resectable 262 C1D1 Gemcitabine, Abraxane 
 
0 0 0 
P 03 M 74 Resectable 20523   
 
0 0 0 
P 04 F 56 Resectable 24   
 
2 1 1 
P 05 F 69 Resectable 160 Gemcitabine/Abraxane 
 
2 0 2 
P 06 F 62 Resectable 518 Gemcitabine 
 
3 0 3 
P 07 M 73 Resectable 94 Gemcitabine/Cisplatin 
 
3 0 3 
P 08 M 73 Resectable 27 FOLFIRINOX 
 
3 0 3 
P 09 M 55 Resectable 90 none 
 
4 4 0 
P 10 M 46 Resectable 18   
 
4 2 2 
P 11 F 72 Resectable 1103 Gemcitabine 
 
4 2 2 
P 12 F 73 Resectable 376   
 
5 0 5 
P 13 M 70 Resectable 35   
 
5 0 5 
P 14 M 68 Resectable 158 Gemzar/Xeloda, Capecitabine 
 
5 0 5 
P 15 F 74 Resectable 29 Gem/Cisplatin 
 
6 3 3 
P 16 M 73 Resectable 46 OSH 
 
6 0 6 
P 17 F 68 Resectable 173   
 
8 0 8 
P 18 M 69 Resectable 64 Gemcitabine 
 
8 0 8 
P 19 M 72 Resectable 688 Gemcitabine 24.4/36Gy 9 3 6 
P 20 F 78 Resectable 132   
 
12 3 9 
P 21 M 46 Resectable 14 Gem/Abraxane 
 
12 3 9 
P 22 F 67 Resectable 243   
 
12 0 12 
P 23 M 69 Resectable 35 none 
 
13 4 9 
P 24 F 63 Resectable 95 Gemcitabine (Xeloda starting 3/13/16) 
 
13 11 2 
P 25 F 62 Resectable 24 Gemcitabine, Capecitabine (OSH) 
 
13 0 13 
P 26 F 82 Resectable 
 
  
 
13 0 13 
P 27 M 72 Resectable 16  NAB-PACLITAXEL + GEMCITABINE 
 
18 18 0 
P 28 F 59 Resectable 9 none 
 
23 15 8 
P 29 M 51 Resectable 2058 Oxaliplatin/5-FU 
 
27 11 16 
P 30 M 79 Resectable 19 Gem/Abraxane 
 
28 0 28 
P 31 M 82 Resectable 60 none 
 
33 22 11 
P 32 F 58 Resectable 105 FOLFIRINOX 
 
46 34 12 
P 33 F 77 Resectable 307 none 
 
52 26 26 
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P 34 F 86 Resectable 51 Capecitabine 
 
57 34 23 
P 35 M 85 Resectable 43 Gemcitabine 
 
61 23 38 
P 36 M 72 Borderline Resectable 2884 FOLFIRINOX 
 
3 0 3 
P 37 M 72 Borderline Resectable 3079   
 
5 5 0 
P 38 M 60 Borderline Resectable 271 FOLFIRINOX, FDR-Gemcitabine 52.5 Gy 5 0 5 
P 39 M 62 Borderline Resectable 83   
 
5 0 5 
P 40 F 59 Borderline Resectable 15 mFOLFIRINOX 
 
6 3 3 
P 41 F 49 Borderline Resectable 163   
 
6 0 6 
P 42 M 56 Borderline Resectable <2 2011.007 trial: FOLFIRINOX, FDR-Gemcitabine + IMRT 50 Gy 6 0 6 
P 43 F 65 Borderline Resectable 104 UMCC 2011.007: mFOLFIRINOX, Gemcitabine + IMRT 50 Gy 6 0 6 
P 44 M 71 Borderline Resectable 56 GEMCITABINE + ABRAXANE 
 
12 4 8 
P 45 F 77 Borderline Resectable 1524   
 
13 4 9 
P 46 F 56 Borderline Resectable 425 FOLFIRINOX - OSH 
 
13 0 13 
P 47 M 70 Borderline Resectable 1150   
 
15 5 10 
P 48 M 69 Borderline Resectable 1671 1. FOLFIRINOX, 2. Gemcitabine 50 Gy 16 0 16 
P 49 M 66 Borderline Resectable none   
 
20 13 7 
P 50 F 58 Borderline Resectable 1674 Gem/Abraxane 
 
21 3 18 
P 51 M 60 Borderline Resectable 14 Neoadjuvant at OSH 
 
22 18 4 
P 52 F 86 Borderline Resectable none 
1. GEMCITABINE + ABRAXANE, 2. Gemcitabine,   
3. Capecitabine  
22 22 0 
P 53 F 75 Borderline Resectable 4818 Gem/Abraxane 
 
23 10 13 
P 54 M 63 Borderline Resectable 135 mFOLFIRINOX 
 
25 23 2 
P 55 F 65 Borderline Resectable none GEMCITABINE + ABRAXANE at OSH 
 
26 13 13 
P 56 M 68 Borderline Resectable 1159 1. FOLFOX, 2. FOLFIRINOX  
 
26 20 6 
P 57 F 58 Borderline Resectable 215 GEMCITABINE + ABRAXANE at OSH 
 
27 18 9 
P 58 F 54 Borderline Resectable 518 UMCC 2011.007 M-FOLFIRINOX 50 27 5 22 
P 59 M 82 Borderline Resectable 329 Gemcitabine at OSH (then added Abraxane) 
 
31 22 9 
P 60 M 54 Borderline Resectable 345 Gemcitabine AZD-1775 IMRT, 52.5 Gy 31 13 18 
P 61 F 69 Borderline Resectable 1289   
 
33 0 33 
P 62 M 62 Borderline Resectable 241 FOLFIRINOX (12 cycles)  
 
58 22 36 
P 63 F 49 Borderline Resectable 188 FOLFIRINOX IMRT, 50 Gy 71 45 26 
P 64 F 84 Borderline Resectable 1337 1. GEMCITABINE, 2. GEMCITABINE + ABRAXANE 
 
71 49 22 
P 65 F 62 Borderline Resectable none 
1. GEMCITABINE + ABRAXANE, 2. GEMCITABINE + 
ABRAXANE  
IMRT, 55 Gy 80 80 0 
P 66 M 59 Borderline Resectable 5 FOLFIRINOX 
 
101 56 45 
P 67 F 71 Borderline Resectable 510 FOLFIRINOX 
 
117 67 50 
P 68 F 67 Locally Advanced 82   
 
0 0 0 
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P 69 F 69 Locally Advanced 2209 GEMCITABINE 52.5 0 0 0 
P 70 F 78 Locally Advanced 553   
 
3 3 0 
P 71 M 63 Locally Advanced 179   
 
3 0 3 
P 72 M 56 Locally Advanced 1618   
 
4 0 4 
P 73 M 62 Locally Advanced 204   
 
5 5 0 
P 74 M 81 Locally Advanced 41 Gem/Abraxane  
 
6 0 6 
P 75 F 68 Locally Advanced 2402 Wee-1 clinical trial 52.5 6 0 6 
P 76 M 66 Locally Advanced 6 Gemzar/Abraxane 
 
6 0 6 
P 77 F 62 Locally Advanced 2245   
 
7 0 7 
P 78 F 52 Locally Advanced 2436 none 
 
8 4 4 
P 79 F 68 Locally Advanced 2   
 
9 3 6 
P 80 F 54 Locally Advanced 
 
OSH 
 
9 0 9 
P 81 M 56 Locally Advanced 29   
 
11 9 2 
P 82 M 60 Locally Advanced none none 
 
16 13 3 
P 83 M 68 Locally Advanced 524 GEMCITABINE + ABRAXANE 52.8 Gy 17 0 17 
P 84 F 59 Locally Advanced 4348 Gemcitabine  52.5 23 0 23 
P 85 M 79 Locally Advanced 1678 1. Gemcitabine, 2. Capecitabine, 3. 5-FU/LV 
 
23 23 0 
P 86 M 67 Locally Advanced 510 1. FOLFIRINOX, 2. Gemcitabine 
 
26 13 13 
P 87 F 58 Locally Advanced 169 Gemcitabine  IMRT 27 13 14 
P 88 F 58 Locally Advanced 4 FOLFIRINOX 
 
27 9 18 
P 89 F 70 Locally Advanced 2002   
 
27 21 6 
P 90 F 57 Locally Advanced none 
1. FOLFIRINOX at OSH, 2. GEMCITABINE + 
ABRAXANE   
31 27 4 
P 91 F 84 Locally Advanced 204 none 
 
31 15 16 
P 92 F 80 Locally Advanced 687 Gemcitabine 
 
64 49 15 
P 93 F 72 Metastatic 2657 1. FOLFOX 6, 2. GEMCITABINE + ABRAXANE 
 
0 0 0 
P 94 M 68 Metastatic 671 
1. UMCC 2013.030 PHASE 2: ALPINE  
2. Gem/Abraxane  
0 0 0 
P 95 M 65 Metastatic 
 
OSH 
 
0 0 0 
P 96 M 63 Metastatic 346 Gemcitabine 
 
3 3 0 
P 97 F 51 Metastatic 1982   
 
3 0 3 
P 98 M 80 Metastatic 229 C1D1 Gemcitabine, Abraxane 
 
3 0 3 
P 99 F 69 Metastatic 6345 1. UMCC 2013.030, 2. FOLFOX 
 
4 4 0 
P 100 M 70 Metastatic 1653 Gemcitabine 
 
4 2 2 
P 101 M 75 Metastatic 17217   
 
5 0 5 
P 102 M 64 Metastatic 61881 1. UMCC 2013.030 PHASE 2: ALPINE 2. FOLFOX 
 
6 6 0 
P 103 F 63 Metastatic 
 
  
 
6 0 6 
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P 104 M 64 Metastatic 9377 1. Gemcitabine/Cisplatin, 2. Olaparib  
 
6 0 6 
P 105 F 46 Metastatic 
 
  
 
6 0 6 
P 106 M 59 Metastatic 1444 UMCC 2015.055 Gemcitabine/Abraxane  
 
8 3 5 
P 107 F 46 Metastatic 2391 
1. GEMCITABINE + ABRAXANE, 2. FOLFOX6, 3. 
Gemcitabine + Cisplatin + Lynparza, 4. FOLFIRI  
8 4 4 
P 108 M 53 Metastatic none unknown 
 
8 4 4 
P 109 M 61 Metastatic 1825 Gem/Abraxane 
 
8 0 8 
P 110 M 54 Metastatic 605 FOLFIRINOX 
 
8 0 8 
P 111 M 69 Metastatic 481 1. Gemzar/Abraxane, 2. FOLFOX 
 
9 9 0 
P 112 F 47 Metastatic 2463 1. FOLFIRINOX 2. Gem/Abraxane 
 
9 6 3 
P 113 M 59 Metastatic 397 UMCC 15.055 Gem/Abraxane 
 
9 9 0 
P 114 F 67 Metastatic 163   
 
9 0 9 
P 115 M 81 Metastatic 3561 Gemcitabine 
 
9 0 9 
P 116 M 66 Metastatic 429   
 
9 0 9 
P 117 F 47 Metastatic x   
 
10 6 4 
P 118 M 52 Metastatic 91   
 
10 0 10 
P 119 F 51 Metastatic 35477 alternative regimen - OSH 
 
10 0 10 
P 120 M 61 Metastatic 22711   
 
11 0 11 
P 121 M 79 Metastatic 1393634 Gemcitabine 
 
11 0 11 
P 122 F 56 Metastatic none none 
 
12 8 4 
P 123 M 65 Metastatic 149 GEMCITABINE + ABRAXANE at OSH 
 
13 13 0 
P 124 M 44 Metastatic 7064 GEMCITABINE + ABRAXANE 
 
13 13 0 
P 125 M 76 Metastatic 34   
 
13 9 4 
P 126 M 59 Metastatic 7373 clinical trial: Gemcitabine, Cisplatin 
 
13 0 13 
P 127 F 77 Metastatic 50974 Gemcitabine 
 
16 3 13 
P 128 F 66 Metastatic 4030   
 
16 5 11 
P 129 F 75 Metastatic none none 
 
17 4 13 
P 130 F 55 Metastatic 34   
 
18 9 9 
P 131 F 69 Metastatic 2   
 
18 0 18 
P 132 M 66 Metastatic 931   
 
21 2 19 
P 133 M 75 Metastatic 159   
 
23 10 13 
P 134 F 66 Metastatic 624 1. UMCC 2013.030, 2. M-FOLFOX6  
 
31 18 13 
P 135 M 67 Metastatic 464   none 31 22 9 
P 136 M 62 Metastatic 6980 FABLOx phase I clinical trial 
 
34 17 17 
P 137 M 68 Metastatic 30 
1.YOSEMITE study: Gemzar/Abraxane,  
2. Gemcitabine/Abraxane  
46 0 46 
P 138 M 75 Metastatic 8493 1. GEMCITABINE, 2. GEMCITABINE + ABRAXANE 
 
53 53 0 
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P 139 F 68 Metastatic 1907 
1. GEMCITABINE + ABRAXANE, 2. GEMCITABINE + 
ABRAXANE   
58 58 0 
P 140 M 78 Metastatic 343   
 
62 62 0 
P 141 F 34 Metastatic 120082 
1. ALPINE trial (OMP-59R5 in Combination With Nab-
Paclitaxel and Gemcitabine), 2. FOLFOX6  
97 57 40 
H 01 M 52 
  
  
 
0 0 0 
H 02 F 51 
  
  
 
0 0 0 
H 03 M 55 
  
  
 
0 0 0 
H 04 F 66 
  
  
 
2 0 2 
H 05 M 50 
  
  
 
0 0 0 
H 06 F 77 
  
  
 
0 0 0 
H 07 F 57 
  
  
 
0 0 0 
H 08 M 63 
  
  
 
8 0 8 
H 09 M 66 
  
  
 
2 0 2 
H 10 M 51 
  
  
 
3 0 3 
H 11 M 73 
  
  
 
6 0 6 
H 12 M 81 
  
  
 
0 0 0 
CA19-9, Carbohydrateantigen19-9; P, patient sample; H, healthy controls 
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Table ‎9-9: Clinical characterization of patients with pancreatic cancer pre and post-surgery (Labyrinth) 
Sample Gender Age 
Tumor status 
pre-Surgery 
Tumor status 
post-surgery 
Total CTCs 
pre- Surgery 
Total CTCs 
post-Surgery 
Epithelial CTCs 
pre- surgery 
Epithelial CTCs 
post- surgery 
EMT-like CTCs 
pre- surgery 
EMT-like CTCs 
post-surgery 
P 01 F 49 Borderline Resected 71 3 45 0 26 3 
P 02 M 65 Resectable Resected 22 3 / 0 / 3 
P 03 F 86 Resectable Resected 57 64 34 37 23 27 
P 04 M 85 Resectable Resected 61 0 23 0 38 0 
P 05 M 59 Borderline Resected 101 10 56 0 45 10 
P 06 M 82 Resectable Resected 16 70 0 54 16 16 
P 07 M 55 Resectable Resected 17 17 9 9 9 9 
P 08 F 86 Borderline Resected 22 6 22 0 0 6 
P 09 F 66 Borderline Resected 71 0 / 0 / 0 
 P 10 F 53 Borderline Resected 4 3 / 0 / 3 
P 11 F 73 Resectable Resected 5 3 / 3 / 0 
P 12 F 74 Resectable Resected 6 6 3 6 3 0 
P 13 M 68 Resectable Resected 26 8 20 3 6 5 
P 14 F 68 Resectable Resected 8 2 0 0 8 2 
P 15 F 54 Borderline Resected 27 16 5 0 22 16 
P 16 M 69 Resectable Resected 8 10 0 0 8 10 
P 17 F 78 Resectable Resected 12 29 3 6 9 23 
P 18 F 63 Resectable Resected 13 3 11 0 2 3 
P 19 M 63 Borderline Resected 25 9 23 0 2 9 
P 20 M 63 Resectable Resected 13 12 3 0 10 12 
P 21 M 46 Resectable Resected 6 6 0 0 6 6 
P 22 F 73 Resectable Resected 5 14 0 0 5 14 
P 23 F 62 Resectable Resected 13 6 0 3 13 3 
P 24 M 70 Resectable Resected 5 6 0 3 5 3 
P 25 M 68 Resectable Resected 5 3 0 0 5 3 
P 26 M 73 Resectable Resected 6 0 0 0 6 0 
P 27 M 73 Resectable Resected 3 17 0 0 3 17 
P 28 M 74 Resectable Resected 0 3 0 0 0 3 
P 29 M 64 Resectable Resected 5 10 0 5 5 5 
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Table ‎9-10: Clinical characterization of patients with pancreatic cancer pre- and on-Chemotherapy (Labyrinth) 
Sample Gender Age 
Tumor status pre- 
Chemotherapy 
Tumor status on- 
Chemotherapy 
Total    
CTCs       
pre-Chemo 
Total    
CTCs       
on-Chemo 
Epithelial 
CTCs        
pre-Chemo 
Epithelial 
CTCs       
on-Chemo 
EMT-like 
CTCs       
pre-Chemo 
EMT-like 
CTCs       
on-Chemo 
P 01 M 59 Borderline Resected 101 10 56 0 45 10 
P 02 M 67 Locally Advanced Metastatic 26 10 13 / 13 / 
P 03 F 46 Metastatic Metastatic 8 60 4 / 4 / 
P 04 F 58 Locally Advanced Locally Advanced 27 14 9 3 18 11 
P 05 F 66 Metastatic Metastatic 31 15 18 3 13 12 
P 06 F 65 Borderline borderline 26 0 13 0 13 0 
P 07 F 69 Metastatic Metastatic 4 26 4 5 0 22 
P 08 M 44 Metastatic Metastatic 13 0 13 0 0 0 
P 09 M 54 Borderline Locally Advanced 31 9 13 9 18 0 
P 10 F 53 Borderline Borderline 4 0 / 0 / 0 
P 11 F 74 Resectable resected 6 6 3 6 3 0 
P 12 F 58 Locally Advanced Locally Advanced 17 21 13 6 14 15 
P 13 M 65 Metastatic Metastatic 16 3 / 3 / 0 
P 14 M 67 Metastatic Metastatic 0 22 / 3 / 19 
P 15 F 58 Resectable resectable 46 3 34 0 12 3 
P 16 F 63 Resectable resected 13 3 11 0 2 3 
P 17 F 59 Borderline borderline 6 36 3 10 3 26 
P 18 M 81 Metastatic Metastatic 16 16 / 0 / 16 
P 19 M 62 Metastatic Metastatic 34 0 17 0 17 0 
P 20 M 51 Borderline Resectable Borderline Resectable 27 10 11 0 16 10 
P 21 M 60 Borderline Resectable Borderline Resectable 5 0 0 0 5 0 
P 22 M 80 Metastatic   3 5 0 0 3 5 
P 23 M 69 Borderline Resectable   16 3 0 0 16 3 
P 24 F 68 Unresectable Unresectable 6 3 0 0 6 3 
P 25 M 68 Metastatic Metastatic 46 0 0 0 46 0 
P 26 M 68 Resected Resected 3 5 0 0 3 5 
P 27 M 64 Metastatic Metastatic 6 3 0 0 6 3 
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P 28 F 46 Metastatic Metastatic 0 6 0 0 0 6 
P 29 M 56 Borderline Resectable Borderline Resectable 6 5 0 0 6 5 
P 30 M 64 Unresectable Unresectable 12 3 6 0 6 3 
P 31 M 73 Resected Resected 17 6 0 0 17 6 
P 32 M 66 Unresectable Unresectable 6 1 0 0 6 1 
P 33 M 59 Metastatic Metastatic 13 7 0 0 13 7 
P 34 M 76 Resectable Resectable 0 0 0 0 0 0 
P 35 M 54 Metastatic Metastatic 8 0 0 0 8 0 
Chemotherapy, Chemo 
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Table ‎9-11: Clinical characterization of patients with pancreatic cancer pre- and post-Chemotherapy (Labyrinth) 
Sample Gender Age 
Tumor status pre- 
Chemotherapy 
Tumor status post- 
Chemotherapy 
Total    
CTCs       
pre-Chemo 
Total   
CTCs     
post-Chemo 
Epithelial 
CTCs 
Pre-Chemo 
Epithelial 
CTCs 
Post-Chemo 
EMT-like 
CTCs        
pre-Chemo 
EMT-like 
CTCs 
post-Chemo 
P 01 M 82 Borderline Resectable 31 16 22 0 9 16 
P 02 F 62 Borderline Locally Advanced 80 21 80 0 0 21 
P 03 F 58 Locally advanced Metastatic 27 14 9 3 18 11 
P 04 F 84 Borderline Locally Advanced 71 12 49 12 22 0 
P 05 F 86 Borderline Resected 22 6 22 0 0 6 
P 06 F 68 Metastatic Metastatic 58 18 58 3 0 15 
P 07 F 53 Borderline Resected 4 3 / 0 / 3 
P 08 F 59 Borderline Locally Advanced 3 7 0 0 3 7 
P 09 M 68 Resectable Resected 26 8 20 3 6 5 
P 10 F 54 Borderline Resected 27 16 5 0 22 16 
P 11 F 75 Borderline Borderline 23 6 10 0 13 6 
P 12 M 61 Metastatic Metastatic 8 23 0 0 8 23 
P 13 M 69 Resectable Resected 8 10 0 0 8 10 
P 14 F 59 Borderline Locally Advanced 6 3 3 0 3 3 
P 15 M 63 Borderline Resected 25 9 23 0 2 9 
P 16 M 81 Metastatic Metastatic 16 6 / 3 / 3 
P 17 F 61 Metastatic Metastatic 24 3 / 0 / 3 
P 18 M 59 Metastatic Metastatic 8 6 3 0 5 6 
P 19 F 58 Borderline Borderline 21 33 3 6 18 27 
P 20 M 51 Borderline Resectable Borderline Resectable 27 4 11 0 16 4 
P 21 M 46 Resectable Resectable 12 6 3 0 9 6 
P 22 F 56 Borderline Resectable Borderline Resectable 13 0 0 0 13 0 
Chemotherapy, Chemo 
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Table ‎9-12: Clinical characterization of patients with pancreatic cancer pre- and post-Radiation (Labyrinth) 
Sample Gender Age 
Tumor status    
pre-Radiation 
Tumor status 
post-Radiation 
Total      
CTCs 
pre-Rad 
Total     
CTCs      
post-Rad 
Epithelial 
CTCs 
pre-Rad 
Epithelial 
CTCs      
post-Rad 
EMT-like 
CTCs 
pre-Rad 
EMT-like 
CTCs      
post-Rad 
P 01 F 49 Borderline Resected 71 3 45 0 26 3 
P 02 F 62 Borderline Locally Advanced 80 21 80 0 0 21 
P 03 F 87 Resected Resected 6 5 0 0 6 5 
P 04 F 73 Locally Advanced Locally Advanced 20 8 0 1 20 7 
P 05 M 54 Borderline Locally Advanced 31 9 13 9 18 0 
P 06 F 53 Borderline Resected 0 3 0 0 0 3 
P 07 F 59 Borderline Locally Advanced 3 7 0 0 3 7 
P 08 F 58 Locally Advanced Locally Advanced 17 21 13 6 14 15 
P 09 F 75 Borderline Borderline 23 6 10 0 13 6 
P 10 F 63 Resectable Resected 13 3 11 0 2 3 
P 11 F 59 Borderline Locally Advanced 6 3 3 0 3 3 
P 12 M 51 
Borderline 
Resectable 
Borderline 
Resectable 
10 4 0 0 10 4 
Radiation, Rad  
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Table ‎9-13: Clinical characterization of patients with NSCLC 
Sample Gender Age Stage 
Node 
status 
Tumor 
Adenocarcinoma 
subtype 
Smoking 
status 
Mutation Treatment 
P 01 F 39 IV N0 T2 ALK No Alk Mutation Crizotinib 
P 02 F 55 IV N3 T2 ROS-1 80 PY ROS1 Mutation 
Crizotinib (switched from Carbo/Taxol 
due to neuropathy - was taking 
Carbo/Taxol prior to baseline) 
P 03 F 40 IV N2 T1 ROS-1 No ROS1 rearrangement 
Crizotinib (stopped 12/10/2017). Started 
Entrectinib 12/26/2017. 
P 04 M 85 IV N1 T2 ROS-1 30PY ROS1 rearrangement Crizotinib 
P 05 F 78 IV N2 T3 EGFR No EGFR mutant AC with T790M mutation Osimertinib 
P 06
¶
 F 49 IV N0 T4 EGFR 25PY T790M mutation Osimertinib 
P 07 F 77 IV N1 T3 EGFR No EGFR mutant AC 
Disease progression on Erlotinib so 
switched to Afatinib on 1/10/2017 
P 08 M 81 IV N2 T1 EGFR No EGFR mutant AC 
Afatinib reduced dose started on 
12/31/2016. On hold as of 2/14/2017 to 
improve QOL 
P 09
¶
 F 43 IV N2 T2 ROS-1 No ROS 1 Mutation 
Progressed on Crizotinib. Started on 
Ceritinib 
P 10 M 58 IV N0 T3 ROS-1 No ROS 1 Mutation Crizotinib 
P 11 M 60 IV N0 T2 ALk 23PY Alk translocation + Crizotinib 
P 12 F 57 IV N0 T4 EGFR 5PY EGFR mutation Erlotinib and Zometa 
P 13 M 62 IV N2 T3 EGFR No EGFR mutation 
Afatinib, Switched to Osimertinib  (due to 
rash) 
P 14 F 58 IV N0 T2 EGFR 5PY EGFR mutation 
Pemetrexed maintenance - cycle 1 
initiated on 7/12/2017; prior to this 
patient received 4 cycles of 
Carbopltin/Pemetrexed. 
P 15 F 61 IV N0 T2 EGFR 10PY EGFR exon 19 deletion Tarceva 
P 16 F 80 IV N0 T2 EGFR No EGFR L858R, T790M Osimertinib 
P 17 M 58 IV Nx T3 Alk No TTF-1, Napsin, ALK positive Alectinib (stopped Crizotinib) 
P 18 F 61 IV N3 T2 EGFR No EGFR L858R, T790M Osimertinib 
P 19 M 50 IV N2 T2 Alk Former ALK EML-4 fusion Alectinib 
P 20 F 45 IV N3 T4 EGFR Former EGFR, Exon 19 deletion, PDL1 10% Tagrisso 
P 21 F 63 IV N3 T3 ROS-1 No ROS-1 Carboplatin/Pemetrexed 
P 22* F 49 IV Nx T2 EGFR No 
EGFR insertion/deletion19 and a variant 
of unknown significance in ERBB2. ALK1 
and ROS1 negative. 
Afatinib + Cetuximab. 10/27/2017 
switched to Taxotere+Cyramza+Tagrisso 
P 23* F 43 IV N0 T2A RET No RET Mutation Alectinib 
P 24** M 53 / / / / / CK7, TTF-1, Napsin-A positive PD-L1 5% 
Pembrolizumab + ePancreatic 
cancerdostat 
¶ 
Analyzed for PanCK CTC only.  * Discarded from the analysis due to the different sample processing. ** Withdraw from the project by the clinic due to the PDL1 mutation. 
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Table ‎9-14: CTC enumeration of patients with NSCLC 
Sample PanCK+ CTCs 
EpCAM+ 
CTCs 
Vimentin+  
CTCs 
Double+ 
CTCs 
Total  
CTCs 
Processed with 
P 01 121.4 0.0 11.3 8.5 141.2 Single Labyrinth 
P 02 34.4 0.0 7.4 54.0 95.7 Single Labyrinth 
P 03 96.9 14.2 23.6 33.1 167.8 Single Labyrinth 
P 04 100.9 38.2 30.0 2.7 171.8 Single Labyrinth 
P 05 273.8 5.0 7.5 0.0 286.3 Single Labyrinth 
P 06
¶
 76.8 0 0 0 76.8 Single Labyrinth 
P 07 24.0 0.0 57.6 122.4 204.0 Single Labyrinth 
P 08 167.3 0.0 2.4 12.1 181.8 Single Labyrinth 
P 09
¶
 631.4 0.0 0.0 0.0 631.4 Single Labyrinth 
P 10 30.1 7.5 0.0 7.5 45.2 Single Labyrinth 
P 11 350.0 0.0 7.9 44.7 402.6 Single Labyrinth 
P 12 189.3 5.2 59.6 25.9 280.0 Single Labyrinth 
P 13 31.6 0.0 0.0 7.9 39.5 Single Labyrinth 
P 14 21.8 0.0 9.5 2.7 34.1 Single Labyrinth 
P 15 42.4 4.4 0.0 5.9 52.7 Single Labyrinth 
P 16 7.3 0.0 1.5 1.5 10.2 Single Labyrinth 
P 17 71.3 0.0 11.3 56.3 138.8 Single Labyrinth 
P 18 38.5 0.0 52.5 0.0 91.0 Single Labyrinth 
P 19 6.4 6.4 22.4 35.2 70.4 Single Labyrinth 
P 20 82.5 0.0 20.6 4.1 107.3 Single Labyrinth 
P 21 41.6 6.9 263.5 239.2 551.2 Single Labyrinth 
P 22* 0.0 0.0 0.0 3.2 3.2 Double Labyrinth 
P 23* 13.8 0.0 4.2 0.0 18.0 Double Labyrinth 
P 24** NA NA NA NA NA Single Labyrinth 
HC 01 3.0 0.0 0.0 0.0 30 Single Labyrinth 
HC 02 0.0 0.0 0.0 0.0 0.0 Single Labyrinth 
HC 03 0.0 0.0 0.0 0.0 0.0 Single Labyrinth 
¶ 
Analyzed for PanCK CTC only.  * Discarded from the analysis due to the different sample processing. ** Withdraw from the project by the clinic due to the PDL1 
mutation.
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Table ‎9-15: Clinical information of NSCLC patients (P 03 and P 22) over the treatment. 
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ROS1 
rearrangement 
Crizotinib (stopped 
12/10/2017).  Started 
Entrectinib 12/26/2017. 
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11/21/2017- progressed in the brain. 
1/20/2018- MRI Brain- slight increase in fullness of L 
frontal brain tumor.  CT (chest, abdomin, pelvis) no 
change in bone mets, no new mets. 
3/19/2018- cancer progression in the brain only, but at 
several spots.  Entrectinib continued as treatment. 
7/11/2018- Continue Entrectinib for now, has likely 
stable disease, recent MRI findings more likely 
treatment-related/radiation necrosis and less likely 
progression. 
P 22 
EGFR 
insertion/ 
deletion19 
10/27/2017 Docetaxel + 
Ramucirumab 
Discontinued Docetaxel on 
4/13/2018 (due to fatigue 
and taste changes). 
Discontinued Ramucirumab 
on 6/15/2018 due to 
progression on MR brain 
with two new lesions. 
6/15/2018 started on 
Osimertinib. 
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Disease progression to liver and new lung, brain tumor 
increasing in size. 
12/29/2017 Brain MRI- No significant interval change. 
2/13/2018 Chest CT- Interval decrease in lung nodules 
and liver lesions. 
Withdrew consent further blood draws on 6/15/2018. 
Brain MR on 6/11/2018 demonstrated two new brain 
lesions.  Discontinued ramucirumab due to new lesions 
and started on Osimertinib. 
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